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Variceal bleeding is the most serious complication of portal hypertension and 
substantially alters the natural history of patients with compensated alcoholic 
cirrhosis (Villanueva 2009).   One-third of deaths from cirrhosis are related to portal 
hypertension, and are due mainly to oesophageal variceal bleeding (Garcia-Pagan 
2008).  Up to 30 per cent of initial variceal bleeding episodes are fatal, and as many 
as 70 per cent of survivors, if inadequately treated, have recurrent variceal bleeding 
(Kravetz 2007).   
 
The treatment of variceal haemorrhage has evolved markedly in the past decade 
(Krige 2009a, Garcia-Tsao 2008).  Substantive advances have included new drug 
combinations (Dell’Era 2008), improved endoscopic techniques and refinements of 
variceal band ligation (Tait 1999, Krige 2005, Baron 2009), the selective use of 
radiologically inserted transjugular intrahepatic portosystemic shunts (Boyer 2005),  
the recognition of the diminishing role of narrow diameter polytetrafluoroethylene 
interposition portacaval shunts (Rosemurgy 2005)  and the exponentially increasing 
indications for liver transplantation (Busuttil 2008) in patients who have progressive 
hepatic decompensation and persistent variceal bleeding.  Although these advances 
in treatment have reduced overall mortality (Chalasani 2003, Carbonell 2004), 
uncontrolled or recurrent bleeding from varices and the consequences of progressive 
liver failure remain the commonest causes of early death in alcoholic cirrhotic 
patients (Mihas 2004).  The spectrum of interventions required to control variceal 
bleeding and achieve efficient and successful treatment of the severe and potentially 





necessitate advanced skills. (Treiber 2005).  No single modality is applicable to all 
patients and knowledge of the alternatives allows the well-informed surgeon to 
choose the appropriate therapy for each clinical situation.  A co-ordinated 
multidisciplinary team approach is essential as each of these therapies may be 
required at different stages in different patients (Krige 2007b, Krige 2009a).    
 
The ideal treatment of portal hypertension and bleeding varices should be universally 
effective, safe, easy to administer and inexpensive.  Currently no such treatment 
exists and the surgeon or physician is obliged to select the most appropriate 
intervention from a menu of currently available therapeutic options, none of which is 
ideal or applicable to all patients.  The rational treatment of oesophageal varices 
depends on a clear understanding of the risks of rebleeding and the response to 
each specific intervention.   The selection of the correct and appropriate intervention 
is critical and requires a comprehensive understanding of the relative efficacy and 
safety of each treatment compared to other competing options.  In addition, the 
chosen intervention requires detailed knowledge of the criteria underpinning the 
correct selection of patients for treatment in order to maximize the therapeutic 
benefits of the appropriate choice while minimising the side effects of the treatment.  
The optimal management of bleeding oesophageal varices therefore requires a full 
appreciation of portal, gastric and oesophageal venous collateral anatomy, the 
pathogenesis and haemodynamic consequences of variceal bleeding and the utility 
of each available therapy at specific stages in the natural history of portal 






Endoscopic treatment has become the principal first-line intervention in patients with 
bleeding oesophageal varices, both during the acute event and for long-term therapy 
to prevent recurrent bleeding (Krige 2005).  After control of the index bleed, there is 
a 70% chance of rebleeding with a similar mortality.  The risk of rebleeding is 
greatest during the first few days after initial variceal haemorrhage (Sharara 2001).  
Survival after variceal bleeding depends largely on the rapidity and efficacy of initial 
primary haemostasis and the presence and severity of underlying liver disease and 
hepatic functional reserve (Krige 2009b).  Early rebleeding has been shown to be a 
strong predictor of mortality and recurrent variceal bleeding substantially increases 
the risk of complications which further contribute to mortality (Krige 2009b), 
emphasizing that rapid and sustained control of variceal bleeding remains the 
principal imperative of endoscopic intervention (Triantos 2006).  Several important 
clinical considerations influence the choice of therapy as well as the prognosis in 
individual patients.  These include the natural history of the disease causing the 
portal hypertension, the location of the bleeding varices, residual hepatic function, 
the presence of associated systemic disease, continuing drug or alcohol abuse, 
patency of major splanchnic veins and the response to each specific treatment 
(Henderson 1998).   
 
In order to address these unresolved questions, each of the three clinical studies in 
this thesis evaluated a specific aspect of variceal bleeding in a large cohort of 
alcoholic cirrhotic patients treated with endoscopic injection sclerotherapy.   In the 
literature review, the historical perspective of the evolution of endoscopic treatment 
of varices, the natural history of variceal development and pathogenesis of 





technique and complications of endoscopic injection sclerotherapy of oesophageal 
varices were evaluated as well as a comparison of the efficacy of injection 
sclerotherapy in the treatment of acute bleeding oesophageal varices with alternative 
therapies including beta-blockers, sclerotherapy plus beta-blockers, variceal band 
ligation, surgical shunts and transjugular intrahepatic portosystemic shunts.   
 
Study 1 
Patients who survive a first episode of variceal bleeding have a high risk of further 
bleeding and death. The median incidence of variceal rebleeding during the first 24 
months after the index bleed in untreated controls of 20 prospective randomised 
controlled trials of non-surgical treatment for prevention of recurrent bleeding is in 
excess of 60% (D’Amico 1997).  Present knowledge suggests that the risk of 
rebleeding is higher in Child-Pugh C patients.  Although the utility of endoscopic 
injection sclerotherapy in controlling acute variceal bleeding has been extensively 
reported, the long term efficacy and safety of injection sclerotherapy in a high risk 
cohort such as patients with alcohol-induced cirrhosis are poorly defined and 
documented.  Since endoscopic treatment of varices must be performed repeatedly 
until varices are eradicated and then followed by life long surveillance endoscopy to 
identify recurrent varices, a long term follow-up study would be important to 
determine the rebleeding and recurrence rates as well as the cumulative survival 
rates in alcoholic cirrhotic patients who have received injection sclerotherapy.  Such 
a study would clarify the benefits of a long term surveillance programme and would 







In order to answer this question, the first study reported in chapter 4 of this thesis 
evaluated the incidence of variceal eradication, variceal recurrence, rebleeding 
before variceal eradication and after variceal recurrence and death in a large cohort 
of patients with alcohol-induced cirrhosis and bleeding varices treated with repeated 
endoscopic variceal injection sclerotherapy.  In addition, the study sought to 
determine the long term survival in alcoholic patients with cirrhosis who had bled 
from oesophageal varices and were treated with serial injection sclerotherapy.  The 
study tested the validity of the hypothesis that eradication of oesophageal varices by 
repeated injection sclerotherapy would reduce recurrent variceal bleeding and death 
from bleeding varices.   
 
The study evaluated 287 consecutive alcoholic cirrhotic patients who presented with 
acute oesophageal variceal bleeding and underwent a total of 2565 upper 
gastrointestinal endoscopic sessions which included 353 emergency and 1015 
elective variceal injection treatments during the study period.  In order to assess risk 
factors for rebleeding and death in a defined population and to minimize possible 
confounding variables, only those patients who had bleeding oesophageal varices 
due to alcohol related cirrhosis and who were treated with injection sclerotherapy 
were analysed.  Patients with non-alcoholic cirrhosis or other causes of portal 
hypertension as well as those treated by endoscopic variceal ligation were excluded 
from the analysis.  The diagnosis of cirrhosis was established by clinical evaluation, 
laboratory data, findings on radiological imaging including ultrasound and portal 
venous doppler assessment, and in selected patients, liver biopsy and hepatic vein 






In all patients any variceal rebleeding episode that occurred after the index injection 
but before eradication was recorded as well as the percentage of patients in whom 
varices were eradicated. Patients whose varices recurred after eradication were 
documented and long term survival after eradication of varices was recorded.  All 
oesophageal complications, including mucosal ulceration, perforation and strictures 
which occurred following the index sclerotherapy treatment or during subsequent 
endoscopic intervention were documented.  The causes of death were recorded and 
cumulative overall survival in this study cohort was assessed at 1, 3 and 5 years by 
life table analysis.   
 
Study 2 
There is consensus that endoscopic control of bleeding is the emergency treatment 
of choice if actively bleeding oesophageal varices are present during diagnostic 
endoscopy (D’Amico 2006, Burroughs 2008).  However, data on the endoscopic 
control of major variceal bleeding and immediate mortality from uncontrolled 
bleeding in alcoholic cirrhotic patients is not sufficiently robust for an accurate or 
reliable estimate to be made from the existing literature.  In 8 published studies 
which included 1488 patients, the median mortality in patients with uncontrolled 
bleeding within 48 hours of admission was 8% (D’Amico 1997).  In addition to initial 
uncontrolled variceal bleeding, a substantial number of patients have early variceal 
rebleeding after successful initial endoscopic haemostasis.  Early variceal rebleeding 
is associated with a significantly increased risk of death within 6 weeks, emphasizing 
that prevention of variceal rebleeding should be the primary objective of endoscopic 
intervention. The reported incidence of early rebleeding in the first 6 weeks after 





mortality after the first variceal bleed varies from 30% to 50% in high risk patients 
(D’Amico 1997). No accurate or representative data exist for alcoholic cirrhotic 
patients with acute variceal bleeding.   
 
The objective of the second study which is reported in chapter 5 of this thesis was to 
evaluate the efficacy of emergency endoscopic variceal injection sclerotherapy in 
achieving control of acute variceal bleeding and the frequency of acute variceal 
rebleeding and death within six weeks in a large cohort of alcoholic cirrhotic patients 
who presented to hospital with a first episode of acute variceal haemorrhage.  In this 
study 310 alcoholic cirrhotic patients with acute variceal bleeding underwent 786 
endoscopic variceal injection treatments of which 342 were emergency injections to 
control acute bleeding and 444 were subsequent elective injections during the first 6 
weeks after the first variceal bleed. The study evaluated patients treated between 
January 1984 to December 2006.  Most patients were Child-Pugh grades B and C. 
Endoscopic control of bleeding, variceal rebleeding, and survival were recorded in 
relation to Child-Pugh grades.  Emergency endoscopic injection sclerotherapy, 
supplemented with balloon tamponade when necessary, controlled acute variceal 
bleeding in 304 of 310 (98%) patients.  In 6 (1.9%) patients, variceal bleeding was 
not controlled despite using pharmacologic and endoscopic therapy and balloon 
tamponade.  A further 32 patients had recurrent variceal bleeding within 5 days of 
initial endoscopic control and required further emergency endoscopic variceal 
injection procedures to achieve definitive endoscopic variceal haemostasis.  The 5 
day endoscopic failure rate in achieving variceal haemostasis was 12.3% (38 of 310 
patients).  Rebleeding after the initial 5 day assessment and up to 6 weeks after the 





more than 5 days.  Of the 44 patients who rebled, 13 (29.5%) died in the 6 week 
period.  Overall 75 (24.2%) patients rebled during the 6 week assessment period 
after initial control during the index admission.  The incidence of rebleeding 
increased according to the Child-Pugh scores. Twenty five (15%) of the 166 patients 
who were Child-Pugh grade A and B rebled compared to 50 (34.7%) of the 153 
patients in Child-Pugh grade C.  Significantly more Child-Pugh grade C patients 
rebled than Child-Pugh grade A or B patients (p<0.001). 
 
Seventy seven patients (24.8%) died during the 6 week study period.  Twenty-nine 
(9.3%) died within 5 days of admission and 48 (15.4%) between day 6 and 42.  No 
Child-Pugh grade A patients died, 14 Child-Pugh B patients died, and 63 Child-Pugh 
grade C patients died. Liver failure was the commonest cause of death and occurred 
in 29 patients.  Twelve patients died of hepatorenal failure and 11 died of pneumonia 
and respiratory failure.  Death in 25 patients was a consequence of continued or 
recurrent variceal bleeding.  Survival at 5 days and 6 weeks in Child-Pugh grade A 
patients was 100% and 100%, in Child-Pugh grade B patients 96% and 92.7%, and 
in Child-Pugh grade C patients 83.4% and 73%, respectively. Significantly more 
Child-Pugh grade C patients died than Child-Pugh grade A or B patients. Mortality 
increased exponentially as the Child-Pugh score increased with a mortality of 78% 
for a Child-Pugh score of 14 and 83% for a Child-Pugh score of 15.   
 
A total of 338 complications were documented in 159 patients during surveillance or 
unscheduled endoscopy after a prior variceal injection.  Minor complications of 
sclerotherapy were common after acute injection for active bleeding and included 





injection site was found at follow-up endoscopy on 333 occasions in 155 patients.  
An oesophageal stricture at the injection site occurred in 5 patients after 




Alcoholic liver disease is the leading cause of cirrhosis and portal hypertension in the 
developed world (Propst 1995). The natural history of alcoholic cirrhosis depends on 
the degree of liver decompensation, the presence of complications such as variceal 
bleeding, ascites or spontaneous bacterial peritonitis and the efficacy of the applied 
therapy. Progressive liver decompensation occurs more rapidly in patients with 
alcoholic cirrhosis than in those with cirrhosis due to viral hepatitis B or C and is 
aggravated by superadded alcoholic hepatitis.  Once decompensation occurs in 
cirrhotic patients, mortality without organ replacement is as high as 85% over 5 years 
(Schuppan 2008).  Defining prognosis is an essential part of the initial assessment of 
cirrhosis and constitutes the basis for treatment decisions. (D’Amico 2006). A 
number of patient features, characteristics and variables are related to and influence 
the course and outcome of cirrhosis and are relevant in formulating the prognosis. 
Several prognostic variables can be combined into a prognostic model to improve 
the prediction of outcome. While in theory the concept of prognostic modelling in 
cirrhotic patients may seem elementary, in practice the analysis is complex because 
there is a wide spectrum of clinical variations between patients.  Patients may thus 
present at various stages of progression of cirrhosis and with different combinations 
of clinical features, different laboratory liver function values and different responses 





and differences among patients with cirrhosis make formulation of a prognostic 
model complex. To overcome the complexities of these variations, a large patient 
data base which includes the outcome variables and the intervention component for 
each patient is required. (Christensen 1997).   
 
While several previous studies have attempted to develop a classification system 
that both characterises the degree of liver injury and predicts the prognosis of 
patients with cirrhosis on the basis of clinical and laboratory values, there currently is 
no consensus which specific risk factors have the best prognostic value for early 
rebleeding and mortality after variceal bleeding in alcoholic cirrhotic patients.  The 
Child-Pugh classification is widely used because of its simplicity but because the 
classification was originally developed empirically, there are major flaws with poor 
discrimination between patients. The Child-Pugh scores may vary significantly 
between patients if single variables are modified or manipulated by medical 
treatment such as overzealous diuretic therapy, albumin infusion or ascitic 
paracentesis (Huo 2008).  The original data in these scoring systems are variable 
and conflicting because of small sample sizes, referral bias, dissimilar study end-
points, differences in patient selection, aetiologies of cirrhosis, techniques of 
endoscopic intervention and the precise definition of rebleeding (de Franchis 2003).   
 
Early rebleeding is the most consistently reported prognostic risk indicator of death 
at 6 weeks (Bureau 2008, Burroughs 2008, Krige 2009b).  Accurate indicators 
predicting an increased risk of early rebleeding and early death could allow the 





portosystemic shunting before their condition deteriorates precluding further therapy.  
Unfortunately the risk indicators identified to date are mainly indicators of poor liver 
or renal function which are also associated with a high operative risk and 
consequently are of limited clinical value (Triantos 2006).     
The objective of the third study which is detailed in chapter 6 therefore was to 
identify by multivariate analysis in a large longitudinal cohort study a set of robust 
prognostic variables which could predict early rebleeding and death at 6 weeks in 
alcoholic cirrhotic patients admitted to hospital with a first variceal bleed and to 
confirm these risk factors by internal validation in a subsequent group of patients 
with bleeding oesophageal varices.  As in the previous 2 studies outlined in chapters 
4 and 5, the patient data in this study were recorded prospectively on a standard 
proforma and entered on a computer programme maintained by a dedicated 
research assistant.  All patients received their first emergency and all subsequent 
endoscopic variceal sclerotherapy injections in our unit and only those patients who 
had bleeding oesophageal varices due to alcohol related cirrhosis and who were 
treated with injection sclerotherapy were analysed.  Patients with non-alcoholic 
cirrhosis or other causes of portal hypertension as well as those treated by 
endoscopic variceal ligation were excluded from the analysis.  The diagnosis of 
cirrhosis was confirmed by clinical evaluation, laboratory data, radiological imaging 
and, where necessary, by liver biopsy.  The initial and the second sclerotherapy 
session, a week later, were performed during the index admission to hospital.  
Endoscopic details including the size of varices, the presence of active bleeding and 
the volume of sclerosant injected at each intervention were recorded.  Subsequent 
sclerotherapy was undertaken at regular intervals at an outpatient clinic until the 





In this study a retrospective analysis of the prospectively collected data in the 310 
patients was performed to identify potential risk factors which could predict 
rebleeding and death. Fifteen variables related to clinical and biochemical data, as 
well as details of the endoscopic intervention including the size of varices and 
sclerosant volume, were analysed.  The primary endpoints of the study were 
rebleeding and death at 42 days. Time zero was defined as the time of admission to 
our hospital. Failure to control bleeding was defined as continued bleeding despite 
endoscopic injection and the addition of pharmacotherapy and the use of balloon 
tamponade.  Rebleeding was defined as any episode of upper gastrointestinal 
bleeding that occurred after the initial bleeding episode had been successfully 
controlled by sclerotherapy, or bleeding that occurred subsequently between 
scheduled treatment sessions.  Mortality was defined as death from any cause.  The 
study design and analysis was approved by the appropriately convened 
Departmental and Institutional Ethics and Research Committees of the Health 
Sciences Faculty of the University of Cape Town.  Data-validation and quality-control 
procedures followed accepted international good clinical practice guidelines.   
 
Continuous variables were dichotomized on the basis of existing literature.  The 
tested variables included serum albumin level, international normalised ratio, total 
bilirubin level, ascites, encephalopathy, variceal size, sclerosant volume given per 
sclerotherapy session, the need for a blood transfusion and the volume of blood 
transfused during the bleeding episode.  The categorical variables included gender, 
age, pitressin administration, the need for balloon tube tamponade and the number 






In the statistical analysis, bivariate associations between categorical variables were 
analysed using the x2 test.  The Kruskal-Wallis test was used to assess blood 
requirements in units of blood in each of the 3 Child-Pugh grades.  Logistic 
regression was used to estimate the odds ratios with 95% confidence intervals for 
adjusted and unadjusted effects. Initially each risk factor was examined 
independently which produced the unadjusted odds ratios and 95% confidence 
intervals.  The significant candidate variables identified by univariate analysis 
underwent multivariate logistic regression analysis to produce a prognostic model 
(“the training set”) which represented the risk factors for rebleeding and death in the 
first 6 weeks after admission to hospital. The performance and discriminative ability 
of the constructed models to predict rebleeding and mortality at 6 weeks was 
assessed using receiver operating characteristic analysis.  The prediction accuracy 
was quantified using the concordance index (C-index) which is equivalent to the area 
under the receiver operating characteristic curve and reflects the ability of a model to 
discriminate participants (or patients) who develop the event of interest (i.e. 
rebleeding or death) from those who do not.  Values range from 0.5 to 1; a value of 1 
is indicative of a model with perfect predictive power. For all analyses, a p value less 
than 0.05 and a 95% confidence interval that did not span unity were considered the 
thresholds of statistical significance. Stata software was used for statistical analysis.  
In the validation process the developed models were tested for validity and 
concordance in a further set of alcoholic cirrhotic patients with bleeding varices who 
were treated subsequently (“the test set”). Model discrimination between the training 






In the literature review component of this thesis in chapter 2, peer review 
publications were evaluated to assess the historical perspective, natural history and 
pathogenesis of oesophageal variceal rupture.  As knowledge of oesophageal 
venous anatomy is an essential prerequisite and the familiarity with the technique of 
endoscopic injection sclerotherapy of oesophageal varices is a fundamental 
requirement in the treatment of portal hypertensive bleeding, these topics were 
reviewed as well as the specific details of the technique of sclerotherapy, including 
intravariceal injection, paravariceal injection and combined intravariceal and 
paravariceal injection methods, the sclerosing agents used and the conventional 
endpoints of therapy. 
 
In the comparative analysis section, the review assessed the efficacy of injection 
sclerotherapy in the treatment of acute bleeding oesophageal varices compared to 
surgical procedures including portocaval shunt and oesophageal transection.  The 
review also evaluated the benefits and risks of injection sclerotherapy in the 
prevention of recurrent variceal bleeding compared to conservative treatment, beta-
blockers, sclerotherapy plus beta-blockers, variceal band ligation, surgical shunts 
and transjugular intrahepatic portosystemic shunts.  Finally, as injection 
sclerotherapy is an invasive endoscopic procedure which requires a high degree of 
manipulative skills, the spectrum of complications including oesophageal mucosal 
ulceration, rebleeding from patent residual varices, oesophageal perforation, 
intramural haematoma, oesophageal stricture and oesophageal motility disorders 






In the concluding chapter, the synopsis summarises the main findings and 
implications of the three clinical studies and recommendations for future directions of 
research in portal hypertension are suggested.  Because the success of endoscopic 
therapy may be compromised by recurrent bleeding and serious procedure-related 
complications, recommendations regarding the technical aspects of sclerotherapy 
are included as well as the need to supervise trainees when critical decisions are 
required.   Early and close multidisciplinary consultation is emphasized in demanding 
cases to facilitate appropriate therapy and optimal management.  As the treatment of 
acute bleeding and prevention of recurrent variceal bleeding is best accomplished by 
a skilled, knowledgeable, and well equipped team using a multidisciplinary integrated 
approach, modern management requires the provision of the full spectrum of 
treatment options, including pharmacological therapy, endoscopic treatment, 
interventional radiological procedures, surgical shunts and liver transplantation 
 
A review of the literature shows considerable variation in the quality of randomised 
trials in portal hypertension, and despite the plethora of studies, there remain 
deficiencies which leave unanswered questions.  Understanding the problems 
inherent in the design, execution and interpretation of clinical trials in portal 
hypertension is critical in planning future studies. The statistical power of trials 
remains a major problem in portal hypertension studies. Improved appreciation of the 
principles involved in the design and implementation of clinical trials and analysis of 
data will increase the number of high quality of randomised controlled trials which 
should resolve some of the issues. There is a need to use standardised definitions 





quality of life and cost effectiveness are becoming increasingly important concepts to 
include in trial design.   
 
Future research into portal hypertension requires adequately powered, meticulously 
conducted, properly reported multicentre trials to address unresolved issues. As 
patient recruitment becomes an increasing impediment, future studies need 
internationally accepted and uniform protocols to facilitate aggregate analyses and 
future meta-analyses.  In addition, the ever increasing demand for medical fiscal 
discipline and logistic efficiency require the issue of cost to be adequately addressed 
in prospective studies. Identification and knowledge of accurate prognostic predicting 
early rebleeding should ideally provide a powerful tool to identify at an early stage 
those patients in whom conventional treatment is likely to be unsuccessful and who 
require urgent implementation of an aggressive salvage strategy. Future prospective 
studies incorporating and evaluating the full spectrum of prognostic factors including 
clinical variables, liver biochemistry, endoscopy and portal pressures and 
comparative MELD and Child-Pugh assessment will be valuable advances in 
improving the effective and rational management of patients with bleeding 





CHAPTER  2 
2.1 HISTORICAL  PERSPECTIVE OF SCLEROTHERAPY 
 
The first report of the use of endoscopic injection of sclerosant into oesophageal 
varices to control variceal bleeding was published in 1939 by two Swedish surgeons, 
Clarence Crafoord and Paul Frenckner (Crafoord 1939).  The patient was a 19-year 
old woman who had presented 2 years previously with bleeding oesophageal 
varices.  She was noted to have an enlarged spleen with no clinical or biochemical 
evidence of liver disease and had an elective splenectomy.  She remained well for 
two years when she had a further variceal bleed due to recurrent varices identified 
on rigid oesophagoscopy. Frenckner designed a special needle which could be 
advanced down a Jackson rigid oesophagoscope to inject the varices.  During the 
initial intervention a total of 6ml of quinine was injected into three oesophageal 
varices without provoking further bleeding.  When the oesophagoscopy was 
repeated five days later Crafoord and Frenckner found that the varices had reduced 
in size. A further series of injections was given every second day for one month until 
all the oesophageal varices had been eradicated. Follow-up oesophagoscopy at six 
month intervals confirmed that the varices had not recurred. The patient remained 
well without any further bleeding during the next three years when the case report 
was published (Crafoord 1939).  
 
A second case report of injection sclerotherapy was published in 1940 by Herman 
Moersch, a thoracic surgeon at the Mayo Clinic in Rochester, Minnesota (Moersch 
1940).  Moersch treated a 30 year old man with cirrhosis who had first presented at 





patient remained well with no further variceal bleeding for eight years.  He then had 
several recurrent variceal bleeds and was admitted to hospital in 1940.  
Oesophagoscopy confirmed large oesophageal varices, one of which was injected 
with 0.5ml of a 2.5% solution of sodium morrhuate.  The remaining varices were 
injected at four day intervals with 1ml of sodium morrhuate on each occasion.  After 
these injections the varices were reduced in size and no further bleeding occurred in 
the three months up to the time of the report (Moersch 1940). 
 
After these two case reports, injection sclerotherapy was introduced at the Mayo 
Clinic and at Baylor University Hospital in Dallas, Texas, to treat bleeding 
oesophageal varices. In June 1947 Herman Moersch from the Mayo Clinic and Cecil 
Patterson and Milford Rouse from Baylor University Hospital presented their 
experience at the American Gastroenterological Association Meeting in Atlantic City, 
New Jersey, and published their data in the same year in JAMA and 
Gastroenterology, reporting their long-term results of injection sclerotherapy 
(Moersch 1947, Patterson 1947).  Moersch reported his experience in 22 patients 
who had received repeated injections as an elective procedure following variceal 
bleeding.  Twelve of the 22 patients had no recurrence of bleeding after 3 years, 8 of 
whom had been followed for 4 years or more.  Ten patients continued to bleed from 
varices, although only three died as a result.  Moersch noted that most patients with 
recurrent variceal bleeding had gastric fundal varices which were not present in the 
twelve patients in whom therapy was successful.  Moersch reported that two patients 
had died of recurrent variceal bleeding due to gastric varices which could not be 
controlled through the rigid oesophagoscope (Moersch 1947). The second 





detailed the results of injection sclerotherapy in 24 patients who had a total of 76 
sclerotherapy injection sessions using sodium morrhuate over a 4 year period.  Six 
of the 24 patients died as a consequence of variceal bleeding, but the remaining 18 
patients had only 8 bleeding episodes during follow-up (Patterson 1947).   
 
Despite the initial enthusiasm and reported success, the introduction and increasing 
popularity of portocaval shunt operations which were described by Blakemore in 
1946, overshadowed endoscopic injection sclerotherapy which was used 
infrequently during the next decade.  The introduction of portal systemic shunt 
surgery in Great Britain and United States so dominated the management of portal 
hypertension and variceal bleeding that no further developments of injection 
sclerotherapy occurred for a decade (Westaby 1983).  The next major series using 
injection sclerotherapy was published in 1955 in the British Medical Journal by 
Ronald Macbeth from Oxford who reported his experience in 30 patients, 14 of 
whom had cirrhosis and 16 who had portal or splenic vein thrombosis.  Macbeth 
found the technique disappointing in patients with cirrhosis because of the high 
mortality in cirrhotic patients irrespective of the recurrence of variceal bleeding.  
However, in those with an extrahepatic cause of portal hypertension and normal liver 
function, the results were satisfactory and Macbeth recommended that this group 
was suitable for injection sclerotherapy (Macbeth 1955).  Two other important points 
were made in this report.  Firstly, there were no serious complications as a 
consequence of the injection sclerotherapy and, secondly, Macbeth stressed the 
need for further oesophagoscopy at six month intervals following initial obliteration to 






Fearon and Sass-Kortsak from Toronto reported their experience of injection 
sclerotherapy in children who had presented with variceal bleeding.  Fifteen patients 
were treated over a 4 year period, ranging in age from 23 months to 16 years.  
Thirteen of the children had portal vein thrombosis and 2 had cirrhosis and received 
1 to 8 injection sessions.  Sclerotherapy was successful in 9 of the 15 patients with 
few or no further variceal bleeds following injection.  In 6 patients variceal bleeding 
recurred despite repeated injections, and 2 patients died as a result of bleeding 
(Fearon 1959).   
 
The early interventional endoscopists used rigid endoscopes and an intravariceal 
injection technique which was performed on an anaesthetised and intubated patient.  
Wodak, an Austrian surgeon, modified the technique of intravariceal injection 
sclerotherapy in 1960 by injecting not into the varix but in a paravariceal position into 
the submucosa alongside the varices with the aim of creating a fibrotic layer over the 
varices and to leave the underlying patent varices as functioning collaterals (Wodak 
1960).  This technique was adopted by others in Austria and Germany and, in 
particular, Denck and Paquet (Denck 1971, Paquet 1978).  
 
In 1973 George Johnston and Harold Rodgers from the Royal Victoria Hospital in 
Belfast reported their experience of injection sclerotherapy over a 15 year period 
(Johnston 1973).  Whereas Macbeth recommended repeated courses of injection to 
obliterate the varices, Johnston and Rodgers used only a single injection session to 
control the acute bleeding episode (Johnston 1973). Between 1958 and 1972, 177 
patients who had a total of 194 bleeding episodes were treated by injection 





whereas in 30 patients portal or splenic vein thrombosis was present.  Bleeding was 
controlled in 177 of 194 episodes by sclerotherapy with a 93% success rate.  Sixteen 
of 17 patients who continued to bleed, died as a result.  Serious complications after 
sclerotherapy occurred in only 3 patients who developed full thickness oesophageal 
wall necrosis, one of whom died (Johnston 1973).  In 1975 Bailey and Dawson 
described their modification of the rigid 50 cm Negus oesophagoscope in which a 0.5 
x 4.0 cm slot was cut in the distal end diagonally opposite the beak as in a Gabriel 
proctoscope (Bailey 1975).  This modification was a major technical advance and 
facilitated the injection of varices.  The slot allowed a varix to prolapse into the lumen 
of the oesophagoscope which gave improved visibility, thus allowing accurate 
intravariceal injection of sclerosant.  
  
However, by 1975, almost 40 years after the first use of injection sclerotherapy to 
control variceal bleeding, there were still no controlled data to confirm the efficacy of 
the technique and, in particular, whether survival was increased in the treated 
patients (Westaby 1983).  To provide this important information Terblanche from 
Cape Town initiated the first controlled trial in August 1975.  This study included 
patients with cirrhosis and portal or splenic vein thrombosis.  Injections were given 
using the technique described by Bailey and Dawson, which Bailey had introduced to 
Cape Town during a visit in 1974.  Repeated courses of injection were used to 
obliterate the varices.  Although a control group was an integral part of this study, the 
trial design allowed patients in the control group to undergo a single course of 
sclerotherapy if they presented with variceal bleeding.  The results of this trial were 
reported in 1979 when 24 patients were included in the analysis, 11 having received 





(36%) patients treated by injection had further episodes of variceal bleeding 
compared to 9 of 13 (69%) in the control group.  Despite fewer bleeding episodes in 
those receiving repeated injections, survival for the two groups was similar.  The 
failure to show a difference in survival may be explained by the policy of injecting 
those patients in the control group whenever bleeding occurred, which accounted for 
18 separate injections in the 9 patients who had recurrent bleeding.  A further 
analysis of this study showed a similar reduction in variceal bleeding in those 
undergoing repeated injection, but survival again was not improved (Terblanche 
1983).  In 1977 the Kings College group in London started a prospective randomised 
trial and reported their experience using sclerotherapy in 64 patients with a 57.7% 
one year survival.  Of the 22 deaths in their series, 7 were due to uncontrolled 
variceal bleeding and 4 deaths were a result of oesophageal perforation related to 
the procedure (Clark 1980). Two subsequent papers were published with larger 
numbers (Macdougall 1982, Westaby 1985). 
 
The next phase in the evolution of endoscopic control of variceal bleeding was the 
report from King’s College Hospital by Williams and Dawson that a flexible fibre-optic 
endoscope passed through an outer sheath was able to provide effective control of 
variceal bleeding (Williams 1979).  A prospective randomised trial from Cape Town 
which compared the rigid scope with flexible endoscopy showed that the flexible 
endoscope was as effective as the rigid scope in controlling acute variceal bleeding 
and variceal eradication and resulted in fewer complications such as oesophageal 
perforation and strictures (Bornman 1988). The results of the Cape Town trials, 





sclerotherapy in the management of acute variceal bleeding led to a resurgence of 
interest in sclerotherapy in the early 1980s.  
 
As the endoscopic technique evolved, experience showed that the overtube was not 
necessary during injection sclerotherapy, even for acute variceal sclerotherapy, and 
the use of the overtube became redundant. As flexible fibreoptic endoscopy became 
the standard of care, the rigid oesophagoscope became obsolete and patients had 
the procedure performed electively as an outpatient using conscious sedation.  The 
next milestone in the evolution of endoscopic variceal treatment was the 
development of variceal banding by Stiegmann from Denver, Colorado, who had 
spent a sabbatical working with Terblanche and Bornman in Cape Town.  The 
development and introduction of the first prototype used a single band delivery 
system which was passed through an over tube in the oesophagus (Stiegmann 
1986).  Subsequent progress led to a disposable multiband delivery system which 
could apply six bands sequentially without the need for reloading or the use of an 
overtube (Stiegmann 1992, Stiegmann 1996).  Further advances in endoscope 
development have led to video endoscopy and narrow diameter endoscopes which 







2.2   VENOUS ANATOMY OF THE OESOPHAGUS  
 
 
A clear understanding of variceal anatomy has played a key role in the development 
of endoscopic therapy. The adaptations and changes that occur in the venous 
anatomy of the oesophagus in patients with portal hypertension have significant 
clinical implications when endoscopic injection sclerotherapy, which deals directly 
with varices in the lower oesophagus, is used.  Even under normal conditions, the 
lower end of the oesophagus is subject to constant physiological changes (Vianna 
1987).  Variations in venous pressure occur during respiration, which, when 
combined with lower oesophageal sphincter contraction and the interactions of the 
anatomic structures involved in preventing gastro-oesophageal reflux, generate 
complex mechanical effects in the lower oesophagus (Johnson 1966, Cohen 1972). 
The consequences of these mechanical changes are of particular relevance in 
relation to their influence on the low pressure venous drainage of the gastro-
oesophageal junction which functions as a spontaneous communication between the 
portal and azygous venous systems (Kegaries 1934).  
 
To fully appreciate the pathogenesis of acute variceal bleeding and the rationale for 
the efficacy and limitations of injection sclerotherapy, an understanding of the 
pathophysiology of portal hypertension and the changes that occur in the venous 
anatomy of patients with oesophageal varices is necessary.  In the past, logistic 
difficulties and technical complexities prevented accurate studies of the venous 
anatomy of the lower oesophagus in patients with portal hypertension (Arakawa 
1983).  More recently, as technology has evolved and become increasingly 





have provided a clearer understanding of the venous anatomy of the lower 
oesophagus in portal hypertension (Spence 1991, Spence 2000). These 
investigations have included the use of anatomical studies (Kitano 1986), corrosion 
casting, endoscopic ultrasound (Irisawa 2001) ultrasound microprobes (Obara 2006), 
multidetector computed tomographic techniques utilising three dimensional image 
software, Doppler ultrasound (McCormack 1983), percutaneous transhepatic 
portography and cineangiography, histology using image analysis (Spence 1984a, 
1984b) and morphometry applying image analysis programmes (Vianna 1987).   
 
The original studies used injections of silicone rubber, resin, and barium gelatin into 
cadaver and fresh post mortem specimens to demonstrate the angioarchitecture of 
the oesophagus (Arakawa 1985, Butler 1951, De Carvalho 1966, Kegaries 1934, 
Kitano 1986, Noda 1984, Vianna 1987).  In a seminal study in 1934, Kegaries 
demonstrated that the oesophagus had four longitudinal venous draining trunks 
which had few cross anastomoses and a fine capillary anastomosis between the 
portal and systemic circulations (Kegaries 1934).  The next major contribution was 
by Butler who described intrinsic veins consisting of a subepithelial and a 
submucosal plexus and peri-oesophageal extrinsic veins (Butler 1951).  
Subsequently McBeth confirmed Butler’s findings and emphasised the importance of 
subepithelial veins in variceal bleeding.  Beswick and Butler stressed the relevance 
of dilated subepithelial oesophageal veins above the cardia.  De Carvalho published 
a detailed anatomic study of the lower oesophagus in 1966, also using injection 
techniques. He reported that the veins in the distal oesophagus were present mainly 





the gastro-oesophageal junction, whereas in the stomach and proximal oesophagus 
the veins were mostly in the submucosa (De Carvalho 1966).  
 
In an elegant and innovative study by Spence et al., the microvasculature of the 
lower oesophagus in normal and portal hypertensive patients was evaluated 
quantitatively using a computer assisted image analysis system which had been 
developed to assess both normal and diseased microvasculature (Spence 1984a, 
Spence 1984b). Twenty normal specimens of oesophagus and stomach and seven 
specimens from patients with varices were studied (Spence 1984b). The authors 
found that each specimen could be clearly subdivided into three zones. Zone 1 was 
the stomach where the mean relative area occupied by veins in the lamina propria 
was 2.6 per cent (s.e.m. +/- 0.2) in the normal subjects and 3.7 per cent (s.e.m. +/- 
0.8) in the variceal specimens.  Zone 2 began at the oesophagogastric junction and 
extended 2-5 cm into the lower oesophagus. The mean area occupied by veins in 
the lamina propria increased to 19.8 per cent (s.e.m. +/- 1.2) in the normal and 32.8 
per cent (s.e.m. +/- 3.9) in the varices specimens.  Zone 3 was the remainder of the 
proximal oesophagus and the mean area occupied by veins in the lamina propria 
was 4.9 per cent (s.e.m. +/- 0.3) in the normal and 6.1 per cent (s.e.m. +/- 0.5) in the 
varices specimens.  Further analysis revealed that this increase in area occupied by 
veins in the distal oesophagus was due to an increase in both the number and size 
of vessels in the lamina propria of Zone 2. The authors concluded that these findings 
may explain the propensity for oesophageal varices to bleed mainly from the distal 






Doppler ultrasound evaluation of the lower oesophagus through an endoscope has 
demonstrated a constant perforating vein extending from the perioesophageal plexus 
to the subepithelial and submucosal layers at 36 cm (McCormack 1983).  Vianna et 
al. studied the normal anatomy of the distal oesophagus using a combination of 
radiographic techniques, corrosion casting, and morphometry (Vianna 1987).  In their 
study four distinct zones of venous drainage were identified: (i) a gastric zone below 
the gastro-oesophageal junction which is characterised by longitudinal venous 
distribution; (ii) a palisade zone above the gastro-oesophageal junction which is 
composed of parallel veins within the lamina propria; (iii) a perforating zone in which 
veins traversed the wall of the oesophagus to connect the intrinsic and extrinsic 
systems and (iv) a truncal zone composed of four or five deep veins.  These 
investigators suggested that this anatomic pattern implied that venous flow was 
bidirectional in the palisade zone and that this zone acted as a high-resistance 
watershed between the portal and azygos venous systems (Vianna 1987).   
 
In a subsequent investigation the Cape Town group studied the lower oesophageal 
venous anatomy in post mortem specimens of patients who had had portal 
hypertension and oesophageal varices (Kitano 1986). A previously developed 
refined resin-casting technique was used which produced a three dimensional view 
of the angioarchitecture and a high level resolution of the oesophageal 
microvasculature (Kitano 1986).  Four layers of veins were identified: (i) 
intraepithelial channels, (ii) a superficial venous plexus, (iii) deep intrinsic veins and 
(iv) adventitial veins.  The study also confirmed the presence of perforating veins in 
the distal oesophagus.  The superficial venous plexus communicated with the gastric 





These varices were demonstrated to occur in three to five main trunks which had 
multiple communications with the superficial venous plexus.  In the light of these 
anatomical findings, Kitano et al. postulated that a major episode of variceal bleeding 
occurs as a result of rupture of the large deep intrinsic variceal channels that lie 
adjacent to the epithelial surface, or from a major branch of the superficial venous 
plexus at a point near a direct connection to a large varix.  Minor variceal bleeding, 
which stops spontaneously, may occur from a branch of the superficial venous 
plexus via a connection to a large varix or from smaller dilated intraepithelial 
channels (Kitano 1986).   
 
These anatomical studies of the venous angioarchitecture of the lower oesophagus, 
added to the original influential work of the earlier investigators, have clarified the 
detailed anatomy of the critical zone of bleeding, and provided clues to the 
pathogenesis of variceal rupture (Spence 1983a, 1983b).  The modern 
understanding of variceal anatomy is based on these studies and is detailed below.  
 
The intrinsic veins of the oesophagus are divided into four well defined zones.  
1.  The gastric zone extends for 2 to 3 cm below the gastro-oesophageal junction 
and is the junctional or transition venous drainage zone between the stomach and 
lower oesophagus. The veins of the gastric zone are arranged radially, compared to 
the irregular venous network present in the rest of the stomach.  The veins in the 
gastric zone lie in the submucosa and lamina propria and become confluent near the 
gastro-oesophageal junction and drain into the short gastric and left gastric veins 






2.  The palisade zone is a continuation of the gastric zone and begins at the gastro-
oesophageal junction and extends proximally for 2 to 3 cm. This zone corresponds to 
the abdominal oesophagus and anatomically is the segment of oesophagus between 
the gastro-oesophageal junction and the diaphragmatic hiatus.  In this zone the veins 
are parallel and uniformly distributed and run longitudinally in palisades in four trunks 
which correspond to the oesophageal mucosal folds.  Multiple anastomoses link 
these veins which occupy the lamina propria.  There are no perforating veins in the 
palisade zone connecting the intrinsic and extrinsic veins of the distal oesophagus.  
Morphometric studies show that the cross sectional area of the veins at this level is 
increased compared to other levels.  These observations support the notion that the 
palisade zone functions as a watershed between the portal and systemic circulations.  
This is the anatomic location of the lower oesophageal sphincter.  When portal 
pressure rises and impedes venous drainage in the gastric zone into the left gastric 
vein, flow is directed via the veins in the palisade zone into the lower oesophagus 
and ultimately into the azygous system (Vianna 1987). 
 
3.  The perforating or transitional zone extends 2 to 3 cm up the oesophagus above 
the palisade zone and connects the palisade zone to the truncal zone. The main 
feature of this zone are the perforating veins which traverse the muscle wall of the 
oesophagus and link the internal and external oesophageal venous systems. This 
area is of significance in patients with portal hypertension because of variceal 
bleeding.  Both endoscopic and histologic observations of the oesophagus show 
dilated veins in the lamina propria and the submucosa which are at risk for rupture. 
Noda confirmed the frequent occurrence of variceal bleeding in this zone, and 





oesophagus drain into the extrinsic veins primarily in the perforating zone via valved 
perforating veins that normally allow only unidirectional flow. These perforating veins 
occur circumferentially around the oesophageal wall. When flow is increased through 
these veins, as occurs in portal hypertension, the perforator valves become 
incompetent and allow bidirectional flow.  The organized longitudinal venous 
structure in the oesophagus consequently is lost, as the veins become distended and 
form a network.   
 
4.  The truncal zone is 8 to 10 cm long and extends upwards in the oesophagus from 
the perforating zone.  The truncal zone is characterized by four or five large 
longitudinal venous trunks in the submucosa.  Blood in these veins flow in a cranial 
to caudal direction and drain via the perforating veins into the extrinsic veins of the 
oesophagus.   
 
The modern understanding of the venous anatomy of the lower oesophagus explains 
the observation by previous investigators why varices tend to bleed 2 to 5cm above 
the gastro-oesophageal junction (Kitano 1986, Spence 1984b, Spence 1987).  The 
constant perforating veins of the distal oesophagus and interconnections between 
layers of veins explain the re-appearance of varices after eradication (Terblanche 
1983, McCormack 1983).  The detailed anatomy of the critical zone of bleeding 
provides a clue to the pathogenesis of variceal rupture (Spence 1987).  This 
information also provides an explanation for the early success of injection and for the 







Haemodynamic studies of the portal system may provide valuable information on this 
point.  It has been shown that an absence of extravariceal collateral channels, such 
as paraesophageal veins and spleno-gastro-renal veins, is an independent risk 
factor for elevation in portal pressure after sclerotherapy or ligation (Obara 2006).  
Thus, patients with poorly developed extravariceal collateral channels may be at risk 
for the recurrence.  Although ligation is less invasive than sclerotherapy, the 
recurrence of oesophageal varices after ligation remains a significant problem.  The 
recurrence rate of oesophageal varices is significantly higher in patients receiving 
ligation than in those with sclerotherapy (Hou 1995).  This observation could be 
explained by the fact that ligation obliterates only mucosal and submucosal varices.  
In contrast, recent scientific evidence has shown that sclerotherapy obliterates 
deeper oesophageal veins, including perforating veins and para-oesophageal 
collaterals.  Endoscopic Doppler ultrasonography has shown the presence of 
perforating veins as afferent veins in relation to oesophageal varices, suggesting that 
flow into the varices through perforators may be involved in oesophageal variceal 
dilatation and bleeding (Irisawa 2001).  This hypothesis is further supported by 
recent endoscopic ultrasound evaluation in which the number and diameter of 
perforating veins positively correlates with the size of oesophageal varices.  The 
recurrence of oesophageal varices after endoscopic therapy appears to depend on 
several factors, including as the presence of perforating veins, the endoscopic 
therapy technique used; the difference of anatomical features of para-oesophageal 
collaterals, and the development of the extravariceal collateral channels (Obara 





2.3   THE NATURAL HISTORY OF VARICEAL BLEEDING 
 
The modern management of the complications of portal hypertension is based on a 
sound understanding of the pathophysiology and the detailed knowledge of the 
development and natural history of oesophageal varices (Bosch 2003a).  Portal 
hypertension results in the formation of an abundant collateral circulation connecting 
portal blood vessels with the general circulation.  The adaptative capacity of the 
portal circulation is individual-specific and depends mainly on the size of intra- and 
extrahepatic collateral vascular communication between portal and systemic 
circulations (Cichoz-Lach 2008).  From the clinical and haemodynamic perspective, 
the most important collaterals form in the gastro-oesophageal area which results in 
oesophageal varices in 80 to 90% of patients.  
 
Recent research has influenced knowledge on the pathophysiology of portal 
hypertension (Cichoz-Lach 2008).  The observation that the formation of collateral 
veins in response to portal hypertension does not result in decompression of the 
portal venous system and fails to decrease portal pressure suggests that other 
mechanisms besides anatomical mechanical resistance are involved in the 
development and persistence of portal hypertension (Tsai 2007, Cichoz-Lach 2008). 
 
The application of physics dictates that blood pressure in a vascular system is 
defined by the formula: pressure = vascular resistance x blood flow (Cichoz-Lach 
2008). In the portal hypertension model the increase in pressure is a result of 
increased vascular resistance and an increased blood volume in the portal vascular 
bed.  A further significant factor influencing portal pressure is increased blood flow in 





cardiac output and generalized vasodilation of the vascular bed (Tsai 2007).  
Increased portal flow in turn increases further changes within blood vessels thus 
enhancing vascular resistance.  
 
Portal hypertension is associated with changes in the intrahepatic, systemic, and 
portosystemic collateral circulation.  Alterations in vasoreactivity (vasodilation and 
vasoconstriction) play a central role in the pathogenesis of portal hypertension by 
contributing to increased intrahepatic resistance, hyperdynamic circulation, and 
expansion of the collateral circulation.  Portal hypertension is also characterised by 
changes in vascular structure termed vascular remodeling, which is an adaptive 
response of the vessel wall that occurs in response to chronic changes in the 
environment such as shear stress.  These complementary processes of 
vasoreactivity and vascular remodelling contribute to increased intrahepatic 
resistance and represent important targets in the treatment of portal hypertension 
(Shah 2007). 
 
Subsequent research has identified additional factors that influence portal blood flow 
and result in increased portal pressure.  Vitamin A-rich hepatic stellate cells 
constitute 15% of all hepatic cells and once activated, play the role of myofibroblasts 
which are the main source of collagen, fibronectin and other components of 
extracellular matrix (Mallat 1998, Reeves 2002).  Hepatic stellate cells, also called Ito 
cells, are found in perisinusoidal spaces of the liver and significantly modulate blood 
flow through the hepatic sinuses. Their activity is regulated by endothelial factors: 
endothelin (the activation of its receptor constricts muscular cells in the portal 





The initial factor in the pathophysiology of portal hypertension is an increase in 
vascular resistance to portal blood flow (Bosch 2003b).  In alcohol-induced cirrhosis 
this increase in resistance occurs at the hepatic microcirculation level and produces 
sinusoidal portal hypertension.  The increase in hepatic vascular resistance in 
cirrhosis is a consequence of the mechanical distortion of the hepatic architecture 
caused by nodular regeneration and bridging fibrosis and also by a dynamic 
component due to active contraction of portal and septal myofibroblasts, activated 
stellate cells and portal venules (Rockey 1996, Pinzani 1999, Wiest 2002).  This 
increase in intrahepatic vascular tone is modulated by increased activity of 
endogenous vasoconstrictors including endothelin, alpha-adrenergic stimulus, 
leukotrienes, thromboxane A and angiotension II, and is lessened by nitric oxide, 
prostacyclin and vasodilating drugs such as organic nitrates, adrenolytic agents, and 
calcium channel blockers (Bosch 2003b).  A second and major contributing factor to 
portal hypertension is an increase in blood flow through the portal venous system, 
due to splanchnic arteriolar vasodilatation, which is caused by an excessive release 
of endogenous endothelial, neural and humoral vasodilators (Cichoz-Lach 2008). 
 
Biologically active vasodilators including nitric oxide (NO), glucagon, prostaglandins, 
bile acids, TNF-a, and carbon monoxide increase portal flow and play an important 
role.  An imbalance between the hyperresponsiveness and overproduction of 
vasoconstrictors (mainly endothelin-1 and cyclooxygenase-derived 
prostaglandins) and the hyporesponsiveness and impaired production of vasodilators 
(mainly NO) are the mechanisms responsible of the increased vascular tone in the 
sinusoidal/postsinusoidal area. Recent investigations have found different 





presinusoidal area and impaired production in the sinusoidal/postsinusoidal area. 
Decreased vascular resistance in the presinusoidal area of the liver is caused by 
increased concentrations of NO and adenosine. In case of portal hypertension 
however NO is not produced in the presinusoidal system and its production is 
disturbed or substantially decreased in the sinusoidoidal/postsinusoidal area 
(Watanabe 2007, Zipprich 2007).  Thus altered vascular vasoreactivity is considered 
an important pathogenetic factor of portal hypertension which produces 
vasoconstriction or vasodilation which causes increased vascular resistance, 
hyperkinetic circulation and formation of collateral portal circulation (Shah 2007) 
 
The principal factor influencing the clinical significance of portal hypertension and 
determining the development of complications is an increase in portal pressure 
above a critical threshold value.  The threshold pressure for the development of 
varices in alcoholic cirrhosis is 12 mmHg (Garcia–Tsao 2008) while variceal bleeding 





2.4   THE PATHOGENESIS OF VARICEAL BLEEDING 
The pathogenesis of variceal rupture is related to the consequence of several 
physical factors within the wall of the varix. Portal pressure, variceal size, and 
epithelial thickness contribute to the likelihood of variceal rupture as related by the 
law of Laplace.  According to Frank’s modification of Laplace’s Law, variceal wall 
tension is directly proportional to the transmural variceal pressure (the gradient 
between intravariceal and oesophageal luminal pressures) and the radius of the 
varix, and inversely proportional to the thickness of the variceal wall (Bosch 2003b).  
While variceal size is a function of variceal radius, red weal marks may represent 
areas of reduced wall thickness.  Hepatic venous pressure gradient (HVPG) may 
constitute a good surrogate marker of transmural variceal pressure (Escorsell 2000, 
Bosch 2003a, Cichoz-Lach 2008).  Cross-sectional and longitudinal studies 
demonstrate that variceal bleeding does not occur if HVPG remains below 12 mmHg 
(Feu 1995, Vorobioff 1996, Escorsell 2000).  The risk of bleeding is independently 
associated with variceal size.  Physical appearance also predicts bleeding, including 
the endoscopic variceal stigmata including, cherry red spots, haemocystic spots and 
diffuse erythema. 
  
When cirrhosis is first diagnosed, varices are present in 40% of patients with 
compensated cirrhosis and in 60% of patients with ascites.  (de Franchis 2007).   
After the initial diagnosis of cirrhosis, about 5% of patients develop new varices per 
year.  (D’Amico 2006).   Once developed, varices increase in size from small to large 
at a rate of 10-15% per year (Garcia-Pagan 2008). Progression of liver failure has 





improvement in liver function and abstinence from alcohol may result in decrease in 
size of varices (Villanueva 2008a).    
 
Once varices are present, the incidence of variceal bleeding is about 25% at 2 years 
in non-selected patients (de Franchis 2007).  The most important predictive factors 
related to the risk of variceal bleeding are variceal size, presence of variceal 
endoscopic stigmata, and the severity of liver dysfunction as expressed by 
components of the Child-Pugh classification (Villanueva 2008b).  Variceal size is the 
best predictor of variceal bleeding, and this is the variable used to decide whether a 
patient should receive prophylactic beta blockers or not (Sharara 2001).  The risk of 
variceal bleeding is approximately 7% at 2 years in patients with small varices (<5 
mm), and increases to 30% at 2 years in patients with large varices (de Franchis 
2007).  Variceal size and red colour signs are associated with an increased risk of 
bleeding because both contribute to an increase in the tension of the wall of the 
varices, the decisive factor determining variceal rupture (Bosch 2003a). 
 
It has been reported that 30% of cirrhotic patients with an acute variceal bleeding 
episode die within 6 weeks (Bosch 2003b), but it is likely that this figure 
overestimates the current mortality from variceal bleeding (Garcia-Tsao 2008).  A 
more accurate current figure would be a mortality of 20% at 6 weeks (de Franchis 
2007).  Immediate mortality from uncontrolled bleeding is in the range of 5-8% 
(D’Amico 2006). 
 
Active bleeding at endoscopy (Ben Ari 1999), bacterial infection (Goulis 1998) and 





prognostic indicators of failure to control bleeding.  It is important to emphasize that 
variceal bleeding stops spontaneously in 40-50% of patients (de Franchis 2007).  
This is probably influenced by the fact that hypovolemia leads to reflex splanchnic 
vasoconstriction with reduced portal pressure and blood flow, a beneficial response 
that is nullified by blood transfusion (Kravetz 2007).  The incidence of early 
rebleeding ranges between 30 and 40% within the first 6 weeks.  (Krige 2009a).   
The risk peaks in the first 5 days with 40% of all rebleeding episodes occurring in this 
early period (de Franchis 2007).  Bleeding gastric varices, active bleeding at 
emergency endoscopy, low serum albumin levels, renal failure and HVPG > 20 
mmHg have been reported as significant indicators of early rebleeding risk 
(Thomopoulos 2006).  Early rebleeding (Ben Ari 1999) and renal failure (Cardenas 
2001) are important prognostic factors for 6-week mortality, suggesting that their 
prevention should be a primary objective in the therapeutic approach to variceal 
bleeding.     
 
Patients surviving a first episode of variceal bleeding have a high risk of rebleeding 
and death.  The median rebleeding incidence within 1-2 years in untreated controls 
of randomised controlled trials of non-surgical treatment for prevention of recurrent 
bleeding reported after 1981 is 63% and the corresponding mortality figure is 33% 
(D’Amico 2006).  Because of these high risks, all patients surviving a variceal 
bleeding should be treated for prevention of rebleeding independent of other risk 
indicators).  Risk accepted indicators of rebleeding and death are variceal size, 






2.5 INJECTION SCLEROTHERAPY OF OESOPHAGEAL VARICES 
  
Technique of injection 
              2.5.1      Intravariceal injection 
 2.5.2      Paravariceal injection 
   2.5.3      Combined intravariceal and paravariceal injection 
 2.5.4      Sclerosing agents  
 2.5.5      Endpoints of therapy 
 
 
Variceal bleeding usually occurs from the lower 5cm of the oesophagus (Park 2008).  
Endoscopic injection sclerotherapy (EIS) of oesophageal varices is designed to 
control acute variceal bleeding and prevent subsequent bleeding by thrombosing the 
varices or thickening the mucosa overlying the varices (Krige 2005).  Unlike the 
operations used in the treatment of portal hypertension which are specific and 
standardised, sclerotherapy is performed with different protocols using variable 
frequencies of injections and endoscopic review.  A considerable number of 
variables influence the success of endoscopic intervention of bleeding oesophageal 
varices.  Several variables are patient dependent and include the cause of portal 
hypertension, underlying hepatic reserve, hepatic haemodynamics, variceal size and 
the magnitude and effects of variceal bleeding on liver decompensation.  In addition, 
several technical variables may affect the outcome of any individual sclerotherapy 
session or clinical trial (Krige 1999).  These variables include the type and 
concentration of the sclerosant solution, the injection site, injection volume and 
frequency of injections. Despite the widespread popularity of the procedure for 
control of acute variceal bleeding, sclerotherapy technique remains, to a great 
extent, empiric and individualized (Krige 2000b).  Several basic issues of 





that controlled trials comparing sclerotherapy with other specific therapies, including 
variceal ligation, have yielded conflicting results (Krige 2005). 
 
A variety of sclerosants with different mechanisms of action and varying complication 
rates have been used (Krige 2000b, Krige 2005).  Tetradecyl sodium (1-3% 
solution), sodium morrhuate (5% solution) and ethanolamine oleate (5% solution) 
have been the most commonly used sclerosant agents in the USA (Krige 2007b).  
Outside North America, 5% ethanolamine oleate and 1% polidocanol have been 
used; polidocanol has been used predominantly for paravariceal injections (Park 
2008).  The ideal sclerosant and the best route of administration have yet to be 
defined, although the few controlled trials available favour ethanolamine oleate for 
intravariceal and combined therapy. In addition to sclerosants, two types of tissue 
adhesives, histoacryl and bucrylate have been used to treat variceal bleeding (Krige 
2005). These tissue adhesives have proved effective in the control of variceal 
bleeding with a 90% success rate (Park 2008). 
 
Injection sclerotherapy techniques 
Three different endoscopic techniques are used for injection sclerotherapy (Figure 
2.5.1). Bleeding from oesophageal varices may be controlled by injecting the 
sclerosant directly into the variceal channel (i.e. intravariceal method), into the 
submucosa adjacent to or overlying the variceal column (i.e. paravariceal method), 
or a combination of both. Intravariceal injection is favoured by most endoscopists in 
the United States. Usually 1 to 5 ml of sclerosant, depending on the size of the varix, 
is injected directly into the variceal lumen immediately above the gastroesophageal 





the varix is large. The goal of this technique is thrombosis of the varix and eventual 
obliteration of all channels in the distal 5 cm of the oesophagus.  
 
 
A    B    C 
Figure 2.5.1  Technical variants of injection sclerotherapy.  A: Intravariceal injection 
   B: Paravariceal or submucosal injection.  C: Combined intravariceal 
   and paravariceal injections (Krige 2007a) 
 
The paravariceal technique, which has been widely used in Europe, is performed by 
placing multiple injections using 0.5 to 1.5 ml of 0.5% or 1% polidocanol at each site 
beside the varices, commencing at the oesophagogastric junction, and proceeding 
upwards in a helical fashion, raising a wheal at each injection site. The theory is that 
paravariceal injection produces oedema of the submucosa to stop acute variceal 
bleeding and provokes fibrogenesis which subsequently causes thickening of the 
submucosa with a protective fibrous cover to sheath the varices and prevent 
bleeding while preserving the underlying varices as collateral channels. Both 





endoscopy departments, including the unit in Cape Town, use a combination of 
these two techniques (Krige 2007a).  
 
Most endoscopists perform sclerotherapy as described above using no special 
equipment other than the endoscope and injector needle (‘freehand technique’). A 
variety of ancillary devices including flexible endoscopic overtubes and balloons 
have been used in the past to improve the visibility and accuracy of sclerosant 
injection. In general, such devices have not produced results superior to freehand 
injection for control of acute bleeding, nor has the routine use of postsclerotherapy 
balloon tamponade been shown to improve outcome for treatment of active bleeding. 
With few exceptions, sclerotherapy is performed using a fibre-optic endoscope and a 
freehand technique without an oversheath.  
  
The Cape Town endoscopy unit protocol advises a combined para- and intravariceal 
technique for the management of acute variceal bleeding and utilizes a 
predominantly intravariceal technique for long-term management when varices are 
small (Krige 2007a). The Cape Town endoscopy unit sclerosant of choice is 5% 
ethanolamine oleate. In most endoscopy units, injection treatments are continued at 
weekly intervals until the varices have been eradicated. Thereafter, the patient is 
assessed with surveillance endoscopy at 3 months and then at 6-monthly intervals. 
Whenever recurrent varices are found, a repeat course of weekly sclerotherapy is 
undertaken until re-eradication is achieved (Krige 2006b).  
 
Trained assistants are essential and adequate resuscitative facilities must be 





anesthesia.  Either an end-viewing or side-viewing instrument can be used.  The 
end-viewing instrument is more versatile for both diagnosis and therapy, although 
the oblique-viewing instrument has the advantage of better visualization of the 
greater and lesser curves of the stomach, while the built-in forceps elevator helps to 
aim the injector, particularly for small varices during elective sclerotherapy.  Several 
disposable sclerotherapy injectors with retractable needles within a Teflon coated 
plastic sheath are commercially available and are preferable to the flexible, reusable, 
metal injectors. Injectors have either a 23- or 25-gauge needle attached.  The larger 
needle is preferred because this facilitates injection of the viscous sclerosant solution 
(Krige 1994). 
 
Stuporous or comatose patients must have the airway protected by prior 
endotracheal intubation. If the patient has a balloon tube in situ, the balloons are 
deflated and the tube removed only when the endoscopy staff is ready to begin 
endoscopy and variceal sclerotherapy or ligation.  Once the bleeding varix has been 
controlled, the remaining varices are injected or banded and the diagnostic 
endoscopy completed. 
 
Elective sclerotherapy technique 
Elective sclerotherapy is performed in the endoscopy clinic where two assistants 
who are trained in endoscopy techniques are available. One assistant reassures the 
patient, provides suction of the patient’s mouth to avoid aspiration, and ensures that 
the bite guard is not dislodged. The other nurse assistant advances and retracts the 
injector needle and administers the sclerosant under the direction of the endoscopist. 





the head on a pillow and the neck slightly flexed.  The pharynx and posterior tongue 
are anesthetized with 10% Xylocaine topical spray.  A small butterfly needle is 
inserted into a superficial hand vein for administration of sedation.  The Cape Town 
unit uses small incremental doses of midazolam up to 5 mg.  All the instruments 
including the endoscope are checked prior to use, and commands such as ‘advance 
needle’ and ‘retract needle’ are rehearsed if an inexperienced assistant is present.  
Each time an injection is required, this is called for by the endoscopist and 
acknowledged by the assistant.  The assistant is instructed to comment if resistance 
is encountered during injection because this may indicate that the varix is 
thrombosed or that the needle is not correctly positioned (Krige 1994, Krige 2007). 
 
The endoscope is inserted through the mouthguard and passed through the 
cricopharynx into the oesophagus.  Small amounts of air are insufflated intermittently 
to maintain sufficient distention of the lumen for adequate visibility.  Mucus and fluid 
are removed through the suction channel and the lens cleared with a water jet when 
necessary.  The entire oesophagus is examined and the presence of oesophageal 
varices noted.  The number, size and extent of varices and the presence of 
endoscopic variceal stigmata (cherry red spots and red wheal marks) are 
documented.  During elective endoscopy, the varices are usually not bleeding and a 
full diagnostic panendoscopy is performed to exclude other lesions before injecting 
the varices.  The presence and extent of gastric varices and portal hypertensive 
gastropathy are noted and documented (Krige 2007a). 
 
On completion of the panendoscopy, the endoscope is partially withdrawn into the 





varices in the lower 5 cm of the oesophagus can be injected.  The endoscope tip is 
manoeuvred into position and the target varix identified.  The endoscopist then 
passes the injecting catheter through the biopsy channel into the field of view and 
the tip of the catheter is positioned 2 cm beyond the end of the endoscope. To 
prevent the needle damaging the injector sheath or the endoscope channel, the 
injecting catheter is only passed when the endoscope tip is in a non-flexed position. 
The needle should remain in the retracted position until the tip of the injecting 
catheter has passed through the endoscope and is visible to the endoscopist.  All 
movements and manipulations of the injector are performed only by the endoscopist.  
A practice aiming pass of the catheter, with the needle retracted within the sheath 
before the first injection, is useful to determine the precise direction of the advancing 
needle in relation to the target varix.  The assistant advances the needle on 
instruction, and a small volume of sclerosant solution is discarded into the lumen of 
the oesophagus to ensure that the injecting catheter is filled with sclerosant and that 
residual air has been expelled.  The endoscopist inserts the needle directly into the 
centre of the most prominent part of the varix, near to the oesophagogastric junction, 
by advancing the injector a further 5 mm.  Once the needle has been satisfactorily 
placed within the lumen of the varix, the assistant is instructed to inject 1ml of 
sclerosant (Fig. 5.2.2).  If this is achieved without resistance, further sclerosant is 
placed within the lumen of the varix, the assistant is instructed to inject 1 ml of 
injected under instruction.  The varix should be seen to blanch and distend above 
and below the injection site.  A total volume of no more than 5 ml of ethanolamine 
oleate is usually sufficient for a large varix.  Smaller varices require less sclerosant. 





is placed 2–3 cm higher in large varices. Usually, only 2–3 ml of sclerosant is 
injected into the upper site (Krige 1994, Krige 2007a). 
 
 
Figure 2.5.2  Intravariceal injection technique (Krige 2007a). 
 
Accurate positioning and placement of the needle is critical to achieve effective and 
accurate delivery of sclerosant and to avoid complications which may follow incorrect 
injection.  A flat angle for needle insertion is preferable and avoids a deep injection: a 
perpendicular approach may transfix the varix and penetrate the underlying 
esophageal wall, resulting in an intramural injection of sclerosant. In this situation 
increased resistance to injection will be noted by the assistant and no blanching or 
distention of the varix will occur.  The needle should be withdrawn and a further 
injection performed after accurate placement of the needle.  Only the needle should 
enter the varix.  Care must be taken to ensure that neither the needle hub nor the 
injecting sheath are inadvertently pushed through the variceal wall as this will leave a 





made to inject the varices while the patient is restless or heaving.  Uncontrolled 
injections may result in laceration of the varix by the needle with resultant major 
bleeding (Krige 2007a).  After the procedure, the patient is observed in the 
endoscopy suite recovery room until fully awake and then discharged home in the 
care of a family member or friend.  It is unusual for bleeding to complicate an elective 
sclerotherapy session.  Subsequent sclerotherapy injections are performed at weekly 
intervals until all the varices have been eradicated.  Severe local oesophageal 
mucosal ulceration may delay injection of a specific underlying varix, but the other 
variceal channels can be injected.  Once varices have been eradicated, a further 
endoscopic assessment is performed at 3 months to confirm eradication.  Further 
evaluations are performed 6-monthly or annually for life.  If recurrent varices are 
noted during surveillance endoscopy, these are injected and repeat endoscopy and 
injections are performed at weekly intervals until the varices have been re-eradicated 
(Krige 2000b). 
 
Emergency sclerotherapy technique 
The emergency resuscitative measures required are presented in chapter 3.  The 
patient should be as stable as possible before commencing sclerotherapy.  The 
procedure is performed in a specially equipped endoscopy suite.  If the patient is 
obtunded or severely encephalopathic, an endotracheal tube will have been inserted.  
Severely ill patients should have the injection treatment performed in the intensive 
care unit. When major bleeding has occurred, the endoscopy is performed in the 
operating room where full resuscitative facilities, appropriate monitoring, intubation 






The patient is placed in the left lateral decubitus position, as for elective 
sclerotherapy.  However, if active bleeding is present and visibility is obscured, the 
table head is elevated to 30º to improve visualization.  The lower oesophagus is 
flushed with saline through the irrigation channel and residual blood and fluid 
aspirated through the suction channel.  Further insufflation usually provides 
adequate visualization to perform the first injection. 
 
Intravariceal Injection 
Active variceal bleeding is immediately dealt with by controlling the bleed with 
intravariceal sclerotherapy.  Urgent control of bleeding with accurate placement of 
the needle and sclerosant injection should be performed without delay while there is 
adequate visibility.  No attempt should be made to insert the needle into the bleeding 
point, because this may enlarge the hole and aggravate bleeding with extravasation 
and loss of sclerosant.  A technique similar to elective intravariceal sclerotherapy is 
used with needle insertion immediately proximal to the bleeding site (Fig. 5.2.3).  A 
total volume of 5 ml of sclerosant is usually sufficient.  Distention and blanching of 
the varix indicate that the needle is in the correct position and that the appropriate 
volume of sclerosant has been injected.  After the bleeding has been controlled, the 
remaining variceal channels are sclerosed.  A second series of injections is usually 
performed at a higher level.  Panendoscopy is undertaken on completion of 
sclerotherapy to exclude other mucosal lesions (Krige 1996).  
 
Combined paravariceal and intravariceal injection technique 
The Cape Town endoscopy unit recommends this technique to control active 





position and 5% ethanolamine oleate injected proximal to the bleeding point to  
 
 
Figure 2.5.3 Emergency sclerotherapy: intravariceal injection technique (Krige 
2007a). 
 
compress the bleeding site by raising a wheal (Fig. 5.2.4).  Sufficient sclerosant is 
injected to control the bleeding.  If this does not completely control the acute 
bleeding, the paravariceal injection is repeated alongside the bleeding point.  The 
procedure is completed by injecting the varix intravariceally (Fig.5.2.4).  The volume 
injected paravariceally should not exceed 1 ml at each site to avoid ulceration of 
mucosa. The remaining variceal channels are then sclerosed.  If variceal bleeding is 
profuse, vigorous lavage through the endoscope channel and elevation of the head 
of the table to 30º usually improves visibility and allows identification of the bleeding 
site. No blind attempts at injection should be used.  If immediate sclerotherapy 
cannot be performed because of lack of expertise or inadequate visibility, bleeding 
should first be controlled by balloon tube tamponade before the patient has further 






A    B    C 
Figure 2.5.4  Emergency sclerotherapy: combined paravariceal and intravariceal  
  injection technique.  A:  The initial paravariceal injection proximal to the 
  bleeding point.  B: Bleeding is controlled by the paravariceal  
  submucosal injection.  C: An intravariceal injections completes the  
  procedure (Krige 2007a). 
 
Most patients (70%) respond to a single injection treatment and have no further 
bleeds.  If bleeding does recur, intravenous octreotide or somatostatin is 
recommenced and the patient is re-endoscoped.  Further bleeding varices are 
treated as before.  If bleeding results from an injection site oesophageal ulcer, the 
intravenous octreotide or somatostatin infusion is continued and oral sucralfate 
administered.  The success rate of a single injection treatment is 70%. Some 30% of 
patients will have a further bleed and require an additional injection treatment.  Two 
injection treatments usually control variceal bleeding in over 95% of patients.  
Subsequently, repeated sclerotherapy sessions are undertaken at weekly intervals 






If further bleeding occurs after two injection treatments during a single hospital 
admission, this is defined as failure of emergency endoscopic therapy and the 
patient should have a Sengstaken balloon tube inserted.  After resuscitation the 






2.6   COMPARATIVE STUDIES IN ACUTE VARICEAL BLEEDING  
 
2.6.1. Sclerotherapy compared to vasoconstrictors in acute bleeding varices   
 
Two major classes of vasoactive drugs, vasopressin and somatostatin, have been 
used to treat acute variceal bleeding. These drugs exert their effects either by 
reducing inflow of portal blood or by diminishing intrahepatic or collateral resistance.  
Varices are unlikely to bleed when portal venous pressure is below 12 mm Hg.  
Vasopressin is a potent but non-selective vasoconstrictor. Its use, however, is 
hampered by frequent and serious systemic vasoconstrictive side effects, especially 
in patients who have cardiac ischaemia and peripheral vascular disease.  
Consequently the role of vasopressin has declined appreciably since the introduction 
of newer and safer drugs.  Terlipressin (triglycyl lysine vasopressin), a vasopressin 
analogue which has replaced the original vasopressin, undergoes cleavage of the 
glycyl residue after administration to allow the slow release of lysine vasopressin 
which does not have the deleterious cardiac side effects of vasopressin (Villanueva 
2008).  Somatostatin and its long-acting analogues, octreotide and vapreotide, are 
increasingly being used in the management of active variceal bleeding because both 
have selective vasoconstrictive effects on the splanchnic circulation and inhibit the 
production of the vasodilator, glucagon (Dell’Era 2008). 
 
The efficacy of emergency endoscopic injection sclerotherapy in patients with 
acutely bleeding oesophageal varices has been compared with vasoactive drugs in 
15 randomised controlled trials and assessed in a Cochrane meta-analysis (D'Amico 
2003)  The authors performed a meta-analysis comparing emergency sclerotherapy 





2002), and the Cochrane Library (2002) to retrieve randomised controlled trials 
comparing sclerotherapy with vasopressin (+/-nitroglycerin), terlipressin, 
somatostatin, or octreotide for variceal bleeding in cirrhosis.  Two independent 
reviewers identified eligible trials and extracted data. Outcome measures were 
failure to control bleeding, five-day treatment failure, rebleeding before other elective 
treatments, 42-day rebleeding, mortality before other elective treatments, 42-day 
mortality, number of blood transfusions, and adverse events. Data were analysed by 
a random effects model according to the vasoactive treatment. Sensitivity analyses 
included combined analysis of all the trials irrespective of the vasoactive drug, fixed 
effects model analyses, type of publication, methodological quality, and adequacy of 
generation of the randomisation list and of allocation concealment.  
 
Fifteen trials were identified.  Sclerotherapy was not superior to terlipressin, 
somatostatin, or octreotide for any outcome and to vasopressin for rebleeding, blood 
transfusions, death, and adverse events; it was superior to vasopressin for the 
control of bleeding in a single trial flawed by a potential detection bias.  
Sclerotherapy was associated with significantly more adverse events than 
somatostatin. In a predefined sensitivity analysis, combining all of the trials 
irrespective of the control treatment, risk differences (sclerotherapy minus control) 
and confidence intervals (CIs) were as follows: failure to control bleeding, -0.03 (-
0.06 to 0.01); mortality, -0.035 (-0.07 to 0.008); adverse events, 0.08 (0.02 to 0.14). 
Mortality risk difference was -0.01 (-0.07 to 0.04) in good-quality trials and -0.08 (-
0.14 to -0.02) in poor-quality trials.  The authors concluded that available evidence 
did not support emergency sclerotherapy as a single first-line treatment of variceal 





83% of patients and suggested that endoscopic therapy might be added in 
pharmacologic treatment failures. 
 
A further meta-analysis from the group at the Royal Free Hospital, London, had a 
different conclusion (Triantos 2006).  Their meta-analysis was performed to evaluate 
whether sclerotherapy remains a gold standard in acute variceal bleeding. 
Sclerotherapy was evaluated across four randomised trial groups: (a) combined with 
vasoconstrictors compared to vasoconstrictors alone (five trials with 400 patients); 
(b) compared to vasoconstrictors alone (15 trials with 1296 patients); (c) compared 
to a combination of vasoconstrictors and sclerotherapy (eight trials with 1026 
patients); (d) compared to endoscopic variceal ligation (12 trials with 1309 patients). 
The authors used the risk difference (absolute risk reduction) as their main effect 
measure. The efficacy of acute sclerotherapy was highest compared to ligation at 
95% with a small advantage for ligation (an overtube was used in eight trials) of 
2.5% (95% CI 0.4% to 4.6%) (p=0.018), but no survival difference. Efficacy of 
sclerotherapy combined with vasoconstrictors compared to vasoconstrictors alone 
was 86%, whereas it was 83% for sclerotherapy compared to vasoconstrictors alone. 
In both these groups sclerotherapy was superior for control of bleeding at, 
respectively, 16.3% (95% CI 8.7% to 23.9% (p<0.0001) and 5.9% (95% CI, 1.5% to 
10.3%) (p<0.008) with increased survival in the latter.  In the combination group of 
sclerotherapy with vasoconstrictors, the efficacy of sclerotherapy alone was 69%, 
with the combination superior in controlling bleeding, at 13.2% (95% CI, 8.4% to 
18.1%) (p<0.0001) but with no survival difference.  The authors concluded that the 
comparison of sclerotherapy across trials demonstrated a problem in defining its real 





combination of vasoconstrictors with sclerotherapy as better therapeutic approaches 
has not been provided in randomised trials.  Sclerotherapy remains a gold standard 
in variceal bleeding but there is scope for further studies of ligation and vasoactive 
drugs. 
 
In a meta-analysis which combined data from 13 randomised trials, octreotide 
demonstrated improved control of acute oesophageal variceal bleeding compared to 
all the alternative therapies combined (relative risk [RR], 0.63; 95% confidence 
interval [CI], 0.51-0.77); vasopressin or terlipressin (RR, 0.58; 95% CI, 0.42-0.81) or 
no additional intervention or placebo (among patients who received initial 
sclerotherapy or banding before randomisation) (RR, 0.46; 95% CI, 0.32-0.67) 
(Corley 2001). Octreotide had comparable efficacy to immediate sclerotherapy for 
control of bleeding (RR, 0.94; 95% CI, 0.55-1.62), fewer major complications than 
vasopressin or terlipessin (RR, 0.31; 95% CI, 0.11-0.87), and a complication profile 
comparable to no intervention or placebo (RR, 1.06; 95% CI, 0.72-1.55). No specific 
alternative therapy demonstrated a mortality benefit. The authors of the meta-
analysis concluded that the effects of octreotide were comparable to immediate 
injection sclerotherapy with fewer major complications and that further trials were 
required to determine the optimal dose, route, and duration of octreotide treatment  
(Corley 2001). 
 
Because endoscopic therapy and vasoactive drugs are both effective in controlling 
acute variceal bleeding and preventing recurrent variceal bleeding, it seemed logical 
to combine injection sclerotherapy with vasoactive drugs in order to achieve an 





drugs would improve the efficacy of endoscopic therapy (injection sclerosis or band 
ligation) in the control of acute variceal bleeding and thus increase survival rates. 
(Bañares 2002). In this meta-analysis computer databases and scientific meeting 
abstracts from 1994 to 2001 were used to search for randomised trials that 
compared the combined use of endoscopic and drug therapy with endoscopic 
therapy alone in the control of acute variceal bleeding. Eight trials involving 939 
patients fulfilled the selection criteria and the following criteria were evaluated by 
standard meta-analysis methods: initial haemostasis, 5-day haemostasis, 5-day 
mortality, and adverse events. Combined treatment improved initial control of 
bleeding (relative risk [RR], 1.12; 95% confidence interval (CI), 1.02-1.23), and 5-day 
haemostasis (RR, 1.28; 95% CI, 1.18-1.39), with numbers of patients needed to treat 
(NNT) of 8 and 5, respectively. The difference in favour of combined treatment 
remained significant when trials that used drugs other than octreotide or that 
included a low proportion of alcoholic patients (<40%) or high-risk cirrhotic patients 
(<35%) were excluded. Mortality was not significantly decreased by combined 
therapy (RR, 0.73; 95% CI, 0.45-1.18). Severe adverse events were similar in both 
groups.  The authors concluded that in patients with acute variceal bleeding, 
pharmacologic agents improve the efficacy of endoscopic therapy to achieve initial 
control of bleeding and 5-day haemostasis, yet fail to affect mortality (Bañares 2002). 
 
2.6.2 Sclerotherapy compared to surgery 
Four prospective randomised trials conducted in San Francisco, Durban, London 
and Barcelona have compared injection sclerotherapy with either portacaval shunt 






2.6.2.1 Sclerotherapy compared to portacaval shunt  
In a study from San Francisco, 52 patients who had severe cirrhosis and scored 
Child grade C and had variceal bleeding requiring six or more units of blood were 
randomly assigned to either injection sclerotherapy or portacaval shunt surgery 
(Cello 1982).  Of 38 pretreatment characteristics, only the frequency of active 
alcoholism differed significantly between the groups. During the initial hospitalization, 
the patients in the shunt group required significantly more blood (21.5 +/- 3.1 units) 
than did those in the sclerotherapy group (12.3 +/- 1.3 units), although the latter had 
significantly more rebleeding during hospitalisation after the procedure (14 of 28 vs 5 
of 24 patients). There was no difference in short-term survival, with 13 patients in the 
sclerotherapy group discharged alive, compared to 10 patients in the shunt group. 
Patients were followed for a mean of 263 days after the initial discharge (range: 8 to 
1117 days). The sclerotherapy group required significantly more days of 
hospitalisation for rebleeding, but the study failed to demonstrate any significant 
difference in long-term survival between the sclerotherapy and shunt groups. Total 
health-care costs per patient were significantly higher for the shunt group (+23,957 
+/- +3,111) than for the sclerotherapy group (+15,364 +/- +2,220). The authors 
concluded that sclerotherapy was less costly than portacaval shunt and as effective 
for the treatment of bleeding oesophageal varices due to portal hypertension 
secondary to severe cirrhosis. 
 
2.6.2.2 Sclerotherapy compared to oesophageal transection 
Three prospective randomised controlled trials conducted in Durban, London and 
Barcelona compared injection sclerotherapy with oesophageal transection in patients 






In the prospective randomised trial from Durban, 76 high risk patients (Child-Pugh 
grade B and C) with bleeding oesophageal varices were evaluated and randomised 
to either transection of the lower oesophagus using an EEA autosuture stapling 
device or emergency injection sclerotherapy (Huizinga 1985). Thirty-nine patients 
underwent oesophageal transection and 37 patients were randomised to 
sclerotherapy and underwent a total of 92 injection procedures (2.4 per patient). The 
overall perioperative mortality (<30 days) was 29%.  The perioperative mortality was 
34% in the group of patients who had an oesophageal transection and 24% in those 
who had injection sclerotherapy (x2 = 0.375, p>0.05). Gross ascites, severe 
encephalopathy and emergency operations were associated with a high mortality in 
the transection group.  Other risk factors such as age and hypersplenism did not 
influence the outcome in either group. Only patients in Child-Pugh class C died after 
oesophageal transection, but patients who died in the sclerotherapy group (mainly 
from recurrent bleeding) included patients from both Child-Pugh class B and C. Early 
recurrence of nonfatal variceal bleeding occurred in one of 39 patients (2.5%) after 
oesophageal transection but was evident in 18 of 37 patients (49%) after 
sclerotherapy (x2=19.12, p<0.0005), six of whom died. Bleeding did not recur after 
oesophageal transection during a follow-up period of two years, but a further 22 
bleeding episodes occurred in 13 patients receiving sclerotherapy of whom 5 died. 
Postoperative complications and long term morbidity were similar in the two groups. 
Including readmissions for bleeding and repeat procedures, the mean hospital stay 
per patient was shorter for oesophageal transection (14.5 vs 19.1 days) and the 
requirements for blood were less (1.9 units per patient vs 3.6 units per patient) than 





protected patients from short term recurrence of bleeding. Preoperative control of 
gross ascites further reduced the mortality and the authors recommended that 
comatose patients should be excluded from undergoing an operation. The authors 
stressed the problem of recurrent variceal bleeding which persisted until variceal 
eradication had been achieved in patients receiving injection sclerotherapy. 
 
In a clinical trial conducted in Barcelona, 70 consecutive cirrhotic patients with 
persistent or recurrent variceal bleeding were randomised to compare the efficacy 
and safety of portacaval shunt (PCS) and oesophageal transection (OT) in patients 
with low surgical risk, and oesophageal transection and endoscopic sclerotherapy 
(EIS) in patients with high surgical risk (Teres 1987). To classify the patients into 
low- and high-risk groups a new scoring system was used, based on an analysis of 
factors influencing operative mortality in an earlier series of emergency portacaval 
shunt. Thirty-eight low-risk patients were randomly allocated for treatment with 
portacaval shunt (19 patients) or stapler transection (19 patients), and 32 high-risk 
patients for stapler transection (17 patients) or EIS (15 patients). The operative 
mortality of patients treated by PCS was close to that expected according to 
retrospective data, indicating that the proposed scoring system was highly 
discriminant. In low-risk patients, portacaval shunt showed greater haemostatic 
efficacy and fewer complications than stapler transection. However, hepatic 
encephalopathy during follow-up was more frequent in the portacaval shunt group 
and there were no significant differences in operative mortality and long-term survival 
between the two groups. In high-risk patients, stapler transection and sclerotherapy 
had a similar haemostatic efficacy, operative mortality and long-term survival. 





authors recommended stapler transection for low-risk patients and sclerotherapy as 
an alternative for high-risk patients in the emergency treatment of uncontrolled 
variceal bleeding. 
 
In the trial conducted in London at the Royal Free Hospital, 101 patients with 
persistent variceal bleeding were randomised to receive either injection 
sclerotherapy (n=50) or transection of the lower oesophagus (n=51) using an EEA 
autosuture staple gun (Burroughs 1989). Patients were enrolled in the study if 
conservative medical treatment failed to control bleeding within 5 days of the index 
episode.  Four patients assigned to sclerotherapy and 12 assigned to staple 
transection did not undergo those procedures, but all analyses were made on an 
intention-to-treat basis. Total mortality did not differ significantly between the two 
groups; the relative risk of death for staple transection compared with sclerotherapy 
was 0.88 (95 percent confidence interval, 0.51 to 1.54). Mortality at six weeks was 
44% in those assigned to sclerotherapy and 35% in those assigned to staple 
transection. Complication rates were similar for the two groups. An interval of five 
days without bleeding was achieved in 88% of those assigned to staple transection 
and in 62% of those assigned to sclerotherapy after a single injection (p< 0.01) and 
82% after 3 injections. In only 2 of the 11 patients who received a third sclerotherapy 
injection was bleeding controlled for more than five days, and 9 died.    
 
At 6 and 12 months, there was no significant difference in survival.   The severity of 
encephalopathy, ascites, prolongation of prothrombin time, and balloon tamponade 
were independently associated with death at 6 weeks.    With surgical intervention, 





initiation of therapy. Sclerotherapy failed to control bleeding (three sessions) in nine 
patients, five of whom underwent oesophageal transection.    Although bleeding was 
controlled in all five, only one of these patients survived.  The authors concluded that 
staple transection of the oesophagus was as safe as sclerotherapy for the 
emergency treatment of bleeding oesophageal varices and recommended that 
surgical salvage should be used after two injection treatments have failed.     
 
These data support the efficacy of stapling transection of the oesophagus in the 
management of an episode of variceal bleeding.  Previous concerns that transection 
without devascularisation might be associated with a high rate of rebleeding remain 
largely unsubstantiated.  However, the beneficial effect of reduced rebleeding 
represents the only major advantage over injection sclerotherapy.  It should be 
stressed that in each of the studies the opportunity to do immediate sclerotherapy at 
the time of the presenting diagnostic endoscopy was missed in favour of an initial 
period of observation or vasoconstrictor therapy.  This, therefore, represents less 
than optimum use of injection sclerotherapy and is not standard practice in modern 
endoscopy units.  The possible adverse effect of previous abdominal surgery upon 
the outcome following liver transplantation applies to oesophageal transection, 
particularly if a devascularisation has been done.  The only role for transection of the 
oesophagus and gastric devascularisation in current practice is in patients with 
refractory variceal bleeding who are not suitable for a TIPS stent and who do not 






2.7 INJECTION SCLEROTHERAPY TO PREVENT RECURRENT 
 BLEEDING OF OESOPHAGEAL VARICES 
 
2.7.1   Sclerotherapy versus conservative treatment   
 
The role of emergency endoscopic injection sclerotherapy to control acute variceal 
bleeding and followed by repeated long term injection sclerotherapy to thrombose 
and eradicate residual oesophageal varices and thus prevent recurrent variceal 
bleeding has been investigated in eleven prospective randomised controlled trials 
(Barsoum 1982, Terblanche 1983, EVASP 1984, Westaby 1985, Soderlund 1985, 
Korula 1985, Burroughs 1985, Paquet 1985, Rossi 1991, Gregory 1994, Wu 2007)   
 
In a study from Cairo 100 patients with bleeding oesophageal varices were 
randomized into two treatment groups after resuscitation (Barsoum 1982). One 
group was managed by tamponade only (group 1); the other group (group 2) was 
treated by endoscopic injection of oesophageal varices. The patients in group 2 were 
further subdivided into 25 patients (group 2a), who had tamponade applied 
immediately after sclerotherapy, and 25 patients (group 2b), who had sclerotherapy 
without subsequent tamponade. Injection of varices controlled the acute bleeding 
episode more effectively than tamponade (74% in group 2 vs 42% in group 1). There 
was no significant difference in the overall mortality rate of the two groups, but group 
2 had a significantly higher proportion of Child's grade C patients (38/50 vs 29/50 = 
76% vs 58%). If only Child's grade C patients are considered, 16 of 29 (55%) died in 
group 1, whereas 12 of 38 (32%) died in group 2 (p<0.05). Tamponade applied after 
sclerotherapy had no demonstrable effect on the outcome of sclerotherapy. The long 





was less in the sclerotherapy group (8.1%) than in the tamponade only group 
(27.6%; p<0.05). 
 
In a landmark study published in the Lancet, the Cape Town group evaluated the 
long term role of sclerotherapy in the management of patients after oesophageal 
variceal bleeding by comparing repeated sclerotherapy using a rigid 
oesophagoscope in 37 patients with a control group of 38 patients who received 
conventional medical management (Terblanche 1983). Varices were eradicated in 
21 of 22 (95%) patients analysed in the sclerotherapy group, but recurred in 13 of 21 
patients at an average of 21.5 months. Varices persisted in 13 of 14 surviving control 
group patients. The sclerotherapy patients had fewer recurrent bleeds than control 
patients (43 versus 73) and most of the bleeds occurred before variceal eradication 
and were mild.  However, there was no difference in survival in the two groups. The 
commonest cause of death was liver failure which occurred in 37 patients. Thirty two 
complications occurred in 24 patients during 258 injections. Repeated sclerotherapy 
failed to improve survival in this trial, although varices were eradicated and recurrent 
variceal bleeds were prevented with adequate follow-up. An important consideration 
in the methodology of the study was that the control group received acute injection 
sclerotherapy whenever further variceal bleeding occurred. This trial therefore in 
reality compared acute control of variceal bleeding followed by repeated 
sclerotherapy to eradicate varices with sclerotherapy “on demand” whenever variceal 
rebleeding occurred.  
In a prospective randomised multicentre trial conducted by the members of the 
Copenhagen oesophageal varices sclerotherapy project in Denmark, 187 





assigned to medical treatment including balloon tamponade or to medical treatment 
supplemented with intensive, paravariceal sclerotherapy (EVASP 1984). Follow-up 
period ranged from 9 to 52 months. The overall mortality in the sclerotherapy group 
(hazard) was 76% (95% confidence limits, 54-107%) of that in the medical-regimen 
group. The relative mortality in the sclerotherapy group, determined by stratifying 
according to degree of encephalopathy and ascites, was 63% of that in the medical-
regimen group (95% confidence limits, 44-91%). The main effect of sclerotherapy 
may be a reduction of long-term mortality, which after day 40 was only 43% (95% 
confidence limits, 23-79%) of that in the medical-regimen group. Sclerotherapy had 
no significant influence on the initial haemorrhage as judged from the duration of 
bleeding or of balloon tamponade, the number of blood transfusions needed, or 
immediate mortality. Forty-five patients in the sclerotherapy group had 64 episodes 
of recurrent bleeding, as compared with 138 episodes among 51 patients in the 
medical-regimen group. This difference was due to a pronounced reduction of 
rebleeding after day 40 in the sclerotherapy group. The authors concluded by 
recommending sclerotherapy for patients with cirrhosis who have bled from 
oesophageal varices. 
 
In a prospective controlled trial conducted in Stockholm, 107 cirrhotic patients with 
major variceal bleeding were randomised to either a control group who received 
conservative therapy which included vasopressin and balloon tamponade or a 
treatment group who received endoscopic variceal injection sclerotherapy for acute 
bleeding and rebleeding. (Soderlund 1985).  Variceal eradication was achieved in 22 
variceal sclerotherapy patients in the first year after a median of 6 months and 5 





9 sclerotherapy sessions.  Eleven variceal sclerotherapy patients and 11 controls 
rebled on 30 and 45 occasions during a total follow-up time of 1364 and 696 months 
and 0.0220 and 0.0647 bleeds per patient-month, respectively (p = 0.098).  Eight 
variceal sclerotherapy patients experienced 12 variceal bleeds, 11 controls had 39 
bleeds due to varices, 0.0088 and 0.0560 bleeds per patient-month (p = 0.016), 
respectively.  Five variceal sclerotherapy patients had recurrent varices on nine 
occasions with five bleeding episodes at a median of 13 months after completion of 
the initial serial variceal sclerotherapy. Re-eradication was achieved with a median of 
three variceal sclerotherapy sessions during 3 months, but three patients had a 
second variceal recurrence 14-24 months later, successfully treated with one 
variceal sclerotherapy sessions.  There was no difference in survival (Soderlund 
1985). 
 
In a prospective randomised trial conducted in London, the group from Kings College 
Hospital randomised 107 patients with cirrhosis and variceal bleeding to receive 
either endoscopic injection sclerotherapy or conservative medical therapy 
(Macdougall 1982). In the sclerotherapy group 22 (43%) of the 51 patients had 
recurrent variceal bleeding while undergoing variceal sclerotherapy, but in only 4 did 
bleeding occur after the varices had been obliterated.  This contrasted with recurrent 
bleeding in 42 (75%) of the 56 patients receiving standard medical management 
which was a significant difference.  The overall risk of bleeding per patient-month of 
follow-up was reduced threefold with sclerotherapy. Of 22 patients followed up for 
one year after obliteration of varices, 14 had no evidence of recurrent varices and, by 






In a subsequent analysis the same group published the long-term results of the 
earlier report published in the Lancet (Westaby 1985). The 116 patients (56 
sclerotherapy, 60 control group) entered into the completed controlled trial of 
endoscopic variceal sclerotherapy (median follow-up: 37 months; range: 19 to 68 
months) showed a total of 18 deaths in the sclerotherapy group, including five from 
variceal bleeding compared with 32 deaths in the control group (p<0.01), of whom 25 
were due to variceal bleeding (p<0.001). Survival as assessed by cumulative life 
analysis was significantly better in those treated by sclerotherapy (p<0.001). Both the 
cumulative proportion of patients rebleeding and the total number of episodes of 
variceal bleeding were also significantly less in the sclerotherapy group (p<0.01). 
Recurrence of varices was observed in 27 of 45 patients in whom variceal 
obliteration was initially observed at a median of 11 months (range: 2 to 27 months) 
later, although in only 12 of whom did bleeding recur and caused the death in one 
(Westaby 1985). 
 
In a prospective, randomised controlled trial of chronic oesophageal variceal 
sclerotherapy conducted at the University of Southern California in Los Angeles over 
a 38-month period 120 patients were randomised after a variceal bleed.  Sixty three 
patients were randomised to endoscopic injection sclerotherapy and 57 to the control 
group (Korula 1985). Mean follow-up was similar in both groups (oesophageal 
variceal sclerotherapy, 12.5 +/- 8.8 months; control, 14.9 +/- 6.6 months). Twenty-
one percent of the patients in each group were lost to follow-up.  Oesophageal 
variceal sclerotherapy decreased rebleeding as evidenced by a decrease in the 
mean bleeding risk factor, transfusion requirement and by an increase in bleeding 





were especially significant after variceal obliteration. A high incidence of 
asymptomatic ulceration and low frequency of strictures were notable effects of the 
oesophageal variceal sclerotherapy. Cumulative life table analysis revealed no 
differences in survival between oesophageal variceal sclerotherapy and control 
groups. However, when patients who received portal-systemic shunt surgery 
(oesophageal variceal sclerotherapy, 6%; control, 28%) were removed from the 
analysis at the time the shunt surgery was performed (defining the shunt as an 
endpoint, a significant difference in survival (p<0.05) in favour of oesophageal 
variceal sclerotherapy was seen. 
 
In a prospective randomised controlled clinical trial performed at the Heinz Kalk 
Clinic in Bad Kissingen in West Germany 43 consecutive cirrhotic patients with 
endoscopically proven bleeding oesophageal varices were randomly selected to 
have either oesophageal tamponade with a Sengstaken-Blakemore tube (n=22), or 
endoscopic sclerotherapy of the oesophageal varices (n=21) (Paquet 1985). The two 
groups were similar in demographic, clinical and laboratory data. Bleeding was 
controlled with a Sengstaken-Blakemore tube in 16 of 22 patients (73%) and by 
endoscopic sclerotherapy in 20 of 21 (95%) patients. Among those controlled by the 
Sengstaken-Blakemore tube, seven (44%) rebled and three (43%) were again 
controlled by the Sengstaken-Blakemore tube; in the endoscopic sclerosis group, 
four (20%) rebled and three (75%) were controlled. Thus, bleeding was definitively 
controlled in 52% of patients and 66% of bleeding episodes in the Sengstaken-
Blakemore tube group and in 90% of patients and 92% of bleeding episodes in the 
endoscopic sclerotherapy group. The definite control of bleeding was significantly 





tube patients received no definitive therapy after bleeding had been controlled. 
Within 30 days, six patients (27%) in the Sengstaken-Blakemore tube group had 
died compared to 2 (10%) in the endoscopic sclerotherapy group which is 
statistically significant (p<0.01) in favour of endoscopic sclerotherapy. The frequency 
of complications was similar in the two groups. Endoscopic sclerotherapy patients 
received serial endoscopic sclerosis after bleeding had been stopped during the 
whole period of follow-up. After 6 months 11 patients in the Sengstaken-Blakemore 
tube group had died (55%) compared to 3 patients (16%) in the endoscopic 
sclerotherapy group.  Cumulative survival was statistically better in the endoscopic 
sclerotherapy group after 6 months (p<0.01) and after 3 years of follow-up (p<0.001).  
Survival was related to Child grade on admission.  This trial showed that endoscopic 
sclerotherapy was effective and superior to using a Sengstaken-Blakemore tube in 
stopping active bleeding from oesophageal varices and was significantly superior to 
using a Sengstaken-Blakemore tube in reducing short and long-term mortality 
(Paquet 1985). 
  
In a trial from the Royal Free Hospital in London, 206 cirrhotic patients with bleeding 
oesophageal varices were randomised to either weekly sclerotherapy (n=103) or no 
injection (n=103) during a 62 month period (Burroughs 1985).  The latter group were 
given sucralfate 1g qid.  A standard protocol was used to treat all bleeds and 
randomisation took place after a 5 day bleed-free interval from admission stratified 
by the initial treatment used.  Trial groups were matched for age, gender, aetiology 
of cirrhosis, previous bleeding, treatment variables at index bleed and Pugh’s grade 
A, B and C (sclerotherapy 35; 42; 26, sucralfate 22; 57; 24).  Separate episodes of 





regardless of severity or source.  Deaths occurred in 55 (53%) of sucralphate group 
and in 48 (47%) of the sclerotherapy patients (log rank test p = 0.49).  Oesophageal 
and gastric variceal rebleeding occurred in 59% in the sucralfate group versus 56% 
in sclerotherapy patients (log rank test P = 0.46).  Total number of variceal rebleeds 
were 183 in the sucralfate group and 130 in patients receiving sclerotherapy.  
However, a rebleeding index evaluating all sources and taking into account intervals 
without rebleeding was not significantly different.  In each trial group 3% of patients 
had liver transplants, 7% had shunts and 1% had a devascularisation operation.  The 
authors concluded that long-term sclerotherapy did not significantly benefit patients 
when emergency treatment for bleeding was kept constant.  The reduction in 
variceal bleeding episodes is marginal; 50 episodes for 100 patients treated over 5 
years (Burroughs 1985). 
 
A prospective randomised controlled study conducted in the Service d'Hépato-
Gastroentérologie, Centre Hospitalier Universitaire, Angers, France, evaluated the 
effectiveness of sclerotherapy compared to a control group in the prevention of 
variceal rebleeding in alcoholic cirrhotic patients (Rossi 1991).  In the 79 patients, the 
distribution according to Child-Pugh classification was: A, 22%; B, 40%; and C, 38%. 
Sclerotherapy was performed weekly using 1% polidocanol. End points were 
rebleeding or death. During the mean follow up of 19 +/- 16 months, 43 patients bled 
and 22 patients died.  The cumulative percentages of patients free of rebleeding at 1 
year were: sclerotherapy, 64% (95% CI: 45-82); control, 54% (95% CI: 36-71); these 
differences did not reach statistical significance. The cumulative percentages of 
patients alive at 1 year were: sclerotherapy, 79% (95% CI: 58-91); control, 81% 





withdrawal, which occurred in 66% of patients, was an independent predictive factor 
associated with a decreased risk of rebleeding or death.  
 
Sclerotherapy and sham-sclerotherapy were compared in male alcoholic patients 
with cirrhosis and bleeding oesophageal varices in a prospective, single-blind, 
randomised clinical trial which entered 253 patients at 12 Veterans Affairs Medical 
Centres (Gregory 1994).  Patients were either actively bleeding from oesophageal 
varices at randomisation or had a history of such bleeding. Patients were treated 
either by endoscopy with sham-sclerotherapy or endoscopy with sclerotherapy at 
randomisation, and then subsequently at 4 to 6 days, 9 to 11 days, 1 month, 3 
months and every 3 months for 2 years and followed for the remainder of the study 
period. Of the patients randomised, 131 were assigned to sham-therapy and 122 
were assigned to sclerotherapy.  At entry the two patient groups were comparable.  
The upper gastrointestinal rebleeding rates during the study were 101 and 66 per 
100 person years of follow-up in sham-therapy and sclerotherapy, respectively (RR, 
1.54; 95% CI, 1.06 to 2.22; p = 0.01). A significantly higher number of episodes were 
attributable to oesophageal varices in the sham-therapy group (112 vs 52; p = 
0.005). Seventy-four sham-therapy patients (56%) and 77 sclerotherapy patients 
(63%) died (p = 0.54; RR, 0.91; 95% CI, 0.66 to 1.25).  The mean transfusion 
requirement was higher in the sham-therapy group (16.0 units vs 9.4 units; p=0.002) 
and more patients in this group required shunt surgery (18 vs 5; p=0.005). The rate 
of recurrent bleeding, number of episodes of bleeding due to oesophageal varices, 
mean transfusion requirement, and need for shunt surgery were significantly higher 






In a study from Taipei, Taiwan, fifty patients with repeated bleeding from 
oesophageal varices were entered into a prospective randomised controlled trial (Wu 
2007).  Twenty five patients were randomised to a sclerotherapy arm and 25 patients 
to a control arm.  Thirty-seven of the 50 patients had postnecrotic cirrhosis and 13 
patients had primary hepatocellular carcinoma. A combined intra-variceal and para-
variceal injection technique was used in the sclerotherapy group. In all 25 
sclerotherapy patients (100%) haemostasis was successful, which was a statistically 
significant success rate compared to the control group (52%) (p<0.01). In the 
sclerotherapy group 5 of the 25 patients (20%) rebled, which was less than the 12 
patients (48%) who had either continued bleeding (7) or rebleeding (5) in the control 
group (p<0.05). Four patients (16%) in the sclerotherapy group died of erosive 
gastritis with massive bleeding compared to 8 deaths (32%) in the control group who 
had uncontrolled oesophageal variceal bleeding. The authors concluded that 
endoscopic sclerotherapy was an effective method for arresting bleeding from 
oesophageal varices and for decreasing the rebleeding rate. 
 
These eleven trials included and randomised a total of 1,336 patients.  In four trials, 
emergency sclerotherapy was used to treat variceal rebleeding in the sclerotherapy 
arm of the trial but not in the control arm.  The incidence of rebleeding was reduced 
in seven studies in the sclerotherapy treated patients. Mortality was reduced in the 
sclerotherapy treated group in six studies, was no different in four and increased in 
another.  On an individual basis, all the trials showed a benefit for injection 






Meta-analysis of seven of the long-term studies showed a significant 25% overall 
reduction in mortality in patients receiving endoscopic sclerotherapy, compared with 
medical management (D'Amico 1995).  Cumulative significant non-bleeding 
complications associated with sclerotherapy in these trials, however, totalled 23% 
per patient.  Two meta-analyses have confirmed a significant benefit in favour of 
injection sclerotherapy with regard to recurrent bleeding and survival and both these 
endpoints improved by 50% in the sclerotherapy treated groups. (Infante-Rivard 
1989, D'Amico 1995)   
 
Despite the evidence offered by meta-analyses in favour of long-term injection 
sclerotherapy, an important area of controversy remains concerning the treatment 
permitted for patients in the control groups who presented with recurrent variceal 
bleeding.  In most trials, this treatment was restricted to conservative measures, 
such as vasoconstrictor drugs or balloon tamponade.  All the trials which showed a 
significant survival benefit for injection sclerotherapy used a protocol restricted to 
conservative treatment.  In contrast, no survival benefit was observed in the trials in 
which a single session of injection sclerotherapy was permitted for recurrent bleeding 
episodes in the control groups.  It has therefore been suggested that restricting 
sclerotherapy to episodes of recurrent bleeding alone has the same survival 
advantage as a long-term regimen.  The available data cannot definitively answer 
this question.  If a survival benefit does not accrue from long-term injections 
sclerotherapy, justification for its use would depend on the extent of the reduction in 







2.7 INJECTION SCLEROTHERAPY TO PREVENT RECURRENT 
 BLEEDING OF OESOPHAGEAL VARICES 
 
2.7.2    Sclerotherapy compared to beta-blockers  
 
Seven meta-analyses have shown that beta-blockers decrease the risk of recurrent 
bleeding in patients with cirrhosis (Pagliaro 1989, Poynard 1987, Hayes 1990, 
Pagliaro 1990, Pignon 1988, Bernard 1994, D’Amico 1995), although only two of 
these studies showed an increase in long-term survival (Hayes 1990, Bernard 1994). 
Two meta-analyses have shown that endoscopic sclerotherapy significantly 
decreases the risk of variceal rebleeding in patients with cirrhosis (Pagliaro 1989, 
D’Amico 1995) and three meta-analyses have shown an improvement in long-term 
survival (Pagliaro 1989, D’Amico 1995, Infante-Rivard 1989).  In the randomised 
clinical trials which have compared the efficacy of beta-blockers and sclerotherapy 
(Fleig 1987, Dollet 1988, Alexandrino 1988, Westaby 1990, Andreani 1990, Martin 
1991, Rossi 1991, Dasarathy 1992, Teres 1993), three have demonstrated the 
superiority of sclerotherapy in preventing rebleeding (Alexandrino 1988, Dasarathy 
1992, Teres 1993), and one has shown a significant difference in survival in favour of 
sclerotherapy (Dasarathy 1992).  In the two meta-analyses which compared beta-
blockers and endoscopic sclerotherapy and their effect on the risk of rebleeding and 
survival (Pagliaro 1989, D’Amico 1995), only one showed a significant difference in 
favour of sclerotherapy for rebleeding (D’Amico 1995), and no difference was found 
in survival (Pagliaro 1989, D’Amico 1995).   
 
In the most recent assessment Bernard and her colleagues from Hôpital Pitié-
Salpêtrière in Paris performed a meta-analysis of nine randomised trials which 





rebleeding and on survival in patients with cirrhosis and bleeding oesophageal 
varices (Bernard 2007). Five end points were assessed in the meta-analysis: the 
overall rebleeding rate, oesophageal variceal rebleeding, overall death, death due to 
bleeding, and adverse events. Analyses were performed according to an intention-
to-treat design. For each end point, heterogeneity and treatment efficacy were 
assessed by Der Simonian and Peto calculations. When a significant difference was 
observed, sensitivity analyses were performed by successive stratification according 
to treatment duration, type of publication, severity of cirrhosis, and methodological 
quality. The authors found that the mean percentage of patients free of rebleeding, 
the mean survival rate and the mean percentage of patients free of death from 
bleeding were not significantly different between patients treated with propranolol 
and those treated by sclerotherapy. The mean percentage of patients free of variceal 
rebleeding was 39% in propranolol group and 55% in sclerotherapy group (mean 
difference: 17%, 95% confidence interval: 9-25%, p<0.001). The mean percentage of 
patients free of adverse events was significantly higher in the propranolol group than 
in the sclerotherapy group (mean difference: 22%, 95% confidence interval: 6-38%, 
p<0.007). The authors concluded that in patients with cirrhosis and oesophageal 
varices, endoscopic sclerotherapy was more effective than propranolol in preventing 
variceal rebleeding, but that the incidence of adverse events was significantly higher 










2.7 INJECTION SCLEROTHERAPY TO PREVENT RECURRENT 
 BLEEDING OF OESOPHAGEAL VARICES 
 
2.7.3   Sclerotherapy versus sclerotherapy plus beta-blockers 
 
When used without adjuvant vasoactive drugs, endoscopic sclerotherapy controls 
bleeding in 80% to 90% of patients with acutely bleeding varices.  Vasoactive drugs, 
such as somatostatin and terlipressin, have been shown to be as effective as 
endoscopic sclerotherapy in controlling variceal bleeding and preventing early 
rebleeding (Banares 2002).  The question arises whether adjuvant drugs would 
improve the efficacy of endoscopy without enhancing adverse events. The goal of 
combining both types of therapy would be to add the portal pressure lowering effect 
of vasoactive drugs to the local haemostatic effects of injection sclerotherapy.  To 
answer this question several different vasoactive drugs have been tested in 
randomised trials. Whereas drugs improved the efficacy of endoscopic therapy in the 
control of bleeding in each trial, the impact on overall survival has varied among 
studies.   
 
In a systematic review and meta-analysis from derived data Banares and his 
colleagues from Hospital General Gregorio Marañón and the Universidad 
Complutense in Madrid, assessed whether vasoactive drugs improved the efficacy of 
endoscopic injection sclerotherapy in the control of acute variceal bleeding and thus 
increased survival rates (Banares 2002). The authors searched computer databases 
and scientific meeting abstracts from 1994 to 2001 for all randomised trials which 





therapy alone to control acute variceal bleeding. Eight trials involving 939 patients 
fulfilled the selection criteria.  The end-points evaluated by standard meta-analysis 
methods were initial control of bleeding, 5-day haemostasis, 5-day mortality, and 
adverse events. Combined treatment improved initial control of bleeding (relative risk 
[RR], 1.12; 95% confidence interval, 1.02-1.23), and 5-day haemostasis (RR, 1.28; 
95% CI, 1.18-1.39), with numbers of patients needed to treat (NNT) of 8 and 5, 
respectively. The difference in favour of combined treatment remained significant 
when trials which used drugs other than octreotide or those which included a low 
proportion of alcoholic patients (<40%) or high-risk cirrhotic patients (<35%) were 
excluded. Mortality was not significantly decreased by combined therapy (RR, 0.73; 
95% CI, 0.45-1.18). Severe adverse events were similar in both groups. The authors 
concluded that in patients with acute variceal bleeding, pharmacologic agents 
improved the efficacy of endoscopic therapy in achieving initial control of bleeding 
and 5-day haemostasis, yet failed to improve survival (Banares 2002). 
 
In a further meta-analysis which included more recent trials and more patients, 
Gonzalez and colleagues from Hospital Universitario Ramón y Cajal in Madrid 
assessed whether the combination of endoscopic and drug therapy prevented 
overall and variceal rebleeding and improved survival better than either therapy 
alone (Gonzalez 2008).  The authors searched Medline, Embase, the Cochrane 
Central Register of Controlled Trials, the Cochrane Database of Systematic 
Reviews, and conference proceedings from 1996 to 2007 to identify randomised 
trials which compared endoscopic plus beta-blocker therapy with either therapy 
alone.  In the analysis two reviewers independently extracted data on interventions 





and stratified analysis were used to explore heterogeneity. Twenty three trials which 
included 1860 patients met the inclusion criteria.  The authors found that 
combination therapy reduced overall rebleeding more than endoscopic therapy alone 
(pooled relative risk, 0.68 [95% CI, 0.52 to 0.89]; I2 = 61%) or beta-blocker therapy 
alone (pooled relative risk, 0.71 [CI, 0.59 to 0.86]; I2 = 0%). Combination therapy also 
reduced variceal rebleeding and variceal recurrence. Reduction in mortality from 
combination therapy did not statistically significantly differ from that from endoscopic 
(Peto odds ratio, 0.78 [CI, 0.58 to 1.07) or drug therapy (Peto odds ratio, 0.70 [CI, 
0.46 to 1.06]). Effects were independent of the endoscopic procedure (injection 
sclerotherapy or banding). No trial-level variable associated with the effect was 
identified through metaregression or stratified analysis. The authors acknowledged 
that although a statistically significant heterogeneity in trial quality and evidence for 
selective reporting and publication bias were found, the meta-analysis supported the 
conclusion that a combination of endoscopic and drug therapy reduced overall and 
variceal rebleeding in cirrhosis more than either therapy alone (Gonzalez 2008).  
 
The authors indicate that their findings suggest that a combination of endoscopic and 
drug therapy is better than either treatment alone in the prevention of overall and 
variceal rebleeding in patients with cirrhosis and an initial variceal bleeding event. 
The effect of combination therapy was observed regardless of whether injection 
sclerotherapy or variceal banding was used, although variceal banding has been 
shown to be safer and more effective than sclerotherapy for prevention of variceal 
rebleeding (Tait 1999).  The authors report that meta-regression and stratified meta-
analyses based on a priori, trial-level covariates showed little association with the 





could not explain the statistical heterogeneity observed for rebleeding outcomes. 
Combination therapy also reduced mortality; however, the effect was more modest 
than that for rebleeding prevention and not statistically significant. Sparse mortality 
data probably contributed to the apparent lack of effect on mortality rate; deaths 
related to acute variceal bleeding episodes have decreased over the past 2 decades 
whereas causes of death unrelated to portal hypertension and varices, such as 
hepatocellular carcinoma, have increased and are unlikely to be modified by 
endoscopic or drug therapy (Gonzalez 2008).   
 
The advantages of adjunctive drug or endoscopic therapy in prevention of rebleeding 
should be weighed against the potential for more adverse events.  Patient 
withdrawals because of side effects occurred almost exclusively in the beta-blocker 
group.  However, the quality of adverse event reporting varied and often quantified 
overall rather than per-patient events.  Also, most trials did not distinguish serious 
from nonserious adverse events and the trials were not double-blinded for both drug 
and endoscopic therapies.  The authors acknowledge that their meta-analysis has 
several limitations. The quality of the studies varied.  Randomisation was adequate 
in all trials; however, 7 papers did not explicitly state whether analysis of data 
adhered to the intention-to-treat principle which could lead to overestimation of 
treatment effect in these trials, and the quality of 4 of the 5 trials reported as 
abstracts could not be assessed. Analyses did not identify an association between 
components of quality and rebleeding risk, and the effect size in favor of combination 
therapy remained statistically significant when trials which were reported as 
abstracts were excluded.  In addition, publication bias might have accounted for 





less methodological rigor than larger studies and an asymmetrical funnel plot 
suggests that selective reporting may have led to an overestimation of effect sizes in 
small trials.  The meta-analysis supports combining endoscopic and beta-blocker 
therapy to prevent variceal rebleeding in patients with cirrhosis.  The effect of 
combination therapy on survival remains uncertain, and the findings in this meta-
anaysis cannot be applied to patients different from those in the trials, such as those 
with noncirrhotic variceal bleeding, those already receiving beta-blockers, and those 
who have received endoscopic intervention or had drug therapy as primary 
treatment.  Further studies are needed to define subgroups of patients more likely to 












2.7 INJECTION SCLEROTHERAPY TO PREVENT RECURRENT 
 BLEEDING OF OESOPHAGEAL VARICES 
 
2.7.4   Comparative efficacy of endoscopic variceal treatment 
 
(i) Endoscopic Variceal Ligation compared with Endoscopic Sclerotherapy: 
Data from thirteen peer reviewed prospective randomised controlled trials comparing 
the efficacy and complications of endoscopic variceal ligation (EVL) and endoscopic 
injection sclerotherapy (EIS) have been published in full and are summarised in 
Table 2.7.1.  The first study by Stiegmann et al. found band ligation to have 
improved survival and fewer complications (Stiegmann 1992).  Laine reported a 
significant reduction in local complications but no difference in rebleeding or mortality 
(Laine 1993).  Gimson reported that band ligation obliterated the varices more 
rapidly and reduced the incidence of rebleeding but without affecting mortality or 
complications (Gimson 1993). Lo documented that ligation reduced rebleeding, 
mortality, and complications and achieved obliteration more rapidly (Lo 1995).  Hou 
found that EVL was superior to EIS in reducing rebleeding and complications but not 
mortality (Hou 1995). Eradication was achieved in fewer treatment sessions in the 
trials reported by Sarin and Baroncini with clear benefit in terms of fewer procedure-
related complications (Baroncini 1997, Sarin 1997).  Avgerinos found that EVL 
eradicated varices more swiftly the EIS and with fewer complications (Avgerinos 
1997). Masci et al recorded significantly more major complications with EIS (36% vs 
10%) (Masci 1999). 
 
de la Pena et al found similar rates of variceal eradication, but eradication was 
accomplished sooner and with fewer complications in patients undergoing EVL (de la 





al. required significantly less treatment sessions to eradicate varices and with fewer 
complications with EVL (Fakhry 2000). In 73 adult patients with bleeding 
oesophageal varices due to extrahepatic portal vein obstruction Zargar et al. found 
that EVL achieved variceal eradication with significantly fewer endoscopic sessions 
and less complications than EIS (Zargar 2005).   
 
A meta-analysis of the seven initial randomised trials concluded that EVL reduced 
the rebleeding rate (OR 0.52; 95% Cl, 0.37 - 0.74), mortality rate (OR 0.67; Cl, 0.46 - 
0.98), and rate of death due to bleeding (OR 0.49; Cl 0.24 - 0.996) compared with 
EIS (Laine 1995).  Oesophageal strictures occurred less frequently with EVL (OR 
0.10; Cl 0.03 - 0.29).  The number of endoscopic treatment sessions required to 
achieve variceal obliteration was lower with EVL than with EIS.  On the basis of 
lower rates of rebleeding, mortality, and complications and the need for fewer 
endoscopic treatments, EVL should be considered the endoscopic treatment of 
choice for patients with bleeding oesophageal varices (Laine 1995). 
 
(ii) EVL compared with combination therapy (EVL plus EIS): 
EIS of large oesophageal varices may be technically demanding and generally 
requires greater sclerosant volumes, more commonly results in needle puncture 
bleeding, and requires more endoscopy sessions with an increased risk of serious 
complications (Krige 1999).  In contrast, banding is ideally suited to large varices but 
becomes progressively more difficult with each subsequent session as varices 
reduce in size and less variceal tissue is available to trap in the O rings (Tait 1999).  
The combination of EVL and small volume EIS thus has the potential advantage of 





eradication and less chance of variceal recurrence, thus reducing the likelihood of 
later rebleeding. 
 
(a) Synchronous combination (EVL + EIS) therapy: 
The combination of EVL and synchronous EIS should theoretically achieve more 
rapid variceal eradication, as the sclerosant is injected into a stagnant varix above 
the ligation site.  Laine et al compared EVL alone with EVL plus sclerotherapy 
(EVL/EIS) in 41 patients (Laine 1996).  Twenty-one patients randomised to EVL/EIS 
had their oesophageal varices ligated then 1 ml of sclerosant (1.5% sodium 
tetradecyl sulfate) injected into the varix immediately above the ligature.  However, 
the anticipated benefits were not realised in this study which reported similar 
eradication, rebleeding and deaths rates in the two groups (Table 2.7.2).  More 
treatment sessions (rather than fewer) were required to achieve eradication in the 
combined treatment arm, which caused more complications than EVL alone.  Similar 
results were reported by Saeed et al (1997), Umehara et al (1999), Al Traif et al 
(1999), Djurdjevic et al (1999), Argonz et al (2000) and Hou et al (2001)  that control 
of acute bleeding, rebleeding rates, variceal eradication rates, and mortality were 
similar in the two treatment groups (Table 2.7.2).  However, more endoscopy 
sessions were required to achieve eradication with combination therapy, which was 
associated with a higher incidence of deep mucosal ulceration, dysphagia and 
oesophageal strictures. 
 
A meta-analysis (Singh 2002) found no significant differences between EVL and EIS 
combined versus EVL alone in terms of oesophageal rebleeding (RR = 1.05; 95% CI 





endoscopic sessions to variceal obliteration (RR = 0.23; 95% CI = 0.055-0.51; p = 
0.11).  However, the incidence of oesophageal strictures was significantly higher in 
the EVL plus EIS group than in the EVL alone group.  The meta-analysis of these 
studies suggests that little is to be gained by the addition of low dose sclerotherapy 
to standard ligation techniques.  Based on the available evidence, synchronous 
treatment with EVL and EIS provides no additional benefit and is associated with 
higher patient morbidity. 
 
(b) Sequential combination (EVL + EIS) therapy: 
Recognising the technical limitations of EVL and synchronous EIS, Bhargava and 
Pokharna (1996) adopted a more pragmatic approach to combination therapy (Table 
3).  Patients were randomised to either EVL alone, or to the combination of EVL and 
sequential EIS. Combination therapy used repeated EVL until the varices were 
reduced in size to grade II, followed by weekly small volume sclerotherapy to 
achieve complete eradication. Overall the combined treatment cohort required more 
endoscopic sessions (5.9±2.3 vs. 4.3±1.8; P<0.05), but re-bleeding rates (19% vs 
22%), and complication rates were similar in the two groups.  This study suggested 
that a staged approach to combination therapy was better, as it achieved 100% 
variceal eradication without the associated high rate of iatrogenic complications 
normally associated with EIS.  In their study Lo et al (1998) found that eradication 
and number of sessions needed were similar in both groups.  However, the mortality 
(2.7% vs 8.6%), rebleeding (8% vs 31%) and variceal recurrence (14% vs 43%) 
rates were lower with combination therapy than with EVL alone.  Masumoto (1998) 







(b) EIS alone compared to combined EVL and EIS therapy: 
Iso et al (1997) compared EIS alone with a step-wise combination of EVL as initial 
treatment followed by weekly EIS (Table 2.7.4).  There were significantly less 
iatrogenic complications with the combined EVL/EIS strategy.  Garg et al (1999) 
found that more complications (20% vs 3%) and rebleeding (16% vs 3%) occurred 
with sclerotherapy alone.  Nishikawa (1999) found the number of treatment sessions 
for eradication was significantly less (2.3 vs 3.9, p<0.001) for EVL and EIS as was 
total sclerosant used.  In the study by Shigemitsu (2000) eradication was achieved 
with significantly less sclerosant in the combined EVL/EIS group (17 vs 25ml, 
p<0.05).   
Table 2.7.1  Randomised trials comparing endoscopic sclerotherapy with band  ligation 
    Rebleed Variceal Comp  Recurrence    Eradication   Survival 
Author (year) (total number) Patients Group Sessions (%) bleeding (%) (%) (%) (%) 
Stiegmann  (1992) (n = 129) 65 EIS 5± 2 48 52 22 50 56 55 
 64 EVL 4±2 36 48   2 33 55 72 
Laine  (1993) (n = 77) 39 EIS 6.2±0.4 44 31 56 na 69 85 
 38 EVL 4.1±0.3 26 24 24 na 59 89 
Gimson  (1993) (n = 103) 49 EIS 4.90 53 51 57 na 71 37 
 53 EVL 3.40 30 24 67 na 82 52 
Lo (1995) (n = 120) 59 EIS 6.5±1.2 51 36 19 na 63 68 
 61 EVL 3.8±0.4 33 13   3 na 74 84 
Hou (1995) (n = 134) 67 EIS 4.6±1.6 33 43 22 30 79 84 
 67 EVL 3.5±1.6 18 38   5 48 87 79 
Sarin (1997) (n = 95) 48 EIS 5.2±1.8 21 na 50   8 92 94 
 47 EVL 4.1±1.2   6 na 45 29 96 94 
Baroncini (1997) (n = 111) 54 EIS 4.0±0.1 19 30 31 13 93 78 
 57 EVL 3.5±0.1 16 22 11 30 93 79 
Avgerinos (1997) (n = 77) 40 EIS 5.8 ±2.7 47 25 60 44 97 80 
 37 EVL 3.7 ±1.9 27 14 35 31 93 78 
Hou(1999) (n = 168) 84 EIS 5.1±2.2 38 32 na na 86 na 
 84 EVL 3.7±1.7 24 43 na na 88 na 
Masci (1999) (n = 100) 50 EIS 5.3 42 10 38 27 82 na 
 50 EVL 3.4 12 14 18 32 88 na 
de la Pena (1999) (n = 88) 46 EIS 5.3±1.6 50 30 41 28 71 78. 
 42 EVL 6.6±2.4 31 12 14 25 79 81 
Fakhry (2000) (n=84) 41 EIS 4.8±0.9 15 10 65 20 na na 
 43 EVL 2.8±0.5 16 12 2 21 na na 
*Zargar (2005) (n=73) 36 EIS 7.7±3.3 19 19 22 9 92 na 
 37 EVL 3.7±1.2 3 3 3 11 95 na 
na = data not available; Comp = complications 
*Extrahepatic portal venous obstruction 






Table 2.7.2   Randomised trials comparing endoscopic band ligation with 
ligation plus simultaneous sclerotherapy. 
 
Author (year) (patient 
numbers) 
Patient Group Sessions Re-bleed Variceal 
Bleeding 

















































































































































na = data not available 
Significant differences between EVL and EIS highlighted in bold type  
 
Table 2.7.3  Randomised trials comparing endoscopic band ligation with 
ligation plus consecutive sclerotherapy. 
 
Author (year) (patient 
numbers) 
Patient Group Sessions Re-bleed Variceal 
Bleeding 

































































na = data not available 






Table 2.7.4  Randomised trials comparing Injection sclerotherapy with ligation 































































































Significant differences between EVL and EIS highlighted in bold type 







2.7 INJECTION SCLEROTHERAPY TO PREVENT RECURRENT 
 BLEEDING OF OESOPHAGEAL VARICES 
 
2.7.5   Sclerotherapy versus shunt surgery 
  
 
Six prospective randomised controlled trials have compared long term injection 
sclerotherapy with shunt surgery to prevent rebleeding of varices and improve 
survival in cirrhotic patients with bleeding varices.  Two trials compared side to side 
portocaval shunts with long term endoscopic sclerotherapy and four trials used the 
Warren selective distal splenorenal shunt.    
 
Portocaval shunt surgery compared to long term endoscopic sclerotherapy  
In a continuation of a trial by the group from San Francisco for which preliminary 
results were reported in The New England Journal of Medicine two years previously, 
a total of 64 patients with Child Class C cirrhosis and variceal bleeding requiring six 
or more units of blood were randomly assigned to receive either a portacaval shunt 
(32 patients) or endoscopic sclerotherapy (32 patients) (Cello 1987). The duration of 
initial hospitalisation and the total amount of blood transfused during hospitalisation 
were significantly less in the patients receiving sclerotherapy (p<0.001). There was 
no difference in short-term survival (50% of the sclerotherapy group were discharged 
alive, compared with 44% of the shunt-surgery group). Both groups were followed for 
a mean of 530 days after randomisation. Rebleeding from varices, the duration of 
rehospitalisation for bleeding, and transfusions received after discharge were all 
significantly greater in the sclerotherapy group (p<0.001). Forty percent of the 
sclerotherapy-treated patients discharged alive (7 of 16 patients) ultimately required 





Health care costs and long-term survival did not differ significantly between the 
groups (p>0.05). The authors concluded that although endoscopic sclerotherapy was 
as good as surgical shunting for the acute management of variceal haemorrhage in 
poor-risk patients with massive bleeding, sclerotherapy-treated patients in whom 
varices are not obliterated and bleeding continues should be considered for elective 
shunt surgery. 
 
In a second study from the Hospital Universitari Germans Trias i Pujol in Barcelona 
82 consecutive Child-Pugh grade A and B cirrhotic patients were included in a 
prospective randomised controlled trial to assess the efficacy and safety of 
portacaval anastomosis compared to endoscopic sclerotherapy as elective 
treatment of patients who had bled from oesophageal varices (Planas 1991). Forty-
one patients were randomised to a portacaval shunt and 41 to endoscopic 
sclerotherapy. After excluding dropouts, 34 patients underwent a portacaval shunt 
and 35 received endoscopic sclerotherapy. The incidence of variceal rebleeding 
during follow-up (mean +/- SD, 20.6 +/- 14.2 months) was significantly higher in the 
sclerotherapy than in the portacaval group, considering the overall treated group 
and only patients completing sclerotherapy (40% and 25% vs 2.9%; p = 0.0002 and 
p = 0.01, respectively). The 2-year probability of having at least one episode of 
hepatic encephalopathy was significantly higher in patients who had a portacaval 
shunt than in those treated with endoscopic sclerotherapy (40% vs 12%; p = 0.04). 
However, disabling encephalopathy only appeared in 3 of 34 patients who 
underwent surgery (8.8%). Early and long-term mortality did not differ between the 
therapeutic groups; 2-year survival rates were 83% for portacaval shunts and 79% 





mortality were equivalent.  The authors concluded that portacaval shunt surgery 
was more effective than endoscopic sclerotherapy in preventing variceal rebleeding 
in spite of the greater incidence of hepatic encephalopathy.  
 
Distal splenorenal shunt surgery compared to long term endoscopic 
sclerotherapy  
 
In a prospective, randomised clinical crossover trial for those failing therapy, 
Henderson and the Emory Hospital group in Atlanta, Georgia randomised 72 
cirrhotic patients drawn from a total of 420 patients treated during a 4.5-year interval 
to either endoscopic variceal injection sclerotherapy or distal splenorenal shunt to 
prevent recurrent variceal bleeding (Henderson 1990).  Survival was significantly 
(p<0.02) improved in patients assigned to receive sclerotherapy: 13 of these 37 
(35%) patients failed sclerotherapy and required surgical rescue. A survival 
advantage (p<0.01) was seen in patients with alcoholic cirrhosis who had this 
combined therapy; however, in patients with nonalcoholic cirrhosis, survival for those 
receiving sclerotherapy and surgical rescue was not significantly (p<0.36) different 
from that of patients receiving distal splenorenal shunt. Control of variceal bleeding 
was significantly (p<0.001) better in the distal splenorenal shunt group (34 of 35 
[97%] compared with 15 of 37 [41%] in the sclerotherapy group).  Using death, 
uncontrolled rebleeding, or shunt thrombosis as the endpoints resulted in no 
significant difference between treatment groups.  Hepatocyte function (p<0.01) and 
portal perfusion (p<0.001) were significantly better maintained in patients with 
alcoholic cirrhosis who were managed by sclerotherapy rather than shunt.  The 
authors concluded that endoscopic sclerotherapy with surgical rescue for 





and variceal bleeding.  Survival was similar in nonalcoholic patients treated with 
either distal splenorenal shunt or endoscopic sclerotherapy, but shunting provided 
better control of variceal bleeding. 
 
In a prospective controlled trial the group from Barcelona randomised 112 
consecutive Child grade A and B cirrhotic patients to either endoscopic injection 
sclerotherapy or distal splenorenal shunt in order to evaluate the efficacy and safety 
of each treatment in the elective treatment of haemorrhage from oesophageal 
varices (Teres 1987). Fifty-seven patients were randomly allocated to splenorenal 
shunt and 55 to endoscopic sclerotherapy. Four of the 55 patients assigned to 
endoscopic sclerotherapy were excluded after randomisation and before treatment 
compared to 14 of 57 patients assigned to splenorenal shunt, suggesting that the 
applicability of endoscopic sclerotherapy is greater than that of splenorenal shunt. 
One patient in each group died within 30 days of the procedure and two in the 
endoscopic sclerotherapy group were lost to follow-up after discharge. Variceal 
rebleeding during follow-up occurred in 37.5% (18/48) of patients in the endoscopic 
sclerotherapy group and in 14.3% of those in the splenorenal shunt group (6/42) (p< 
0.02), while hepatic encephalopathy was more frequent in patients submitted to 
splenorenal shunt (10/42, 24%) than in those treated by endoscopic sclerotherapy 
(4/48, 8%) (p<0.05). Early and long term mortality was similar in the two groups; the 
2-year survival was 71% in the splenorenal shunt group and 68% in endoscopic 
sclerotherapy group. 
 
Spina and the group from the San Paolo Institute of Biomedical Science in Milan 
conducted a prospective controlled trial comparing endoscopic sclerotherapy (EIS) 





hemorrhage in cirrhotic patients (Spina 1990). The study population included 40 
patients with cirrhosis and portal hypertension drawn from a pool of 173 patients. 
Twenty patients were assigned to DSRS and 20 to EIS. During the postoperative 
period, no DSRS patient died, while one EIS patient died of uncontrolled bleeding. 
One DSRS patient had recurrent variceal haemorrhage despite an angiographically 
patent shunt. Four EIS patients had at least one episode of gastrointestinal bleeding: 
two from varices and two from oesophageal ulceration. Five EIS patients developed 
transitory dysphagia. Long-term follow-up was complete. Two-year survival rates for 
shunt (95%) and EIS (90%) groups were similar. One DSRS patient rebled from a 
duodenal ulcer, while three EIS patients had recurrent bleeding from 
oesophagogastric sources (two from varices and one from hypertensive 
gastropathy). One DSRS and two EIS patients have evolved a mild chronic 
encephalopathy. Data from this trial indicate that DSRS, in a subgroup of patients 
with good liver function and a correct portal-azygos disconnection, more effectively 
prevents variceal rebleeding than EIS. However no significant difference in the 
survival of the two treatment groups was noted. 
 
A long-term follow-up of these trial patients was completed by Santambrogio and 
Spina in 2006 except for 5 patients (2 DSRS, 3 EIS patients) (Santambrogio 2006). 
Five-year survival rates for shunt (73%) and EIS (56%) groups were statistically 
different. In this follow-up period and in subsequent follow-ups this difference 
decreased and ceased to be of statistical relevance. The primary cause of death 
became hepatocellular carcinoma. Four DSRS patients rebled due to duodenal 
ulcer, while eleven EIS patients had recurrent bleeding from oesophago-gastric 





oesophageal ulceration) and two from unknown sources. Nine DSRS and 2 EIS 
patients developed chronic encephalopathy; 13 DSRS and 5 EIS patients had at 
least one episode of acute encephalopathy. Five EIS patients had oesophageal 
stenoses, which were successfully dilated. The authors concluded that in a subgroup 
of patients with good liver function, DSRS with a correct portal-azygos disconnection 
more effectively prevents variceal rebleeding than EIS. However, this positive effect 
did not influence the long-term survival because other factors such as hepatocellular 
carcinoma were more important in deciding the fate of cirrhotic patients with portal 
hypertension. 
  
Rikkers and the group from the University of Nebraska Medical Center in Omaha, 
Nebraska, randomised 60 cirrhotic patients with prior variceal haemorrhage to either 
an elective shunt (distal splenorenal: 26; nonselective: 4) or long term endoscopic 
sclerotherapy (n = 30). Eighty-six percent of the patients had alcoholic cirrhosis, and 
33% were classified as Child's grade C (Rikkers 1993). After a mean follow-up of 87 
months, 60% of patients undergoing sclerotherapy and 17% of shunt patients 
experienced rebleeding (p<0.001). Shunt patients survived longer than those who 
had sclerotherapy (6-year survival rates of 53% and 26%, respectively; p<0.05). In 
part because of the wide geographic distribution of patients, only 4 of 13 patients in 
whom sclerotherapy failed (31%) could undergo salvage by shunt surgery. 
Posttherapy quantitative hepatic function, frequency of encephalopathy, and 
cumulative medical costs were similar for both groups. Hepatic portal perfusion and 
portal pressure at 1 year were better maintained by sclerotherapy than by distal 
splenorenal shunt. The authors concluded that endoscopic sclerotherapy and shunt 





of encephalopathy, and costs and that sclerotherapy was an acceptable, but not 
superior, alternative to shunt surgery for treatment of variceal haemorrhage. 
 
In a meta-analysis of these data, Spina et al evaluated the 4 clinical trials which 
compared distal splenorenal shunt (DSRS) with endoscopic sclerotherapy (EIS) in 
the prevention of variceal rebleeding (Spina 1992).  A questionnaire was sent to 
each author of the published trials to clarify the methods, definitions and results of 
the trials in order to obtain more detailed information. The selected end-points for the 
meta-analysis were rebleeding, mortality and chronic encephalopathy.  The pooled 
relative risk (i.e. the combined odds ratio of each trial as an estimate of overall 
efficacy) of rebleeding was statistically reduced by DSRS (0.16; 95% confidence 
interval 0.10-0.27). Despite this, the overall risk of death following DSRS was only 
marginally decreased (0.78; 95% confidence interval 0.47-1.29); the lack of 
homogeneity in the results did not permit any significant conclusions on this end-
point. However, in non-alcoholic patients, the decrease in risk of death was greater, 
and this without heterogeneity, following DSRS than EIS (0.59; 95% confidence 
interval 0.23-1.50). The overall risk of chronic encephalopathy was slightly increased 
after DSRS (1.86; 95% confidence interval 0.90-3.86). In conclusion, DSRS 
significantly reduced the risk of rebleeding compared to EIS without increasing the 
risk of chronic hepatic encephalopathy. However, DSRS did not significantly affect 
the overall death risk. Only in non-alcoholic disease did it seem to show an 
advantage over EIS. 
 
The results of elective shunt surgery were superior to those of chronic endoscopic 





recurrent bleeding was significantly less frequent after the distal splenorenal shunt in 
all studies.  Only one study found a significant difference between therapies with 
regard to survival (Henderson 1990).  In that trial, approximately one-third of the 
patients in the sclerotherapy group were successfully salvaged by surgery when they 
failed to improve with sclerotherapy, thus resulting in a survival advantage to this 
treatment.   In contrast to the Atlanta study in which nearly all of the sclerotherapy 
failures could be salvaged by shunt surgery, the majority of sclerotherapy failures in 
the Omaha, Nebraska trial (Rikkers 1987) died of hepatic failure before they could 
undergo surgery.  The reason for the lower salvage rate of sclerotherapy failures in 
the latter trial was the inclusion of patients from a wider geographic area.    Many of 
the sclerotherapy failures in this trial died in peripheral hospitals or were not 
salvageable by the time they were referred for alternative treatment.  Two of the 
randomized studies (Rikkers 1987, Henderson 1990) showed no difference in 
postoperative encephalopathy after distal splenorenal shunt and endoscopic 
sclerotherapy, while the third investigation (Teres 1987) demonstrated a higher 
encephalopathy rate in the shunt group. Two of the trials (Rikkers 1987, Henderson 
1990) evaluated the effect of these interventions on postoperative hepatic portal 
perfusion and quantitative tests of liver function.  Significantly more patients had 
continuing portal flow to the liver at the 1 year assessment in the sclerotherapy 
groups of both these trials. This haemodynamic advantage resulted in superior 
hepatic functional reserve in one trial (Henderson 1990), but not in the other (Rikkers 
1987). 
 
An objective assessment of the results of all three of these studies suggests that 





from oesophageal varices .However, approximately one-third of the patients in these 
studies eventually failed sclerotherapy and required operative intervention for control 
of recurrent variceal bleeding.  Rikkers concluded that patients who live in remote 
geographic areas or patients who are non-compliant and unwilling to return for 
repeated sclerotherapy sessions should undergo an initial selective shunt rather than 
long term sclerotherapy (Rikkers 1987).  In all the trials, days in the hospital after the 
index bleding episode were significantly fewer in patients undergoing sclerotherapy, 
but on a long-term basis, days in the hospital were equal because of the higher rates 
of recurrent bleeding and complications in the sclerotherapy group.  Teres concluded 
that the applicability of sclerotherapy was wider based on the numbers of patients 
excluded from both treatment arms of the trial (Teres 1987).  
 
In a systematic review by a Cochrane hepatobiliary group from Birmingham, all 
prospective randomised clinical trials which have compared portosystemic shunting 
procedures with endoscopic therapy for variceal bleeding were evaluated (Kahn 
2006).  The search strategy included the Cochrane Hepato-Biliary Group Controlled 
Trials Register, the Cochrane Library, Medline, Embase, conference proceedings, 
and the references of identified trials were searched. Data were collected to allow 
intention-to-treat analysis where possible. For each outcome, a pooled estimate of 
treatment effect (log hazard ratio for time to outcome, Peto odds ratio for binary 
outcomes, and differences in means for continuous outcomes) across trials was 
calculated.  Shunt therapy compared with EIS demonstrated significantly less 
rebleeding (OR 0.24, 95% CI 0.18 to 0.30) at the cost of significantly increased acute 
hepatic encephalopathy (OR 2.07, 95% CI 1.59 to 2.69) and chronic encephalopathy 





mortality (hazard ratio 1.00, 95% CI 0.82 to 1.21) and duration of in-patient stay 
(weighed mean difference 0.78 day, 95% CI -1.48 to 3.05). The proportion of 
patients with shunt occlusion or dysfunction was 7.8% (95% CI 3.8 to 13.9%) 
following DSRS. The authors concluded that DSRS resulted in a significantly lower 
rebleeding rate at the expense of a higher incidence of encephalopathy.  No survival 






2.7 INJECTION SCLEROTHERAPY TO PREVENT RECURRENT 
 BLEEDING OF OESOPHAGEAL VARICES 
 
2.7.6   Sclerotherapy versus transjugular intrahepatic shunt 
 
 
The introduction of minimally invasive, radiologically placed transjugular intrahepatic 
portosystemic shunts (TIPS) has provided a valuable addition to the treatment 
options in the management of patients with portal hypertensive bleeding due to 
decompensated cirrhosis (Rosado 2003, Boyer 2005). The most common indication 
for TIPS is uncontrolled or refractory variceal bleeding unresponsive to standard 
pharmacological and endoscopic therapy (Rosado 2003, Boyer 2005). TIPS 
placement by a skilled interventional radiologists has a mortality rate of less than 1%.  
Life-threatening, procedure-related complications include intraperitoneal 
haemorrhage from puncture of the liver capsule, sepsis, haemobilia due to 
portobiliary fistulae, worsening hepatic failure, and cardiopulmonary failure (Luca 
1999, Papatheodoridis 1999, Burroughs 2002, Khan 2006, Zheng 2008).   
 
The major disadvantages after TIPS are hepatic encephalopathy and stent 
dysfunction.  Hepatic encephalopathy after TIPS placement usually occurs within the 
first month of the procedure and is more likely in patients with advanced liver disease 
but usually responds to standard treatment including lactulose, protein restriction and 
elimination of precipitating factors.  A minority of patients may develop intractable 
encephalopathy requiring shunt modification either by mechanical reduction of the 
shunt diameter or by total occlusion of the shunt.  Ultimately liver transplantation is 







Shunt dysfunction due to stenosis or occlusion remains a major limiting factor in the 
long-term success of TIPS.  Shunt stenosis is the result of pseudointimal hyperplasia 
which causes focal narrowing of the lumen of the shunt at the hepatic venous end of 
the TIPS or diffusely within the parenchymal tract.  Since TIPS stenosis is the most 
important cause of recurrent portal hypertension and variceal bleeding after TIPS 
placement, a surveillance program to monitor shunt patency is mandatory.  The best 
strategy for TIPS surveillance has yet to be defined (Rosado 2003, Boyer 2005). 
 
Endoscopic injection sclerotherapy compared to TIPS 
Eight randomised controlled trials have compared endoscopic injection sclerotherapy 
with TIPS in the prevention of recurrent oesophageal variceal bleeding.  
In a Spanish trial, 63 patients were randomised within 3 days of the onset of variceal 
bleeding to either TIPS (n = 31) or sclerotherapy (n = 32) (Cabrera 1996).  There 
was a significant difference in the rate of recurrent variceal bleeding in favour of 
TIPS (23% vs 51.6%) at a mean follow-up of 15 months.  In 10 patients in the 
sclerotherapy group, recurrent bleeding was uncontrollable and 8 of these patients 
underwent TIPS.  One third of patients who underwent TIPS developed 
encephalopathy or in some patients encephalopathy worsened, compared to 13% of 
those who had sclerotherapy.  There was no significant difference in survival 
between the two groups.   
 
In a study from the University of California at San Francisco, 49 patients were 
randomised to either TIPS (n=24) or sclerotherapy (n=25) within 24 hours of the 





days, the frequency of recurrent bleeding was significantly less for patients who 
underwent TIPS (12.5 % vs 48%).  Six patients (24%) in the sclerotherapy group 
underwent TIPS for recurrent variceal bleeding.  Although a trend toward improved 
survival for TIPS treated patients was noted, the difference was not statistically 
significant.  In this trial, there were no significant differences in the new onset or 
worsening of encephalopathy that existed before randomisation and there were no 
significant differences between the two groups for total days of hospitalisation for 
variceal bleeding and total health care costs.   
 
In the German trial from the University of Freiburg, 61 patients were randomised to 
undergo TIPS and 65 to have sclerotherapy or band ligation, or both, combined with 
propranolol therapy within 24 hours of the onset of bleeding (Rossle 1997).  
Episodes of bleeding had occurred before randomisation in 61% of patients in the 
study.  The cumulative 1 year and 2 year recurrent bleeding rates were significantly 
less in the TIPS group compared with sclerotherapy (15% vs 41%, and 21% vs 
52%).  At 1 year the rate of clinically significant encephalopathy was considerably 
higher in the TIPS group (35% vs 18%), but there was no significant difference in 
mortality between the two groups.     
 
Forty one patients were randomised to TIPS and 39 to sclerotherapy in an American 
trial by Sanyal and colleagues after an episode of variceal bleeding (Sanyal 1997).  
At 3 years, the rates of recurrent variceal bleeding after TIPS or sclerotherapy were 
similar (22% vs 20.5%).  Six patients (15%) in the sclerotherapy group underwent 
TIPS for recurrent bleeding.  Encephalopathy developed in 29.3% of patients who 





contrast to the studies by Cabrera et al. and Rossle et al. in which there were no 
deaths as a result of variceal bleeding in the TIPS treatment group, in this study 5 
patients in the TIPS group and 3 who underwent sclerotherapy died as a result of 
bleeding.  
 
In the German study from the University of Heidelberg, Sauer and colleagues 
compared TIPS and endoscopic sclerotherapy plus propranolol in cirrhotic patients 
after a first variceal bleed (Sauer 1997). Eighty-three patients were randomised to 
either TIPS (n = 42) or EVS (n = 41).  Median observation time was 1.6 years in the 
TIPS group and 1.45 years in the EVS group. Cumulative rates of rebleeding were 
23% in the TIPS group and 57% in the EVS group (p<0.0001). Hepatic 
encephalopathy occurred in 29% of the TIPS patients and in 13% of the EVS group 
(p<0.041). Cumulative rates of survival were 69% in the TIPS group and 67% in the 
EVS group (p = 0.62). Mortality rates in both groups were positively correlated with a 
higher Child's grade.  The authors concluded that although TIPS significantly 
reduced the rate of rebleeding, survival rates were not improved. Because TIPS was 
associated with an increased risk of encephalopathy and high rates of shunt 
dysfunction, which required reintervention, TIPS could not be recommended for 
elective treatment after the first variceal bleeding episode, but was an effective 
therapy in patients in whom endoscopic sclerotherapy failed to control bleeding.  
 
In a multicentre randomised controlled trial from Rome, the efficacy of TIPS was 
compared to endoscopic sclerotherapy in the prevention of variceal rebleeding (Merli 
1998).  Eighty-one patients were randomised to either TIPS (38 patients) or 





the following criteria: if bleeding had occurred < 1 week (stratum I); if bleeding had 
occurred 1 to 6 weeks (stratum II); and if bleeding had occurred 6 weeks to 6 months 
(stratum III) before enrollment.  Follow-up included clinical, biochemical, Doppler 
ultrasound and endoscopic examinations every 6 months. During a mean follow-up 
of 17.7 months, 51% of the patients treated with sclerotherapy and 24% of those 
treated with TIPS rebled (p<0.011).  Mortality was 19% in sclerotherapy patients and 
24% in TIPS patients (p = 0.50).  Hepatic encephalopathy developed in 26% and 
55% (p<0.006). A separate analysis of the three strata showed that TIPS was 
significantly more effective than sclerotherapy (p<0.026) in preventing rebleeding 
only in stratum I patients.  TIPS was significantly better than sclerotherapy in 
preventing rebleeding only when performed shortly after a variceal bleed; however, 
TIPS did not improve survival and was associated with a significantly higher 
incidence of hepatic encephalopathy.  The overall performance of TIPS did not justify 
its use as the first-choice treatment to prevent rebleeding from oesophageal varices 
in cirrhotic patients. 
 
In a study from Spain, 46 cirrhotic patients with variceal bleeding were randomly 
allocated to receive either TIPS (22 patients) or EVS (24 patients) 24 hours after 
control of bleeding (Garcia-Villarreal 1999). Overall variceal bleeding (50% vs 9%) 
and early variceal bleeding during the first 6 weeks (33% vs 5%) were significantly 
more frequent in sclerotherapy patients.  The actuarial probability of being free of 
variceal bleeding was higher in the shunt group (p<0.002).  Eight patients (33%) in 
the sclerotherapy group and 3 patients (15%) in the shunt group died; the actuarial 
probability of survival was higher for the shunted patients (p<0.05); 6 patients in the 





No difference was found in the proportion of patients with clinically evident hepatic 
encephalopathy.  These results showed that TIPS was more effective than 
sclerotherapy in the prevention of both early and long-term variceal bleeding. 
Moreover, a significant improvement in survival was found in the shunt group. 
 
In a study from Tokyo the efficacy of TIPS was compared with endoscopic 
sclerotherapy in the long-term management of patients with cirrhosis after variceal 
bleeding (Narahara 2001).  Seventy-eight cirrhotic patients with recent variceal 
bleeding were randomly allocated to either TIPS (n=38) or EVS (n=40). Mean follow-
up was 1116 +/- 92 days in the TIPS group and 1047 +/- 102 days in the EVS group. 
Differences in rebleeding from any source (18.4% vs 32.5%) and oesophageal 
variceal rebleeding (15.7% vs 27.5%) were not significantly different between the two 
groups (p>0.05).  The mortality rates were similar in both treatment groups. Shunt 
dysfunction was noted in 27 patients (71%) in the TIPS group.  There were more 
numbers of rehospitalisation during follow-up in the TIPS group than in the EVS 
group (2.6 +/- 0.4 vs 1.1 +/- 0.2) (p<0.01).  TIPS and EVS were equally effective in 
the prevention of variceal rebleeding.  However, TIPS was associated with high 
incidence of shunt dysfunction which led to more rehospitalisation. The authors 
recommended that TIPS should not be used as first-line treatment for the prevention 
of variceal rebleeding in cirrhotic patients who were stable. 
 
The results of these eight randomised controlled trials and subsequent 5 meta-
analyses have shown that TIPS is superior to endoscopic and pharmacological 
therapy in preventing variceal rebleeding (Luca 1999, Papatheodoridis 1999, 





rebleeding rates, TIPS is associated with a significantly increased risk of hepatic 
encephalopathy and long-term shunt dysfunction.  In these trials TIPS resulted in a 
significantly higher incidence of new or worsened encephalopathy, as well as a 
significantly higher incidence of chronic encephalopathy.  New-onset 
encephalopathy or evidence of worsening encephalpathy was observed in one third 
of patients undergoing TIPS compared to 15% of patients treated by sclerotherapy. 
The difference between the two treatment groups with regard to encephalopathy was 
significant in all studies.  In all instances, however, this was reported to be treatable 
and did not lead to disabling encephalopathy (Luca 1999, Papatheodoridis 1999, 
Burroughs 2002, Khan 2006, Zheng 2008).  
 
A further important complication in the TIPS group was shunt insufficiency or 
dysfunction as well as shunt occlusion, as a result of thrombosis.  Shunt dysfunction 
is a major problem that leads to a higher rate of re-intervention, recurrence of 
complications associated with portal hypertension (variceal rebleeding, ascites), and 
increased costs. Such TIPS failure was the commonest cause of rebleeding in this 
group. As the follow-up period of most trials was short (< 2 years), one would expect 
that the rate of rebleeding would increase over time in the TIPS group.  Therefore, 
vigorous surveillance is necessary for the early recognition and treatment of TIPS 
dysfunction.  No consensus exists in the criteria used to define either TIPS 
dysfunction or the frequency, and interval for surveillance.  The long-term results of 
studies using coated stents to prevent shunt dysfunction are awaited.  Future 
investigations exploring issues such as cost effectiveness and quality of life, as 
primary end points are also needed (Luca 1999, Papatheodoridis 1999, Burroughs 





In the detailed analysis of the data there are similarities, differences and deficiencies 
in the results of these 8 trials.  The treatment provided, including TIPS and 
sclerotherapy, were not strictly comparable because of differences in the level of 
operator skill and experience, techniques used and the additional use of other 
treatments such as variceal banding and prophylactic pharmacotherapy.  In these 
trials 32 to 61% of patients had survived prior episodes of bleeding and had been 
treated by endoscopic means.  In some studies, therefore, each treatment group was 
composed of selected patients for whom the natural history of variceal bleeding was 
likely to be different from that for a group of patients with new-onset variceal 
bleeding. In all these studies, recurrent bleeding was the primary endpoint and all 
except two demonstrated a significantly higher rebleeding rate in patients who 
underwent sclerotherapy, probably due to a selection bias as a result of a long lead 
time between randomisation and treatment and failure to adequately reduce portal 
pressure in some patients in the TIPS group.  Furthermore, there was no 
improvement in overall survival with TIPS compared to endoscopic or medical 
therapy (Luca 1999, Papatheodoridis 1999, Burroughs 2002, Khan 2006, Zheng 
2008).   
 
In addition, these trials have shown considerable variation in quality with regard to 
generation of allocation sequence and allocation concealment which raises the risk 
of selection bias (Schulz 1995, Kjaergard 2001).  None of the trials performed 
blinded the outcome assessment which also raises the risk of assessment bias. 
Furthermore, a number of trials had unclear reporting of follow-up, which may 
introduce attrition bias.  The lack of statistical power of several trials is a major 





unless large-scale, multicentre randomised trials are undertaken (Schulz 1995, 
Kjaergard 2001). Further issues have been highlighted at the Baveno Consensus 
Conferences (de Franchis 1992, Franchis 1996, de Franchis 2001, de Franchis 
2005), including appropriate randomisation and blinding, as well as the need for 
accurate data on all evaluable patients, trial events, and costs.  In particular the need 
for accurate data on the timing and assessment of all individual components of 
Child-Pugh grading should be emphasised, especially for encephalopathy (Luca 
1999, Papatheodoridis 1999, Burroughs 2002, Khan 2006, Zheng 2008).   
 
The implications of these studies for clinical practice are that endoscopic therapy 
should be the first-line treatment in the prevention of variceal rebleeding but in 
centres with expertise and experience in shunting procedures the latter options 
should carefully be discussed with the patient.  When recurrent rebleeding occurs 
after endoscopic therapy, selected shunting procedures should be offered at an early 






2.8 COMPLICATIONS OF ENDOSCOPIC VARICEAL INJECTION  
 SCLEROTHERAPY 
 
 2.8.1      Incidence 
 2.8.2      Oesophageal complications 
 2.8.2      Morphologic changes 
 2.8.2.1    Ulceration 
 2.8.2.2     Bleeding 
 2.8.2.3     Perforation  
 2.8.2.4     Intramural haematoma 
 2.8.2.5     Stricture 
 2.8.2.6     Motility disorders 
 2.8.2.7     Other oesophageal complications 
 
 
Endoscopic variceal sclerotherapy has been widely used as a method of treatment 
for control of acute variceal haemorrhage, and repeated injections have been shown 
to reduce the frequency of subsequent episodes of bleeding (Terblanche 1983, 
Terblanche 1985, Terblanche 1989, Krige 2000b).  Although variceal sclerotherapy 
has used as one of the principal endoscopic treatment options for variceal bleeding, 
the procedure is not without risk.  More than 40 different complications which have 
occurred as a consequence of endoscopic variceal injection sclerotherapy, have 
been described (Sanowski 1987, Schuman 1987, Kahn 1989, Baillie 1992, 
Muhldorfer 1992, Krige 2005).  Important factors influencing the complication rate 
are the experience of the endoscopist, the injection technique used, the use of 
ancilliary devices including balloon tamponade, and whether sclerotherapy is 
performed as an emergency or elective procedure.  Other interrelated anatomic 
factors are the close proximity of the oesophagus to vital mediastinal structures, 
repetitive breaching of the oesophageal mucosa by the injecting needle, and the 
potential for pulmonary and systemic dissemination of sclerosant through portal 







There is no consensus regarding the definition or classification of the complications 
that occur after endoscopic variceal sclerotherapy, and consequently the incidence 
varies widely in reported studies (Krige 1999b).   Much of the published data are 
flawed because the reporting process often is biased with subjective and 
retrospective information, short or incomplete follow-up and naïve statistical analysis. 
Complication rates are generally operator dependent (Baillie 1994) and comparative 
analyses of complication rates in many series are hampered by variations in patient 
population, type and severity of the underlying liver disease and the sclerotherapy 
technique used (Krige 2000).  In addition, differences in study design introduce a 
covert selection bias which may influence results. These biases include sampling 
and selection bias (specialist centres, expert endoscopists, different patient 
populations) confounding bias (emergency versus elective procedures) and 
measurement bias (incomplete reporting, delayed complications).   
 
In addition, many patients undergoing endoscopic variceal intervention have a 
limited prognosis and therefore complications may not be identified or treated 
aggressively.  The debilitated state of many patients undergoing endoscopic therapy 
contributes to the medical difficulties encountered, often making the differentiation of 
a true complication of the procedure difficult (Chan 1996).  Complication rates are 
also higher when carefully documented in prospective studies (Krige 2000).  Some 
studies express complication rates in terms of incidence per patient treated while 
others describe complication rates in terms of incidence per procedure performed.  
Surprisingly, in some prospective studies, details of sclerotherapy complications are 





repeated injections also increase the cumulative risk of sclerotherapy-induced 
complications in the individual patient (Krige 2000a).  The most reliable data indicate 
that 10% to 15% of patients undergoing variceal sclerotherapy will develop a major 
complication (Krige 2005) but less than 1% of patients die as a direct result of the 
procedure.  
 
Classification of sclerotherapy complications 
In this dissertation endoscopic sclerotherapy-induced complications have been 
categorised as (i) local effects involving the oesophagus, including ulceration, 
stricture and perforation; (ii) regional respiratory and cardiovascular effects; and (iii) 
distant or systemic consequences (Krige 1999b). Minor events have been defined as 
those that are self-limiting and do not require specific treatment and do not interfere 
with the regular sclerotherapy injection programme.  Major complications are serious 




Oesophageal complications of endoscopic variceal sclerotherapy are invariably a 
consequence of excessive sclerosant-induced submucosal or transmural 
oesophageal necrosis (Krige 1999b).  The few studies that have examined the local 
histopathological effects of sclerosant on the oesophageal wall in detail have been 
based on necropsy studies.  Although the injection techniques, type and volume of 
sclerosant used, and intervals between injections vary in these studies, the 





morphological profile of the effects of variceal sclerotherapy on the oesophagus 
(Helpap 1981, Evans 1982, Papadimos 1986, Pushpanathan 1986) 
 
The earliest changes in the oesophageal wall during the initial 48 hours after variceal 
injection of sclerosant are thrombosis in the superficial veins, submucosal oedema, 
and minor areas of tissue necrosis (Helpap 1981).  Mucosal ulceration is uncommon 
during this phase and no significant cellular reaction occurs (Kage 1987).  After 48 
hours, progressive tissue necrosis occurs, predominantly in the superficial layers and 
to a lesser extent in the deeper tissues.  During the first week, mucosal ulceration 
and a marked acute polymorphonuclear leucocyte inflammatory response occurs 
which is followed by an intense macrophage and fibroblast infiltration (Helpap 1981, 
Ayres 1983).  Intramural microabscesses may develop as a consequence of 
localised necrotising inflammation.  In some cases, extravasation of sclerosant into 
the submucosa and muscle layers results in a giant cell reaction and focal 
calcification.  Some residual varices remain patent, but others contain thrombi in the 
early stages of endothelial and fibroblastic organisation (Papadimos 1986, 
Soehendra 1983). 
 
The extent of sclerotherapy-induced ulceration varies from small, linear, superficial 
defects to extensive, wide-based ulcers (Papadimos 1986).  Although most ulcers 
are limited to the submucosa or inner layer of the muscularis propria, a few extend 
more deeply into the muscularis propria.  A fourth of necropsy specimens show 






The chronic reaction is characterised by an evolution from granulation tissue to 
mature collagen, with an accompanying chronic inflammatory cell infiltrate that 
becomes less prominent with time (Ayres 1983).  Necrosis and ulceration may 
persist for as long as 3 weeks.  Organised thrombi and fibrosis become evident 1 
month after the injection of sclerosant (Evans 1982, Papadimos 1986).  Fibrosis is 
usually limited to the submucosa and the inner muscularis propria but may occur as 
a localised transmural breach in muscle or as diffuse transmural fibrosis encasing 
residual varices (Ayres 1983).  Marked thickening of the oesophageal wall is present 
in seen in some specimens (Kage 1987) 
 
Ulceration 
Small areas of superficial mucosal ulceration are a common finding in the lower 
oesophagus after variceal sclerotherapy (Sarles 1985, Larson 1986, Terabayashi 
1987, Low 1989).  Some investigators have considered ulceration as an inevitable 
and necessary consequence of effective sclerotherapy (Sarin 1986, Kitano 1987).  
The reported incidence ranges from 9% - 87% (Krige 2005).  In a detailed 
prospective study performed in Cape Town, the incidence was 41% on a per-patient 
basis and 19% on a per-procedure basis (Krige 2005).  
 
The prevalence and extent of ulceration is reported to depend on the type (Kitano 
1989, Kitano 1988) and volume (Neeman 1991, Iso 1988) of sclerosant injected, the 
method of variceal injection (Sarin 1987), the interval between injections (Westaby 
1984, Sarin 1986, Higashi 1989) and the size of varices (Choudhuri 1989).  
Robertson et al, in a study using rabbit stomachs, found that 5% ethanolamine 





tetradecyl sulphate, 2% or 3% polidoconal and 5% sodium morrhuate (Robertson 
1989).  In a clinical study, 2% sodium tetradecyl sulphate caused significantly more 
ulceration than 5% ethanolamine oleate when a combined paravariceal and 
intravariceal injection technique was used (Kitano 1988).  Ulceration is reported to 
occur more frequently with Child's class C liver disease and after injection of large 
varices (Choudhuri 1989). 
 
There is evidence that increasing volumes of sclerosant may be implicated in the 
occurrence of deep ulceration.  Madonia et al evaluated forty patients endoscopically 
1 week after sclerotherapy with 1% sodium tetradecyl sulphate (Madonia 1990).  
Those who developed deep ulcers had received significantly greater total volumes of 
sodium tetradecyl sulphate (12.8 ml compared with 9.3 ml) than those with shallow 
ulceration.  The incidence of deep ulceration was also increased with the associated 
use of balloon tamponade.  Singal et al in a clinical study using absolute alcohol, 
found that the incidence and size of the ulcers was directly related to the volume 
injected (Singal 1990).  In a canine model with oesophageal varices, Sugawa et al 
demonstrated that increasing volumes of 5% sodium morrhuate injected 
intravariceally caused greater necrosis and ulceration (Sugawa 1978). 
 
In a randomised study comparing techniques, Sarin et al found no significant 
difference in the incidence of ulceration between paravariceal and intravariceal 
injections using 50% ethanol (Sarin 1987).  The risk of ulceration may be related 
more to the intensity of the sclerotherapy programme than to the technique of 





possible, even in controlled studies, to determine the individual ulcerogenic potential 
of various sclerosants or the factors primarily responsible for oesophageal ulceration. 
 
Superficial ulceration is not necessarily harmful, and has been deliberately produced 
as part of the injection technique proposed by Kitano et al to enhance eradication of 
varices (Kitano 1987).  As described by Kitano, the initial and second injection one 
week later are given intravariceally using a transparent overtube over the flexible 
endoscope.  After variceal thrombosis has occurred, subsequent injections are 
placed submucosally to create a circumferential ulcer involving the lower 5 to 10 cm 
of the oesophagus.  In their study, healing by epithelialisation occurred, and although 
pain, pyrexia and pleural effusions were common, no serious complications were 
encountered.  Varices were eradicated in all survivors without any variceal 
recurrence. An important consideration not reported by the authors is the long term  
incidence of oesophageal strictures after this procedure (Kitano 1987).   
 
In most instances, minor areas of superficial ulceration are asymptomatic and 
usually heal rapidly without the need for specific treatment. Singal et al evaluated the 
symptoms associated with ulceration after 0.5-2ml intravariceal injections of absolute 
alcohol (Singal 1990).  All 40 patients in their study had mucosal ulceration when 
examined endoscopically soon after sclerotherapy but only two thirds were 
symptomatic, with mild dysphagia (53%), mild to moderate retrosternal pain (28%) 
and low-grade fever (15%).  Patients with large ulcers (>1cm in diameter) were more 
likely to be symptomatic.  The dysphagia and chest pain usually improved rapidly 






To prevent sclerotherapy-induced ulcers and their complications, sucralfate, H2-   
receptor blockering agents, and antacids, alone or in combination, have been used  
(Tamura 1991, Pacquet 1991, Roark 1984, Polson 1989).  Although sucralfate may 
reduce recurrent bleeding from ulceration, the frequency and extent of ulcers are 
similar in patients who had not received sucralfate (Polson 1989).  Another controlled 
trial suggested that ulcer healing may be accelerated by sucralfate, especially in 
patients with deep ulceration (Pacquet 1991).  The ulcers healed more slowly in 
patients with a serum albumin level of less than 3 g/dl (Singal 1990).  In the study of 
Kumar et al., 31 patients were randomised to receive sclerotherapy plus ranitidine 
(300 mg per day) or sclerotherapy alone. Varices were treated until eradication, and 
the treatment groups were said to be similar with respect to the mean number of 
treatment sessions, time and volume of sclerosant required for eradication.  
Significant reductions in the frequency of sclerotherapy-associated oesophageal 
ulceration and episodes of recurrent bleeding were observed in the group that took 
ranitidine (Kumar 1993). 
 
A small proportion of ulcers persist, despite prolonged treatment with high-dose H2-
receptor antagonists and sucralfate. In a small group of patients with complicated 
chronic ulcers, Gimson et al achieved complete healing in all patients after an 8-
week course of 40 mg of omeprazole daily (Gimson 1990).  Similar results for a 
small number of patients were reported by Johlin et al (Johlin 1992). The rapid 
healing of resistant ulcers with omeprazole suggests that such ulcers are 
perpetuated by mucosal damage from continuing gastroesophageal reflux.  The 
investigators suggest that consideration should be given to even earlier use of 





Further studies are needed to determine the role of medical therapy for both the 
prevention and treatment of variceal sclerotherapy-induced ulceration. 
 
Bleeding 
Bleeding from the needle puncture site during variceal sclerotherapy is common and 
can usually be controlled without difficulty by an adjacent small volume submucosal 
injection or by tamponade using the side of the flexed tip of the endoscope.  More 
severe bleeding may result from variceal laceration or accidental entry of the hilt and 
needle sheath into the varix in a restless or heaving patient.  This can be avoided by 
retracting the needle into the sheath between injections (Krige 2007).  Early 
recurrent bleeding is the most common major life-threatening event after 
sclerotherapy and occurs in 18 to 55% of patients (Krige 2009b).  Urgent endoscopy 
is important to establish whether recurrent bleeding is from a varix, or from 
sclerosant-induced ulceration, or oesophagitis or another source.  If the recurrent 
bleeding is variceal in origin, further sclerotherapy to control the bleeding is 
indicated.  Although control of acute variceal bleeding is usually achieved with a 
single injection session in 70% of patients, some patients require further injections 
(Kahn 1989).  There is evidence to suggest that somatostatin may be helpful in this 
situation (Jenkins 1992).  If variceal bleeding recurs despite two adequate injections, 
mortality increases exponentially, and some other definitive procedure should be 
employed (Bornman 1986, Burroughs 1989). 
 
Bleeding from ulceration after variceal sclerotherapy may be particularly troublesome 
and occurs in as many as 13.3% of patients (Schuman 1987, Sauerbruch 1985, 





haemorrhage because of the complex venous anatomy of the lower oesophagus 
(Kitano 1986).  Repeat sclerotherapy is inappropriate in patients with deep ulceration 
or oesophagitis, and may aggravate or compound the problem.  Bleeding in most 
ulcers is self-limited or stops with the addition of vasopressin and sucralfate (Kahn 
1989, Roark 1984).  The small group that continue to bleed pose a major 
management problem.  Balloon tamponade increases the risk of pressure necrosis 
and perforation.  Oesophageal transection may be hazardous after previous injection 
sclerotherapy, and shunt surgery may be inappropriate in cirrhotic patients with poor 
liver function (Durtschi 1986).  In this difficult situation, the Jenkins et al were able to 
control severe bleeding in 20 of 22 patients using intravenous somatostatin (250 




Deep ulceration with transmural necrosis may progress to a localised or contained 
perforation without mediastinitis or communication with the pleural cavity (Kahn 
1989, Shemesh 1986).  Such confined perforations should be suspected in patients 
who have persistent pain and pyrexia after variceal sclerotherapy, and the diagnosis 
is confirmed on gastrografin swallow.  Kahn et al recorded this complication in 25 
(8.2%) of 304 patients (Kahn 1989). These patients were treated with antibiotics, 
parenteral hyperalimentation, or enteral feeding via a fine-bore Silastic 
nasoduodenal tube. In most patients, subsequent sclerotherapy was delayed for 3 to 
4 months.  Seven of the 25 patients died; two after a devascularization operation for 
continued bleeding from the ulceration, and five died of progressive liver failure.  The 







Free perforation occurs in 2% - 5% of patients and has a prohibitive mortality rate, 
especially in patients with advanced liver disease.  Perforation was more frequent 
when the rigid oesophagoscope was used for sclerotherapy and was due to 
instrumental injury (Borman 1988, Kahn 1989, Terblanche 1989).  Perforation after 
fibre-optic injection sclerotherapy is usually delayed and is the result of deep 
ulceration and transmural necrosis (McGrew 1985).  The risk of perforation is 
greatest in patients requiring repeated injections for uncontrolled or recurrent 
bleeding during the index admission (Pillay 1990, Bacon 1987).  During these 
sessions, large cumulative volumes of sclerosant are often used, and the risk of 
inadvertant misplaced, deep injections is greatest (Grobe 1984, Soderlund 1983).  
Possible aggravating factors that could predispose the patient to delayed perforation 
include concurrent balloon tamponade, impairment of healing secondary to poor liver 
function, mucosal ischaemia associated with infusion of vasopressin, prolonged 
nasogastric intubation and colonization of the ulcer base with Candida albicans 
(Soderlund 1983, Barthel 1987). 
 
Free perforation generally occurs 10 to 14 days after the index injection session 
(Goldberg 1995).  Analysis of patients for whom detailed clinical information is 
available reveals a prodrome with several features in common (McGrew 1985, 
Bacon 1987, Vickers 1989, Huizinga 1984, Shibuya 1989, Perino 1987).  Most 
patients developed deep local ulceration at the injection site following urgent or 
emergency sclerotherapy during their index admission.  Most patients had severe, 





and worsening encephalopathy.  The effusions were initially sterile, but invariably 
became infected with a variety of organisms (Goldberg 1995).   Gram-negative 
septicaemia, shock, and deteriorating liver function with multiple organ failure was a 
common outcome despite adequate surgical or tube drainage.  Some patients may 
not manifest the clinical features of an oesophageal leak but present only with subtle 
signs of sepsis, worsening encephalopathy or deteriorating liver function, with the 
diagnosis frequently being made at necropsy (Bacon 1987, Korula 1989). 
 
Free oesophageal perforation poses a major management problem.  Oesophageal 
necrosis, mediastinal venous collaterals, and sepsis with multiple organ failure 
preclude conventional treatment for oesophageal perforation.  At thoracotomy, the 
tissues are friable and oedematous, making repair difficult and likely to break down. 
Most reported perforations were managed conservatively with tube thoracostomy, 
and the mortality rate was high for patients who had this complication.  This reflects 
the reluctance to institute major operative treatment for high-risk patients who are 
already considered to have a poor prognosis. 
 
Intramural Haematoma 
Intramural haematoma of the oesophagus is a rare complication of EIS and has a 
reported incidence of 0.3 to 1.6% (van Beljon 2004).  The precise pathogenesis is 
speculative.  Tissue necrosis extending into the submucosa and muscularis may be 
the initiating event and may be compounded by repeated injections (van Beljon 
2004). Raised portal pressure and coagulation defects (Low 1988) may aggravate 
intramural dissection and extension of blood and sclerosant both longitudinally and 





necrosis is at its most severe during the first 3 to 4 days after sclerotherapy and this 
may explain the early manifestation of this complication (Salomez 1991).  Other 
factors implicated in the pathogenesis include the different injection techniques 
(paravariceal versus intravariceal injection), the type of sclerosant solution, the 
volume of sclerosant given per injection, the interval between treatments and the 
occurrence of retching or prolonged valsalva during or shortly after injection 
sclerotherapy (Low 1988, Salomez 1991).   
 
An intramural oesophageal haematoma should be suspected in a patient who 
presents with the triad of sudden onset dysphagia, odynophagia and haematemesis 
or blood stained sputum occurring soon after variceal sclerotherapy (Korula 1985, 
Ou Tim 1982, Shay 1981).  There may however be no evidence of blood loss or 
haematemesis if the haematoma is contained within the oesophageal wall or 
submucosa and the mucosa has not been breached, in contrast to patients with a 
Mallory-Weiss tear who present with upper gastrointestinal bleeding with or without 
pain and no dysphagia (Thompson 1987).  Associated retrosternal chest pain is 
common and is due to epithelial separation by the expanding intramural haematoma.  
The absence of subcutaneous emphysema in the neck differentiates this condition 
from the more serious complication of oesophageal perforation (van Beljon 2004). 
 
In a patient who has recently had EIS and has a clinical presentation compatible with 
an intramural haematoma of the oesophagus, contrast studies provide the simplest 
way of confirming the diagnosis and excluding an oesophageal perforation (van 
Beljon 2004).  A large elongated radiolucent intraluminal filling defect with a smooth 





1982, Thompson 1987).  The contrast study may also reveal a “double barrel” 
oesophagus in which contrast material can be seen in both the lumen of the 
oesophagus and in the intramural cavity (Benjamin 1965, Marks 1968).   
Oesophagoscopy is helpful in establishing the diagnosis but should be reserved for 
inconclusive cases because of the invasive nature of the investigation (van Beljon 
2004).  If performed, endoscopy usually shows a characteristic dark blue intramural 
bulge of mucosa (Ou Tim 1982).  Other imaging studies that have been used include 
CT scan, MRI and oesophageal echo endoscopy. 
 
Treatment depends on a definitive diagnosis of intramural oesophageal haematoma 
(van Beljon 2004).  In contrast to patients with oesophageal perforation after EIS 
which has a poor prognosis and who may require urgent surgical intervention, 
patients with intramural haematoma have a good prognosis (Krige 1999).  The initial 
treatment of intramural haematoma should be conservative (Reed 2001).  Symptoms 
usually begin to resolve spontaneously within 36 – 72 hours and disappear 
completely in 2-3 weeks (van Steenbergen 1984).  Patients should be kept nil per 
mouth and receive intravenous fluids.  Oral feeds are introduced gradually as 
tolerated (van Beljon 2004).  Resolution of the intramural haematoma occurs by 
reabsorption without disruption of the mucosal surface in patients with small 
haematomas or sloughing of the overlying mucosa may occur if the intramural 
haematoma is large (Ou Tim 1982, McGrath 1992).  No adverse long term sequelae 
have been reported after intramural haematoma formation and in most cases 
oesophageal varices had disappeared and were absent on follow up 







The incidence of oesophageal stricture after variceal sclerotherapy ranges from 11% 
to 58% (Krige 2005).  In a prospective study of 204 patients undergoing long term 
sclerotherapy, the Cape Town group found that one in ten patients developed a 
stricture (Krige 2000).  It is difficult to determine from published series precisely 
which factors contribute to stricture formation (Krige 1999b).  Most reports have not 
found a direct relationship with number of sclerotherapy sessions, volume or type of 
sclerosant, and site of injection (van Steenbergen 1984, Waring 1988, Snady 1984, 
Farrell 1992, Kochhar 1992).  Sorensen et al., however, demonstrated a clear 
relationship between the frequency and cumulative volumes of injection and an 
association with pre-existing ulceration (Sorensen 1984).  The 59% incidence of 
stenosis in 20 of 34 patients is among the highest reported.  Their technique, 
however, differed from other studies.  Paravariceal injections extending over the 
lower 10 cms of the oesophagus were performed every 3 days.  Patients who 
developed strictures had received more injections and larger volumes of sclerosant, 
and a significantly greater number had preceding mucosal necrosis. 
 
In the trial by Snady et al., patients undergoing sclerotherapy were randomised to 
receive either sclerotherapy plus acid protection (i.e. antacids, cimetidine, and 
sucralfate; 31 patients) or sclerotherapy alone (31 patients) (Snady 1984). In the 
former treatment group, 9.7% of patients developed symptomatic strictures during 







Sclerotherapy-induced strictures are usually short and localised to the lower 5 cm of 
the oesophagus.  Most strictures can be dilated endoscopically without difficulty.  
Two to three dilatation sessions suffice for more than 85% of patients (Kochhar 
1992).  Persistent oesophageal dysmotility may explain the refractory dysphagia that 
occurs in some patients despite adequate dilatation.  Dilatation does not precipitate 
bleeding from partially treated varices and although the stricture may temporarily 
delay eradication of varices, the sclerotherapy programme can be continued after 
stricture dilatation.  For short, symmetrical strictures, Maloney mercury-filled rubber 
dilators allow easy and safe dilatation although tighter and longer strictures require 
fluoroscopically controlled dilatation over an endoscopically placed guidewire with 
Savary or Eder-Puestow dilators. 
 
Motility disorders 
Several studies have evaluated the short and long term effects of sclerotherapy on 
oesophageal motor function and gastroesophageal reflux (Sauerbruch 1982, Reilly 
1984, Larson 1984).  Serial evaluation of motility patterns in the oesophagus before 
sclerotherapy, 3 days after sclerotherapy and 6 months later, has demonstrated that 
the length of the high pressure zone, peristaltic velocity and swallow-wave symmetry 
are markedly affected.  The length of the high pressure zone increased significantly 
after the initial sclerotherapy session due to intense inflammation in the distal 
oesophagus.  The normal waveform pattern and symmetry are altered considerably 
by sclerotherapy.  Double- and triple-peak waveforms, dropped swallow waves in the 
distal oesophagus and simultaneous and spontaneous contractions have been 
observed (Reilly 1984, Larson 1984, Ogle 1978).  Oesophageal scintigraphy of 





compared with controls (Spence 1990).  These changes increase after sequential 
treatment and this effect probably is a manifestation of sclerosant-induced 
oesophagitis, intramural inflammatory response, or fibrotic changes in the 
oesophageal wall (Snady 1986). 
 
Injection sclerotherapy has had no substantial effect on lower oesophageal sphincter 
pressure in most but not all studies (Reilly 1984, Larson 1984).   In the study of 
Suzuki et al of lower oesophageal sphincter pressures measured in 41 patients 
before and after sclerotherapy, including measurement 6 months after treatment, the 
magnitude of the decrease in pressure was greater in patients with sclerotherapy-
associated ulcers.  The results showed correlation among the occurrrence of reflux 
symptoms, ulceration, and decreases in sphincter pressure. However, these 
abnormalities were transient and had usually resolved by the 6 month follow-up 
examination (Suzuki 1991). 
 
There is some discrepancy concerning the incidence and severity of 
gastroesophageal reflux after sclerotherapy and its effect on oesophageal acid 
clearance (Schuman 1985, Reilly 1984, Larson 1984, Ogle 1978, Cohen 1985, 
Shoenut 1986).  Reilly et al. found that gastroesophageal reflux, as determined by 
standard reflux tests, becomes more prevalent after sclerotherapy and suggested 
that gastroesophageal reflux contributes to stricture formation (Reilly 1984).  In 
contrast, Ogle et al. found no instance of acid reflux into the oesophagus although 
patients who received sclerotherapy did have impaired acid clearance (Ogle 1978).  
The magnitude of these changes are not thought to be severe enough to promote 





long term pH monitoring of 19 patients who underwent sclerotherapy and 15 
untreated patients with cirrhosis who served as controls.  There were no significant 
differences between the two groups with respect to percentage of time that 
oesophageal pH was less than 4 for the mean duration of reflux episodes 
(Sauerbruch 1993).  In a similar study of 24 hour pH monitoring of 16 patients who 
underwent variceal sclerotherapy and 21 untreated patients with varices, Kinoshita et 
al. found a significant increase in the rate of gastroesophageal reflux in treated 
patients.  The severity of reflux directly correlated with the volume of paravariceally 
injected sclerosant (Kinoshita 1992). 
 
Other oesophageal complications 
A variety of unusual local oesophageal complications have been reported after 
sclerotherapy.  Davion et al described the development of gastric bezoars in five 
patients undergoing sclerotherapy which was attributed to possible transient vagal 
nerve damage (Davion 1989). Pneumatosis intestinalis and pneumoperitoneum may 
occur due to intramural air entering through a small mucosal tear in the oesophageal 
wall and dissecting distally into the stomach, small bowel and colon.  Rupture into 
the peritoneum produces free intraperitoneal air.  The condition is benign and 
resolves spontaneously (DeMarino 1988).  Other rare findings include 
pseudodiverticula (Scherl 1983), mucosal bridges (Gottfried 1985), and peri-
oesophageal granulomas (Barsoum 1982).  These findings are usually incidental and 
require no specific therapy. 
 
Sporadic reports have described oesophageal carcinoma, usually the squamous cell 





additional risk factors (e.g. smoking, alcohol intake) can be identified in virtually all 
instances.  Although surveillance of patients undergoing sclerotherapy has been 
recommended, there are no scientific data to support claims of a relationship 




Cardiac complications specifically related to variceal sclerotherapy are rare.  
Anecdotal accounts of coronary artery spasm (Charng 1988), persistent 
bradyarrhythmia (Perakos 1984), and heart failure due to polidocanol (Paterlini 1984, 
Imperiali 1986) have been reported.  Seven cases of pericarditis after sclerotherapy 
have been described (Knauer 1987, Caletti 1990).  Onset is heralded by fever, chest 
pain and dyspnoea.  A pericardial friction rub is usually heard, and 
electrocardiographic and echocardiographic evidence point to a pericardial effusion.  
If pericarditis remains undiagnosed, progression to cardiac tamponade or 
constrictive pericarditis may occur (Brown 1987, Tabibian 1987).  No precipitating 
factors have been clearly identified. 
 
Pulmonary complications are common and range from minor asymptomatic changes 
found incidentally on routine chest x-ray films to aspiration or bronchopneumonia, 
pleural effusions, lobar collapse or consolidation and the adult respiratory distress 
syndrome (Barsoum 1982, Baydur 1990).  It is often difficult to determine to what 
extent respiratory changes are directly attributable to sclerotherapy, because 
underlying parenchymal and vascular abnormalities are commonly found in chronic 





shifts after vigorous resuscitation with crystalloids, massive transfusion, and 
diaphragmatic splinting by tense ascites are additional factors which may contribute 
to a deterioration in pulmonary function (Zeller 1991).  In two cases descibed by 
Crawford and Ryan, acute respiratory insufficiency occurred after sclerotherapy. 
Both patients had ascites, and the respiratory difficulty was reversed by aspirating air 
from the stomach (Crawford 1984). 
 
Several studies have investigated the distribution and potential damaging effects of 
sclerosant solutions on the respiratory system (Sukigara 1985, Conners 1986, 
DePuey 1988).  There is evidence that sclerosant dissemination to the pulmonary 
and systemic circulation after intravariceal injection sclerotherapy occurs through 
oesophagogastric collaterals and the azygous-hemiazygous systems.  Entry of 
sclerosant into the pulmonary circulation has been demonstrated to occur by positive 
uptake on lung scan of 99mTc-labelled sodium tetradecyl sulphate and sodium 
morrhuate solutions when injected into oesophageal varices.  Systemic 
dissemination has also been demonstrated to occur with ethanolamine oleate plus 
99m Tc sodium pertechnetate, but the frequency and consequences appear to be 
minor (Sukigara 1985, Conners 1986, DePuey 1988). 
 
Studies in experimental models, using large volume infusions of sclerosant solutions 
containing fatty acid derivatives (i.e., sodium morrhuate and ethanolamine oleate) 
injected directly into the right atrium, have produced pulmonary endothelial damage, 
transient increases in pulmonary artery pressure and haemorrhagic pulmonary 
oedema (Bailey-Newton 1985, Jones 1982, Spragg 1982, Ashbaugh 1968, Griffith 





fact that oleic acid causes an acute pulmonary injury in animals has raised concern 
that variceal sclerosants containing fatty acids may cause similar injury in humans.   
 
The pulmonary haemodynamic effects of sclerosant injection have been evaluated in 
several small clinical studies.  Transient increases in pulmonary artery pressure from 
normal basal values occur during variceal sclerotherapy but are not associated with 
a change in cardiac output or arterial oxygenation (Glauser 1984).  Intravariceal 
sclerotherapy using absolute alcohol results in significant mean pulmonary artery 
pressure increases at 1 and 5 minutes, with return to basal levels by 15 minutes.  
Equivalent volumes of saline produce similar significant rises in pulmonary artery 
pressure from basal levels, suggesting that the effect results from a volume load 
rather than the consequence of the sclerosant (Sarin 1988).  Although pulmonary 
and systemic vascular resistence indices increase significantly from basal values 
after sclerotherapy with sodium morrhuate, pulmonary artery and pulmonary capillary 
wedge pressure remain stable without alterations in gas exchange (Bailey-Newton 
1985).  The changes in pulmonary haemodynamics after sclerotherapy in humans 
are small in magnitude and not sufficient to cause acute pulmonary capillary injury. 
 
Because premedication and passage of an endoscope may contribute to aspiration 
pneumonitis or hypoxaemia, the incidence of respiratory dysfunction in patients 
receiving variceal sclerotherapy should be compared with those undergoing 
endoscopy for other reasons.  In a controlled study Korula et al found no difference 
in either the short term or long term effects on lung function and gas exchange after 
sclerotherapy in patients with cirrhotic portal hypertension compared to a similar 





found that patients complaining of post-injection retrosternal pain 24 hours after 
variceal sclerotherapy had a larger fall in vital capacity and forced expiratory volume 
than patients without pain (Kitano 1988).  One third of cirrhotic patients with 
oesophageal varices were shown to have pre-existing pulmonary interstitial oedema 
and arterial hypoxaemia (PaO2<80 mm Hg).  In these patients, injection of 5% 
ethanolamine oleate may lead to further deterioration of pulmonary function and a 
decrease in arterial oxygen content (Kitano 1988).  Samuels et al. found significant 
decreases in arterial oxygen tension and vital capacity in cirrhotic patients 
undergoing sclerotherapy.  Samuels et al. suggested that these results indicated that 
sclerotherapy produced a restrictive defect in pulmonary function, possibly caused 
by embolisation of sclerosant to the lungs (Samuels 1994). 
 
Pulmonary and mediastinal abnormalities are frequently found on routine chest x-ray 
and computed tomographic examinations when performed within 48 hours after 
variceal sclerotherapy.  These changes may be explained by peri-oesophageal 
inflammation and by the fact that the oesophagus does not have the serosal layer 
that provides the barrier function for other organs.  Saks et al. found radiological 
changes in 79% of patients after variceal sclerotherapy (Saks 1983). Pleural 
effusions and mediastinal soft tissue densities were the most common findings, and 
atelectasis, linear lung shadows and retrocardiac soft-tissue densities were 
demonstated less often (Saks 1983, Mauro 1986).   
 
Chest pain and effusions occur more frequently in patients who develop deep 
ulceration and are caused by an intense peri-oesophageal, mediastinal and pleural 





small and resolve spontaneously.  Pleural effusions were found by Bacon et al. after 
31 (48%) of 65 sclerotherapy sessions performed in 30 patients (Bacon 1987).  
There was an approximately equal distribution between left-sided, right-sided, and 
bilateral effusions.  The total volume of sclerosant injected was significantly greater 
in patients who developed effusions than in those who did not.  Most of the effusions 
were exudative.  Parikh et al. found pleural effusions in 6 of 31 patients who 
underwent sclerotherapy with absolute alcohol (Parikh 1993).  As in the study by 
Bacon et al., chest pain, frequently persistent, was found to be significantly more 
common in patients with pleural effusions (Bacon 1987).  Most effusions were small, 
developed within 48 hr of a treatment session, and disappeared without treatment 
within 1 week. 
 
Aspiration is the most serious of the respiratory complications and occurs most 
frequently during sclerotherapy for acute bleeding.  Aspiration pneumonia is 
avoidable if the stomach is emptied completely by suction before sclerotherapy is 
initiated and an assistant scrupulously clears the patient’s mouth and hypopharynx 
with a suction catheter during the injection procedure.  Excessive sedation, hepatic 
encephalopathy, and a prolonged procedure without adequate or effective airway 
protection during active bleeding are contributing factors if bleeding is massive.  In 
this situation, endotracheal intubation before endoscopy is essential to avoid this 
potentially lethal complication. 
 
Other uncommon pulmonary complications reported after sclerotherapy are broncho-





subcutaneous emphysema (Barsoum 1982), chylothorax (Gertsch 1983), and 
haemothorax (Rajagopalan 1994). 
 
Systemic complications 
Septicaemia and bacteraemia 
Transient fever due to an acute local inflammatory response or chemical phlebitis 
occurs in a fourth of patients after sclerotherapy.  If a fever persists for more than 2 
days, a search for a septic or local oesophageal complication is mandatory. 
Anecdotal reports have incriminated sclerotherapy as a cause of meningococcal and 
streptococcal pneumoniae septicaemia (Van Zaanen 1990), infective endocarditis 
(Baskin 1989), pyogenic meningitis (Kumar 1991), brain (Wang 1990, Robert 1991, 
Hassig 1992, Cohen 1985) and perinephric abscesses (Ritchie 1987) and bacterial 
peritonitis (Barnett 1987, Tam 1990).  These reports have raised the question 
whether the incidence of septic complications are increased as a consequence of 
sclerotherapy-induced bacteremia. 
  
There are several possible sources of bacterial contamination during injection 
sclerotherapy. The spectrum of organisms associated with bacteraemia and the 
predominance of alpha-haemolytic streptococci strongly suggest the oropharyngeal 
flora as the source of contamination.  During sclerotherapy, these organisms may be 
introduced by the endoscope or injector needle and enter the bloodstream.  The 
length of the needle injector and a contaminated water supply have been implicated 






The incidence of bacteraemia after sclerotherapy ranges from 0% to 50% (Snady 
1985, Gerhartz 1984, Cohen 1983, Camara 1983, Brayko 1985, Sauerbruch 1985, 
Low 1986, Hegnhoj 1988, Ho 1991).  A variety of injection techniques, sclerosant 
solutions, and different lengths of injection needles were used in these studies.  An 
increased incidence of bacteraemia occurs during and up to 5 minutes after after 
sclerotherapy.  Because blood cultures were drawn during both these periods in 
fewer than half of the studies, the extent of bacteraemia in some studies may have 
been underestimated.  Inherent in all studies designed to search for positive blood 
cultures is the difficulty of determining true bacteraemia from contaminants.  Some 
investigators have isolated common skin commensals, and in one study, 23% of 
isolates were coagulase-negative staphylococci (Sauerbruch 1985) which may 
originate from the skin during venepuncture. 
 
Most previous studies and data on bacteraemia after sclerotherapy have been 
derived from blood cultures obtained during or after elective sclerotherapy. The risk 
of bacteraemia may be higher during the technically more demanding and traumatic 
emergency sclerotherapy and in the presence of venous and urinary catheters and 
endotracheal tubes.  In the report of Bac et al., for example, the calculated risk for 
the development of bacterial peritonitis was significantly higher after sclerotherapy 
performed as an emergency than for elective procedures (Bac 1994). Patients with 
alcoholic cirrhosis may develop bacteraemia spontaneously because of decreased 
reticuloendothelial system function, impaired neutrophil chemotaxis, low levels of 






The incidence of infection after sclerotherapy was studied by Rolando et al. in a trial 
that compared sclerotherapy plus antibiotic prophylaxis (i.e. intravenous imipenem or 
cilastatin) with sclerotherapy alone in patients with variceal bleeding.  No significant 
difference was found between the incidence of bacteraemia after treatment sessions 
in the control group and that in the patients who received antimicrobial prophylaxis 
(5.6% vs 1.1%).  Most of the episodes of bacteraemia were associated with 
emergency treatment sessions (Rolando 1993).  In a similar study by Pulanic et al., 
30 patients with bleeding oesophageal varices underwent sclerotherapy without 
antibiotic prophylaxis, and 30 similar patients had sclerotherapy plus intravenous 
infusions of ampicillin with treatment and for 3 days thereafter.  No significant 
differences between the two groups were found in the clinical parameters of infection 
(e.g., temperature, white blood cell count, differential blood cell count, erythrocyte 
sedimentation rate) during a follow-up period of 3 days (Pulanic 1989). 
 
The clinical importance of blood culture isolates after sclerotherapy remains 
questionable.  In none of the prospective studies have organisms (other than 
probable commensals) been isolated more than 30 minutes after sclerotherapy, 
suggesting that bacteraemia is always transient.  No infective complications have 
been reported following bacteraemia in these studies.  Previous recommendations 
advising routine antibiotic prophylaxis are no longer valid, and most authorities now 
recommend prophylaxis only for patients with specific vascular risk factors, such as 
prosthetic valves or previous episodes of endocarditis (Lorgat 1990).  Strict attention 
to routine equipment cleaning and disinfection to avoid contamination of endoscopes 






Haemodynamic and thrombotic effects 
Potential effects of repeated long term after sclerotherapy and obliteration of 
oesophageal varices are an increase in portal pressure, the development of other 
compensatory collaterals, and bleeding from varices at remote sites (Manzione 
1989, Foutch 1984, Korula 1991).  Korula and Ralls demonstrated that, despite an 
improvement in laboratory and clinical parameters of hepatic function, the portal 
venous pressure gradient increased by a third in cirrhotic patients after eradication of 
oesophageal varices (Korula 1991).  Dilawari et al. found that 6 (40%) of 15 patients 
with non-alcoholic portal hypertension developed spontaneous spleno-adreno-renal 
shunts after sclerotherapy (Dilawari 1989).  The same mechanism may explain the 
increased incidence of portal hypertensive gastropathy after repeated sclerotherapy 
(D’Amigo 1990) and the phenomenon of bleeding from varices at other sites, 
including the umbilical vein (i.e. Cruveilhier-Baumgarten syndrome), duodenum, 
ileum, colon, rectum and bowel-related adhesions (Manzione 1989, Foutch 1984, 
Keane 1986, Fry 1988, Arst 1986, Elefthenadis 1988). 
 
Changes and direction of flow in the coronary and azygos systems are complex in 
patients with portal hypertension.  Phasic retrograde oesophageal collateral flow has 
been demonstrated during variceal sclerotherapy using fluoroscopy and endoscopic 
Doppler-flow techniques (Grobe 1984, McCormack 1983).  Aoki et al. demonstrated 
by intra-operative portography that flow could be hepatofugal, to and fro, or 
hepatopetal (Aoki 1988).  Altered venous flow, endothelial damage and a 
hypercoagulable state after repeated intravariceal sclerotherapy may promote 
excessive local venous thrombosis, with propagation into the splanchnic venous 





that a local endothelial inflammatory response after variceal sclerotherapy is the 
initiating event, although others have shown that hypercoagulable states may be 
induced by sclerosant (Kang 1987, Musso 1987, Jacobson 1992).   
 
In an umbilical cord model designed to simulate variceal blood flow, brief exposure to 
even low concentrations of sodium tetradecyl sulphate produces damage and 
stripping of endothelium, which exposes highly thrombogenic factor VIII-rich 
subendothelium (Jacobson 1992).  The effects of sodium tetradecyl sulphate on 
coagulation and platelet function are dependent on sclerosant concentration.  A 
dilute concentration of sodium tetradecyl sulphate induces a hypercoagulable state 
by selective inhibition of protein C and promotion of platelet aggregation.   Activation 
of systemic blood coagulation in cirrhotic patients after sclerotherapy, which may be 
aggravated by vasopressin infusion, may promote venous thrombosis in the 
splanchnic bed.  In experimental studies, higher concentrations of sodium tetradecyl 
sulphate inactivate the coagulation cascade and cause lysis of platelets (Jacobson 
1992). 
 
Because variceal sclerotherapy may lead to thrombosis of gastric varices (Kage 
1987), it is conceivable that thrombus formation may extend further and initiate 
thrombosis in the splanchnic venous system.  Portal vein thrombosis is a well 
recognised complication of cirrhosis and portal hypertension.  The reported 
incidence ranges from 0.5% to 21% (Sarfeh 1979, Okuda 1985, Belli 1986).  Acute 
portal or mesenteric venous thrombosis in association with variceal sclerotherapy is, 
however, uncommon.  Nevertheless, a number of cases of portal or mesenteric 





administration of vasopressin (Thatcher 1986, Goldberg 1989, Ashida 1989, 
Deboever 1989).   
 
In small retrospective series of patients undergoing portosystemic shunt surgery, 
Leach et al. found splanchnic venous thrombosis to be more common in patients 
who had prior sclerotherapy than in those who had no prior injection therapy (Leach 
1989).  Stoltenberg et al., in an autopsy series, demonstrated extension of thrombus 
from oesophageal varices into the portal and mesenteric venous systems that 
resulted in small intestinal infarction and hepatic failure (Stoltenberg 1987).  In two 
cases, splenic vein thrombosis and splenic infarction occurred, suggesting 
propagation of clot through the coronary and left gastric veins. Rice et al. 
demonstrated clots in the portal venous system by means of Doppler sonography in 
patients who had undergone sclerotherapy or a portosystemic shunt operation, 
although this finding was relatively infrequent in the endoscopically treated patients 
compared with the surgically treated patients (i.e. end-to-side shunt 69%, distal 
splenorenal shunt 67%, sclerotherapy 5%) (Rice 1991). 
 
Caletti et al. performed ultrasonography of the portal venous system in 25 patients 
before initiation of sclerotherapy and after obliteration of varices (Caletti 1987).  They 
demonstrated no evidence of thrombosis or alterations in the calibre of the portal 
venous system.  In contrast, Hunter et al. observed portal vein thrombosis in 36% of 
a small series of patients who had undergone sclerotherapy; controls had only a 






An increased incidence of thrombosis of the portal vein or its major tributaries after 
long-term sclerotherapy has been disputed.  In the controlled trial of Kawasaki et al. 
comparing sclerotherapy with distal splenorenal shunt, all patients underwent 
angiographic assessment of the portal, splenic, and superior mesenteric veins before 
and after treatment.  Those who received chronic sclerotherapy provided a unique 
group in which the incidence of thrombosis could be assessed.  Despite frequent 
injections (mean 6.5) and large volumes (mean 62ml), no patient developed splenic 
or portal vein thrombosis (Kawasaki 1992).  
 
Distant histological effects due to sclerosant, including intimal damage and fibrosis in 
the portal vein, have been reported after obliteration of oesophageal varices.  Hunter 
et al. found substantial changes when comparing the morphology of portal and 
splenic veins in patients who had received variceal sclerotherapy with those who had 
not (Hunter 1988).  In addition to the loss of smooth muscle and elastin fibres and 
medial fibrosis in patients with portal hypertension, those who had received variceal 
sclerotherapy also had disruption of normal venous architecture with loss of elastic 
fibres, smooth muscle bundles and an increase in fibrous tissue.  Chaudhary et al. 
demonstrated changes in splenic vein histology in patients undergoing splenorenal 
shunt after variceal sclerotherapy, including increased fibrosis, intimal and medial 
destruction and microthrombi (Chaudhary 1990).  Retrograde flow through collateral 
pathways or abnormal responses of the perivenous lymphatic vessels to the 







Seidman et al. reported the case of a child who developed paraplegia after 
intravariceal injections of ethanolamine oleate.  At autopsy 2 years later, the authors 
found evidence of an infarct of the spinal cord secondary to occlusion of the anterior 
spinal artery (Seidman 1984). 
 
Several studies have demonstrated transient changes in the haemostatic 
mechanisms of patients undergoing sclerotherapy. In a study of 45 patients, Yamaga 
et al. found significant increases in concentrations of various fibrinopeptides and 
fibrin degradation products and observed suppression of platelet aggregation after 
intravariceal sclerotherapy using 5% ethanolamine oleate.  Platelet function 
gradually returned to normal in approximately 1 week (Yamaga 1989).  Ohta et al. 
found evidence of haemolysis, including haemoglobinuria, in patients undergoing 
sclerotherapy with 5% ethanolamine oleate; this finding was significantly more 
frequent in patients with albumin levels of less than 3.0 g/dl but was otherwise 
unrelated to liver function status.  Haemolysis was found to increase with increasing 
concentrations of ethanolamine oleate and could be inhibited by increases in serum 
albumin.  Creatinine clearance decreased in patients with haemoglobinuria, and two 
such patients developed acute renal failure (Ohta 1993).  Miyoshi et al. found 
evidence of renal tubular dysfunction but no significant changes in glomerular 
filtration rate in patients undergoing sclerotherapy with ethanolamine oleate.  
Changes in renal function were suppressed by pretreatment with haptoglobin 
Miyoshi 1991). 
 
de Franchis et al. found that standard coagulation tests (i.e. prothrombin time, partial 





sclerotherapy with 5% sodium morrhuate plus thrombin or sodium morrhuate alone.  
However an abrupt increase in plasma fibrinopeptide A was demonstrated after 
sclerotherapy; in most cases, these levels returned to baseline within 24 hr.  The 
authors suggested that sclerotherapy-related changes in coagulation were of no 
clinical significance (de Franchis 1987).  However, Yuki et al. argued that mild 
transient symptoms such as headache and fatigue could be correlated with changes 
in coagulation parameters in patients who underwent sclerotherapy with a 
combination of hypertonic glucose, thrombin, and 1% polidocanol (Yuki 1991). 
 
Strategies to prevent endoscopic related complications: 
Endoscopic therapy is an established and integral part of the management of acute 
variceal bleeding and the long-term treatment of patients after a variceal bleed. 
Although complications after endoscopic therapy for variceal bleeding are common, 
most are minor and do not interrupt the treatment program (Krige 2005). In a small 
group of patients however, the success of therapy is compromised by recurrent 
bleeding and serious procedure-related complications.  Most of the serious 
complications related to endoscopic therapy occur in patients with severe liver 
disease in whom control of bleeding is difficult.  It is not the complication that is a 
breach of optimal care, but rather the failure to anticipate or recognize, and respond 
appropriately. Mature clinical judgment is necessary in acute problematic or complex 
cases and careful supervision of trainees or assistance by an experienced 
endoscopist becomes essential when critical decisions are required (Krige 1999).   
Early and close multidisciplinary consultation is often useful in demanding cases to 






A number of critical generic precautions are important to avoid both local and 
systemic complications, regardless of the type or technique of endoscopic 
intervention used to control acute bleeding.   Effective resuscitation should precede 
endoscopy in patients with evidence of recent major bleeding.  Diagnostic and 
therapeutic endoscopy should be performed in a well equiped unit with competent 
assistance and careful monitoring (Krige 2005).  It is prudent to perform endosocpy 
with the minimum sedation needed for a safe procedure.  High risk patients and 
those with significant cardio-pulmonary disease need only topical oropharyngeal 
anaesthetic spray and the minimum intravenous sedation.  In a frail patient, a 
benzodiazepine alone may be safer than the combination of a benzodiazepine and 
an opiate (Krige 1996).  Medications used for sedation should be titrated to the 
desired level of sedation using small, incremental doses.  Flumazenil, a 
benzodiazepine antagonist, and naloxone, an opiate antagonist, must be available 
should a cardio-pulmonary complication occur.  Meticulous attention should be given 
to suctioning of the mouth and hypopharynx by a dedicated assistant to avoid 
aspiration. 
 
Early endotracheal intubation is crucial if major bleeding occurs.  Precise and 
accurately placed injections are essential (Krige 2007).  To ensure adequate visibility 
during active bleeding, a large or double channel endoscope with vigorous irrigation 
should be used with the head elevated.  Uncontrolled blind, large volume injections 
during active bleeding must be avoided.  The sclerotherapy needle should not 
exceed 5mm in length and a short bevel reduces the risk of deep injections and 
extravasation of sclerosant and injury to the underlying oesophagus.  Recurrent 





the source.  If variceal bleeding continues or recurs during the index admission 
despite 2 adequate injections, other definitive therapy should be instituted. 
 
If ulceration involves more than one oesophageal quadrant, further injections should 
be delayed until healing has occurred. Treatment with H2-blockers or sucralfate does 
not prevent ulceration, but may accelerate healing.  Omeprazole has been effective 
in the treatment of chronic ulcers.  Special care should be taken in patients with deep 
ulceration and persistent pain, fever, an increasing pleural effusion and deterioration 
of liver function which suggest transmural necrosis and impending perforation.  
Motility abnormalities are usually transient in nature and of minor clinical 
consequence and most symptomatic strictures respond effectively to dilatation.   
 
In countries where cyanoacrylate adhesive is available and licensed for endoscopic 
use, damage to the endoscopic equipment, ulceration and pulmonary embolism, are 
the main potential complications that restrict its use.  Damage to the endoscope is 
preventable if specific precautions are taken.  There have been documented cases 
of cerebral, pulmonary and portal embolism. These complications appear to be 
related to the volume of cyanoacrylate injected.  The volume should be limited to four 
to six ampoules (2.0–3.0g) per session.   
 
Variceal eradication with endoscopic band ligation requires fewer endoscopic 
treatment sessions, and causes substantially less oesophageal complications (Tait 
1999, Baron 2009).  Although the incidence of early gastrointestinal rebleeding is 
reduced by endoscopic variceal ligation (EVL) in most studies, this does not result in 





Simultaneous combination therapy (EVL+EIS) of large varices confers no advantage 
over EVL alone (Karsan 2005).  A staged approach with initial EVL followed by EIS 
when varices are small requires further evaluation as the sequential combination 
may prove to be the optimal method of minimizing variceal recurrence (Krige 2005a).  
Overall, current data demonstrate clear advantages for using EVL in preference to 
EIS.  EVL should therefore be regarded as the endoscopic technique of choice in the 
treatment of oesophageal varices (Krige 2005). 
 
Conclusions 
Although complications after variceal sclerotherapy are common, most are minor and 
do not interrupt the injection programme. In a small group, however, the success of 
variceal sclerotherapy is compromised by recurrent bleeding and serious procedure-
related complications (Schuman 1987).  Most of the serious complications related to 
variceal sclerotherapy occur in patients with severe liver disease in whom control of 
bleeding is difficult.  Several precautions are critical to avoid local and systemic 
complications.  Effective resuscitation should precede endoscopy in patients with 
evidence of recent major bleeding.  Diagnostic and therapeutic endoscopy should be 
performed in a well equiped unit, with competent assistants and careful monitoring.  
Meticulous attention should be given to suctioning of the mouth and hypopharynx by 
a dedicated assistant to avoid aspiration.  Early endotracheal intubation is crucial if 
massive bleeding occurs.   
 
Precise and accurately placed injections are essential.   To ensure adequate visibility 
during active bleeding, a large or double channel endoscope with vigorous irrigation 





blind, large-volume injections during active bleeding must be avoided.  The 
sclerotherapy needle’s length should not exceed 5 mm, and a short bevel reduces 
the risk of deep injections.    
 
Recurrent bleeding after variceal sclerotherapy requires careful evaluation and 
repeat endoscopy to determine the source.  If variceal bleeding continues or recurs 
during the index admission despite two adequate injections, other definitive therapy 
should be instituted.  If ulceration involves more than one oesophageal quadrant, 
further injections should be delayed until healing has occurred.  Treatment with H2-
blockers or sucralfate does not prevent ulceration, but may accelerate healing.  
Omeprazole has been effective in the treatment of chronic ulcers.  Special care 
should be taken in patients with deep ulceration and persistent pain, fever, an 
increasing pleural effusion and deterioration of liver function, all of which suggest 
transmural necrosis and impending perforation.   Motility abnormalities are usually 
transient in nature and of minor clinical consequence. Most symptomatic strictures 
respond effectively to dilatation.    
 
Mature clinical judgment is necessary in acute problematic or complex cases, and 
careful supervision of trainees by an experienced endoscopist becomes essential 
when critical decisions are required.   Early and close multidisciplinary consultation is 








CHAPTER  3: 
 
 
PATIENTS AND METHODS  
 
 
General management strategy 
Patients who presented to Groote Schuur Hospital with a major upper 
gastrointestinal bleed were managed according to the specific upper gastrointestinal 
bleeding protocol used in the gastrointestinal clinic. In summary the protocol 
principles include urgent resuscitation and airway protection which took precedence 
over other investigations.  Rapid and secure large bore peripheral venous access 
was obtained and intravenous fluid replacement initiated.  Central venous access 
was obtained via an internal jugular vein in shocked patients. Standard blood 
component therapy including fresh frozen plasma and type O Rh-negative blood was 
given if required urgently before the availability of cross matched blood. Patients in 
whom oesophageal varices were suspected as the source of bleeding were rapidly 
resuscitated and underwent urgent endoscopy to identify the source of bleeding. 
Patients were nursed in an intensive or high care unit. The specific details of 
management have been published previously (Krige 2005, Krige 2007a, Krige 




The extent and urgency of initial therapy depended on the severity of the 
gastrointestinal bleeding.  Haemodynamically stable patients who were not actively 





the gastrointestinal clinic during office hours where the necessary endoscopic 
equipment required to control bleeding was available.  Unstable patients who  
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continued to have major bleeding had the endoscopic intervention performed in the 
operating theatre.  Patients who had massive or exsanguinating bleeding had a 
balloon tube inserted to control the acute bleeding before endoscopy was performed 
in the operating theatre.  For emergency endoscopy in the operating theatre, a fully 
equipped and prepared mobile endoscopy stack was provided by the endoscopy 
staff.  Emergency endoscopy did not commence until satisfactory venous access 
and central venous pressure lines were established and resuscitation procedures 
and volume replacement with blood transfusions were initiated to correct 
hypovolaemia.  If bleeding was profuse or if the patient was encephalopathic, 
endotracheal intubation was performed before endoscopy was commenced to 
protect the airway and avoid aspiration. 
 
Saline infusions were not used in order to avoid aggravation of ascites.  Overzealous 
expansion of circulating blood volume was avoided to prevent precipitation of further 
bleeding.  Central venous pressure was maintained at between 2 and 5 cm H2O, 
measured from the sternal angle.  Patients who were haemodynamically unstable or 
elderly or had associated cardiac or pulmonary disease were monitored using a 
pulmonary artery balloon catheter to avoid excessive administration of fluids which, 
when combined with vasoactive drugs, would lead to the rapid onset of oedema, 
ascites and hyponatraemia.  Clotting factors, if deficient, were replaced with fresh 
blood, fresh frozen plasma, vitamin K1 and platelet transfusions.  In patients with 
overt bleeding, octreotide was administered as an initial intravenous bolus dose of 
100 g and then as a continuous intravenous infusion of 50 g per hour if bleeding 





lactulose to minimize the onset of encephalopathy and intravenous antibiotics to 
prevent spontaneous bacterial peritonitis (Krige 2005, Krige 2007a, Krige 2007b, 
Krige 2009a).     
 
Therapeutic intervention for variceal bleeding 
A standard injection sclerotherapy technique was used throughout the duration of the 
study (Krige 1994, Krige 1996).  After intravenous sedation with midazolam, the 
diagnostic endoscopy and the variceal injection sclerotherapy was performed using a 
fibreoptic endoscope (model GIF 1T20 or K10; Olympus Corp, Lake Success, NY) 
during the first decade of the study and video-endoscopy during the last decade.  
The sclerosant, 5% ethanolamine oleate, was injected into the bleeding oesophageal 
varix using a combined intra- and paravariceal technique (Krige 1994).  A maximum 
total volume of 25 ml of sclerosant was injected at any one endoscopy session for 
control of acute variceal bleeding or when large varices (grade 4 or 5) were 
encountered during elective sclerotherapy.  An intravariceal technique alone with 
smaller total volumes of sclerosant was used for elective injection sclerotherapy 
when varices were grade 3 or less in size (Krige 1996).  Endoscopic details including 
the location, size and extent of the varices, the site of active bleeding and the volume 
of sclerosant injected at each intervention were recorded.  
 
Failure of emergency endoscopic therapy 
If a major variceal bleed recurred despite effective initial endoscopic and 
pharmacological therapy, the patient had an urgent repeat endoscopy and further 
injection of the bleeding site.  If variceal bleeding was profuse and endoscopic 
injection was not possible or bleeding continued despite endoscopic intervention, 





who rebled after two successive emergency endoscopy treatments during a single 
hospital admission was recognized as having a prohibitively high mortality if further 
endoscopic therapy was pursued.  These patients had a balloon tube inserted to 
control active bleeding, were resuscitated and then treated with a radiologically 
placed TIPS stent.   
 
The initial and the second sclerotherapy injection session a week later were 
performed during the index admission to hospital.  Subsequent injection 
sclerotherapy was undertaken at regular intervals at an outpatient clinic until the 
varices were eradicated.  After variceal obliteration, surveillance endoscopy was 
performed at 3 and 6 months and then annually to identify patients in whom varices 
had recurred.  Repeat injection sclerotherapy was performed whenever residual or 
recurrent varices were identified during surveillance endoscopy.   
 
Once bleeding had been controlled, all patients had a comprehensive and detailed 
medical assessment which included documentation of clinical, biochemical and 
endoscopic factors which might influence or contribute to variceal rebleeding and 
mortality.  A detailed history was obtained regarding the current or previous bleeding 
episodes, the duration and amount of alcohol intake, family history of liver disease or 
previous exposure to viral hepatitis. The physical examination documented the 
presence of stigmata of chronic liver disease including jaundice, peripheral and 
sacral oedema, spider angiomata, gynaecomastia, palmar erythema, testicular 
atrophy, white nails, Dupuytren’s contractures, hypertrophic osteo-arthropathy, 
clubbing, foetor hepaticus, flapping tremor and curaneous purpura and petechiae.  





splenomegaly, ascites, caput medusa and Cruveilhier-Baumgarten syndrome with a 
para-xiphoid venous hum due to retrograde flow in a patent umbilical vein. The 
examination, in addition, sought to establish clinical evidence of encephalopathy, 
asterixis and cognitive dysfunction.   
 
All patients had full laboratory studies including haematologic, biochemical and 
specific serologic testing. Patients’ fluid and electrolyte status was evaluated by 
measuring serum electrolytes, urea and creatinine. Standard biochemical tests of 
liver dysfunction were measured including serum albumin, bilirubin, GGT, alkaline  
phosphatase, AST and ALT.  All patients had hepatitis B surface antigen and anti-
HBc core antigens tested. Hepatitis C was assessed by antibodies to HCV detected 
by enzyme linked immunoabsorbent assay.  Positive results were confirmed by 
recombinant immunoblot assay.  Patients with suspected primary biliary cirrhosis 
had their serum antimitochondrial antibody levels tested. Patients without an evident 
cause of cirrhosis were screened for haemochromatosis including serum ferritin and 
transferrin saturation levels, alpha-1-antitrypsin deficiency and Wilson’s disease.  
Autoimmune hepatitis was tested by antinuclear and smooth muscle antibodies and 
serum IgG levels.  In selected patients in whom a definitive diagnosis was unclear, a 
plugged liver biopsy were done and transjugular portal wedge pressures were 
measured. Transcutaneous abdominal ultrasound was done to assess liver size and 
appearance including the features of steatosis, cirrhosis or atrophy-hypertrophy 
complex, portal vein patency and diameter, direction of portal vein flow, spleen size 








All study data, including the initial baseline and all subsequent follow-up clinical, 
haematologic, biochemical and endoscopic findings were recorded prospectively on 
a standard proforma for each patient and entered on a computer programme data 
base maintained by a dedicated research assistant.  All patients in the study 
received their first emergency and all subsequent endoscopic variceal sclerotherapy 
injections in the unit.   In order to assess risk factors for rebleeding and death in a 
defined population and to minimize possible confounding variables, only those 
patients who had bleeding oesophageal varices due to alcohol related cirrhosis and 
who were treated with injection sclerotherapy were evaluated and analysed in the 
following studies.  Patients with non-alcoholic cirrhosis or other causes of portal 
hypertension as well as those treated by endoscopic variceal ligation were excluded 
from the analysis.  The diagnosis of cirrhosis was established by clinical evaluation, 
laboratory data, findings on radiological imaging including ultrasound and portal 
venous doppler assessment, and in selected patients, liver biopsy and hepatic vein 
wedge pressure measurements.  Cirrhosis was considered to be alcohol related if 
patients gave a history of sustained heavy alcohol consumption over several years 
and exclusion of other causes.   
 
The analysis of all three studies was approved by the appropriately convened 
Departmental and Institutional Ethics and Research Committees of the University of 
Cape Town.  Data validation and quality control procedures followed accepted 








CHAPTER  4:  
 
VARICEAL RECURRENCE, REBLEEDING AND SURVIVAL AFTER LONG-
TERM SEQUENTIAL ENDOSCOPIC INJECTION SCLEROTHERAPY IN 287 




Cirrhosis is the third leading cause of death in urban males in the USA, and alcohol 
abuse is the leading aetiology (Orholm 1985, Grant 1991, Propst 1995).  Major 
bleeding from oesophageal varices is the commonest cause of death in alcoholic 
cirrhotics who have portal hypertension with a reported mortality of up to 50% for the 
initial bleed and 30% for subsequent bleeds (Chedid 1991, Graham 1981, Saunders 
1981, D’Amico 1995, Williams 1995). Endoscopic therapy is the emergency 
treatment of choice if actively bleeding oesophageal varices are present (Krige 2001, 
Krige 2009a, Terblanche 1994, Terblanche 1997).  Even though the initial bleed may 
be controlled effectively by endoscopic therapy, the risk of subsequent rebleeding is 
substantial (Fleischer 1983, De Dombal 1986, Terblanche 1983, Terblanche 1985, 
Bendtsen 1996).  There is general consensus that patients surviving a bleeding 
episode should be treated to prevent rebleeding (Terblanche 1988, Westaby 1992).  
An extensive body of evidence supports the use of repeated endoscopic treatment to 
obliterate oesophageal varices in order to prevent further variceal bleeding (Graffeo 
1994, The Copenhagen Esophageal Varices and Sclerotherapy Project 1984, 
Westaby 1985, Korula 1985, Soderlund 1985, Kitano 1987, Terblanche 1989).  
Although banding of oesophageal varices is now regarded as the most effective 





still widely used to control oesophageal variceal bleeding as well as to eradicate 
varices to prevent rebleeding (Sorbi 2003).  The major limitations of variceal injection 
sclerotherapy are recurrent variceal bleeds from residual varices prior to eradication, 
the cumulative risk of complications in patients having repeated injections (Krige 
1999, Krige 2005, Terblanche 1994)  and the fiscal and logistic implications 
(Terblanche 1990) because of the need for continued and prolonged surveillance 
endoscopy. 
 
Despite the widespread use of endoscopic variceal treatment, data on long-term 
recurrence, rebleeding and survival after variceal eradication and the optimal 
frequency of endoscopic surveillance in alcoholic cirrhotic patients with bleeding 
oesophageal varices are limited (Pugh 1993, Waked 1997, Hartigan 1997, 
Tomikawa 2002).  The present study evaluated the overall long-term clinical results 
of flexible injection sclerotherapy for a large cohort of consecutively treated alcoholic 
cirrhotic patients with endoscopically proven bleeding oesophageal varices followed 
prospectively in a single surgical unit.  The data presented are based on a protocol 
using a standardised injection technique with eradication of oesophageal varices the 
predetermined end-point of repeated sclerotherapy (Krige 1994). 
 
PATIENTS AND METHODS 
Consecutive adult alcoholic cirrhotic patients with endoscopically proven 
oesophageal variceal bleeding who were admitted to the surgical gastroenterology 
unit in Groote Schuur Hospital between January 1984 and December 2001 were 
assessed.  All patients included in the study were either referred at the time of their 





endoscopic sclerotherapy injection in our unit.  All injection treatments, both 
emergency and subsequent elective injections, were analysed to assess the role of 
sclerotherapy in long-term management.  All patients were studied prospectively. As 
indicated in chapter 3, the diagnosis of cirrhosis was confirmed by findings on liver 
function tests, ultrasound and portal doppler assessment and, in selected patients, 
liver biopsy and hepatic vein wedge pressure measurements.  Cirrhosis was 
considered to be alcohol related if patients gave a history of sustained heavy alcohol 
consumption over several years with corroborative histological evidence and 
exclusion of other causes. 
 
During the 210 month study period, 378 consecutive adult alcoholic cirrhotic patients 
were treated for oesophageal variceal bleeding.  Seventy two patients who had 
received variceal band ligation were excluded from the study group and the analysis.  
Nineteen patients who had cirrhosis and an alcohol history and in addition had 
positive viral markers were also excluded from the study.  Data were analysed after 
a minimum 26 month follow-up period. 
 
Technique of sclerotherapy 
A standard injection sclerotherapy technique was used as described in detail in the 
methods (Krige 1994, Krige 1996).  After intravenous sedation with midazolam, 
diagnostic endoscopy and injection sclerotherapy was performed using either a 
fibreoptic endoscope (model GIF 1T20 or K10; Olympus Corp, Lake Success, NY) 
during the first decade of the study or video-endoscopy during the last decade.  The 
sclerosant, 5% ethanolamine oleate, was injected using a combined intra- and 





was injected at any one endoscopy session for control of acute variceal bleeding or 
when large varices (grade 4 or 5) were encountered during elective sclerotherapy.  
An intravariceal technique alone with smaller total volumes of sclerosant was used 
for elective injection sclerotherapy when varices were grade 3 or less in size.  The 
initial and the second sclerotherapy session a week later were performed during the 
index admission to hospital.  Subsequent sclerotherapy was undertaken at regular 
week intervals at an outpatient clinic until the varices were eradicated.  After variceal 
obliteration, surveillance endoscopy was performed at 3 and 6 months and then 
annually to identify patients in whom varices had recurred.  Repeat injection 
sclerotherapy was performed whenever residual or recurrent varices were identified 
during surveillance endoscopy.   
 
Rebleeding 
Recurrent bleeding was defined as any episode of upper gastrointestinal bleeding 
that occurred after the first sclerotherapy session or subsequently between 
scheduled treatment sessions.  All such bleeding episodes were investigated by 
emergency endoscopy, undertaken promptly after admission to hospital.  Rebleeding 
was treated according to endoscopic findings.  Additional sclerotherapy was 
undertaken if bleeding was due to patent residual or recurrent varices.  Other 
sources of bleeding, such as peptic ulcers, gastric varices, erosive or haemorrhagic 
gastritis or portal hypertensive gastropathy were included in the definition of 
rebleeding.  Eradication of varices was defined as the absence of oesophageal 







Actuarial survival was calculated using the Kaplan-Meier method. Differences in 
survival in the three Child-Pugh grades were examined using the log-rank test. A p 
value less than 0.05 was considered significant.  SAS System Package version 8.2 




The 287 patients evaluated in this study included 225 men and 62 women (mean 
age: 51.97 years; range: 24-87 years).  Thirty nine patients were Child-Pugh grade 
A, 116 were grade B and 132 were grade C when assessed on first admission to 
hospital for variceal bleeding. 
 
Recurrent bleeding before variceal eradication: 
Rebleeding after the index injection procedure occurred in 104 of the 287 (36.2%) 
patients before eradication either during their index admission or after discharge 
from hospital.  These 104 patients had a total of 170 bleeds during 164 subsequent 
admissions before the varices were eradicated.  Ninety one patients bled from 
varices and 13 patients bled from non-variceal sources.  The 91 patients had 124 
variceal bleeds which were successfully treated with acute emergency injection 
sclerotherapy on 113 occasions.  The remaining 13 bleeding episodes were from 
gastric varices (2), gastric erosions (1), portal hypertensive gastropathy (5), 
duodenal ulceration (1), Mallory-Weiss tear (1), bleeding oesophageal ulceration (1), 





(who rebled before eradication) was 23.8 months (median 8.1 months) with a mean 
survival in Child-Pugh grades A, B and C of 37.3, 37.6 and 11.0 months.  
 
Eradication of varices 
Eradication and subsequent recurrence of oesophageal varices after sclerotherapy 
was assessed in 182 of the 287 patients who survived and who were followed up for 
more than 3 months (Fig. 4.1).  Of the remaining 105 patients, 90 died within 3 
months of entering the study and 15 patients did not complete the 3 month follow-up 
period.  These 15 patients either moved abroad or lived far from our centre and 
attended other hospitals. 
 






Survival > 3 months     Survival < 3 months (90) 
       Follow-up < 3 months (15) 
 
182 patients       105 patients 
 
Varices eradicated     Varices not eradicated 
147 (81%)       35 (19%) 
 
No recurrence   Recurrence 




Bleeding 45 (58%) 
 
 





Oesophageal varices were eradicated in 147 of the 182 patients (80.7%) after a 
median of 4.9 injections (range: 1 to 14) during a mean of 7.1 months (median 4.6, 
range: 0.23 to 41.6 months) (Table 4.1). Mean survival in these 147 patients who 
had variceal eradication was 47.1 months (median 36.8 months) with the mean 
survival in Child-Pugh grades A, B and C of 40.2, 37.4 and 24.0 months.  
Oesophageal varices remained eradicated in 69 patients (mean follow-up from 
eradication: 34.6 months, median 23.6 months; range 1 to 174). Mean survival in 
these 69 patients in whom varices remained eradicated was 39.6 months (median 
31.7 months) with the mean survival in Child-Pugh grades A, B and C of 47.5, 42.4 
and 30.0 months. 
 




























A 39 37 26 4.8 (1-13) 9.0 (0.23-41.6) 7 
B 116 90 78 4.9 (1-9) 9.4 (1.5-35.2) 26 
C 132 55 43 4.2 (1-14) 5.2 (0.26-25.6) 12 
Total 287 182 147 4.7 (1-14) 8.1 (0.23-41.6) 45 
 
 
The 35 patients whose varices were not eradicated received a mean of 5.3 injections 
during a mean of 17 months.  Twenty four of the 35 patients died (15 died of liver 





and in 2 patients the cause was unknown).  Five patients were lost to follow-up and 6 
patients in whom the varices were not eradicated were alive at the end of the study. 
 
Recurrent bleeding after variceal eradication: 
Forty five of the 78 patients with recurrence of oesophageal varices after eradication 
presented with variceal bleeding.  This occurred after a mean of 16 months (range: 
0.5 to 172 months).  Nine of these 45 patients also had additional bleeding episodes 
from other sites following the first variceal rebleed after eradication (7 due to portal 
hypertensive gastropathy and 2 bled from gastric ulcers).  Twenty two patients 
(48.8%) had several variceal rebleeding episodes.  
 
Oesophageal complications after sclerotherapy: 
The 287 patients received 353 emergency and 1015 elective injection treatments 
during a total of 2565 endoscopy sessions.  Minor complications of sclerotherapy 
were common after acute injection for active bleeding and included dysphagia, 
transient fever and pulmonary atelectasis.  A total of 747 complication events were 
documented in 234 patients during surveillance or unscheduled follow-up endoscopy 
after a prior variceal injection.  If ulceration or stenosis was persistent and identified 
during a subsequent surveillance endoscopy session, this was documented as a 
separate additional event and recorded as such. 
 
Mucosal ulceration at the injection site was found at follow-up endoscopy on 531 
occasions in 199 patients.  Subsequent sclerotherapy was delayed in patients who 
had mucosal ulceration involving more than one quadrant of the oesophageal 





after sclerotherapy, 9 of whom required oesophageal dilatation on 29 occasions with 
relief of symptoms.  Two patients developed an intramural oesophageal haematoma 
after sclerotherapy which resolved on conservative therapy.  Perforation of the 
oesophagus occurred in 8 patients as a consequence of repeated sclerotherapy to 
control of recurrent acute variceal bleeding.  Five of these 8 patients survived, 
including 3 who required surgery to treat the complication.   
 
Survival Analysis:  
The cumulative survival of all 287 patients by life table analysis was 67% at 1 year, 
42% at 3 years, 26% at 5 years and 13% at 10 years (Fig 4.2).  Survival according to 
Child-Pugh grade A was 68 % at 3 years, 48 % at 5 years and 37% at 10 years.   
 
Fig. 4.2 Cumulative survival by life table analysis in all patients 
Survival in 287 Alcoholic Cirrhotic patients



































Survival of Child-Pugh grade B patients at 3 years was 54 %, 34 % at 5 years and 
17% at 10 years, and survival of Child-Pugh grade C patients was 21 % at 3 years, 
13% at 5 years and 7% at 10 years (Fig 4.3).  
 
Fig. 4.3 Cumulative survival rates by life table analysis for patients at 
Child-Pugh risk grades A, B and C.    
 
Complete follow-up (median 32.3 months, mean 42.1 months, range 3-198.9 
months) was achieved in 133 patients of the 182 patients who survived more than 90 
days.  In 49 patients follow-up was incomplete (median 30.1 months, mean 37.6 
months, range 3.5-104.8 months). 
 
Causes of death: 
Two hundred and one (70%) of the 287 patients died during the course of the study.  
Liver failure was the commonest cause of death and occurred in 113 patients. 
Hepatorenal failure was the cause of death in 23 patients.  Twelve patients died of 
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pneumonia, 37 of multi-organ failure, often precipitated by bleeding varices and 3 
died of bleeding from other sites.  Eleven patients died of other causes. These were 
carcinoma in 5 ( lung 1, bladder 1, hepatocellular carcinoma 2, oropharynx 1), 
myocardial infarction 1, cerebrovascular accident 1, perforated gastric ulcer 1, acute 
pancreatitis 1, respiratory failure 1, motor vehicle accident 1.  In 2 patients the cause 
of death could not be established. 
 
DISCUSSION  
Alcoholic liver disease is a major cause of morbidity and mortality worldwide (Orholm 
1985, Grant 1991).  In Western countries, up to 50% of end-stage liver disease has 
alcohol as the main aetiological factor (Propst 1995).  The mortality from alcoholic 
cirrhosis is higher than non-alcoholic cirrhosis and survival at 5 and 10 years is only 
23% and 7% in some studies with 25% of patients dying within one year (Propst 
1995, Chedid 1991).  Thus the mortality rate of alcoholic cirrhosis is greater than 
many of the major categories of carcinoma such as breast, colon and prostate.  
Uncontrolled bleeding from varices and the consequences of ensuing liver 
decompensation are the commonest causes of death in alcoholic cirrhotics (Orholm 
1985, Grant 1991, Propst 1995, Chedid 1991).  Accurate long-term data detailing 
variceal recurrence or rebleeding after eradication, and survival in alcoholic cirrhotic 
patients are scant (Pugh 1993, Waked 1997, Hartigan 1997, Tomikawa 2002).  In 
this prospective study, the long term efficacy of sclerotherapy was evaluated by 
using the specific endpoints of recurrent bleeding, variceal eradication, and survival 







Ultimate survival and outcome of treatment in this consecutive cohort of patients was 
disappointing.  Although varices were eradicated in 82% of patients who survived 
more than 3 months, recurrent varices ultimately developed in 57% of patients, half 
of whom had further variceal bleeding.  Several important and unresolved problems 
related to the role of repeated sclerotherapy in the long-term management of 
patients with oesophageal varices remain.  There is increasing recognition that an 
important limitation of long-term sclerotherapy is the substantial incidence of 
rebleeding which is a particular feature of the early phase after endoscopic therapy 
has begun (Westaby 1985, Terblanche 1989).  The most common source of 
recurrent bleeding before variceal eradication in this study was from patent residual 
varices which occurred in 31.7% of our patients in this study.  Urgent repeat 
endoscopy is essential since in 87.5% of patients with recurrent bleeding, varices 
were the source and were treated by sclerotherapy which was effective in 113 
variceal rebleeds in 91 patients.  In 13 patients a non-variceal source of bleeding 
was identified.  Serial sclerotherapy successfully eradicated esophageal varices in 
80% of our patients.  Although new varices formed following initial obliteration in 78 
of 147 patients, this was associated with rebleeding in 45 of the 147 patients which 
would support the validity of the concept of variceal eradication as a specific 
endpoint of treatment.   
 
The number of sclerotherapy sessions required to achieve variceal obliteration has 
varied considerably within reported series and between centres.  While there is some 
evidence to suggest that the technique of injection sclerotherapy might affect the 
number of sessions necessary to achieve obliteration (Kitano 1987, Sorbi 2003), this 





risk of rebleeding diminishes with time as the variceal channels are obliterated, some 
recurrent bleeds are major and may contribute to deaths from liver failure.  Any 
protocol for long-term endoscopic management of variceal haemorrhage requires a 
firm definition of treatment failure which allows alternative treatment options to be 
instigated.  That such a definition is difficult to formulate, is reflected in the major 
discrepancies in the proportion of treatment failures in the larger controlled trials 
(Westaby 1992, Warren 1986, Rikkers 1987, Teres 1987).  We believe that patients 
who develop life-threatening variceal bleeding after an adequate course of treatment 
should be regarded as failures of long-term treatment and in these a TIPS shunt 
gives the best results (Azoulay 2001).  Other logistic problems with long-term 
sclerotherapy include the need for lifelong follow-up with repeated injections because 
varices recur in time.  Surviving patients place an increasing burden on hospital 
resources, even when sclerotherapy is performed on an outpatient basis. In an 
analysis of the cost benefits of long-term endoscopic surveillance in a university-
affiliated teaching hospital in Los  Angeles of 324 patients who achieved variceal 
obliteration, 104 patients were followed up for >12 months (Waked 1997). In this 
cohort of 104 patients who were eligible for inclusion in the analysis, varices 
reformed in 73 patients (71%), mostly in the first year after obliteration or 
reobliteration.  Nineteen patients (18%) had 23 rebleeding episodes. Survival was 
84% and bleeding-related mortality was 6%. The annual cost of treating variceal 
reformers ($2,117) was significantly higher than variceal nonreformers ($1,735), but 
the overall cost of maintaining a patient on a chronic sclerotherapy program was 
relatively small. The authors concluded that the low rebleeding rate, the low 
mortality, and the relatively low cost in patients managed long term by chronic 






Injection sclerotherapy is an invasive endoscopic procedure which requires a high 
level of manipulative skill and mature judgement.  Complications related to injection 
occur mostly during acute major or recurrent bleeding when varices are large and 
the patient is restless or unco-operative (Krige 2000). The incidence of complications 
varies widely in reported studies because of variations in patient population, the type 
and severity of the underlying liver disease and the different injection techniques 
used (Krige 2000).  In addition, the incidence of sclerotherapy-induced complications 
is higher when carefully documented in prospective studies (Krige 2005).  In the 
present study, complications in the 287 alcoholic patients undergoing both 
emergency and elective sclerotherapy were frequent, occurring in a quarter of all 
sclerotherapy treatments and in more than two-thirds of patients overall.  
Asymptomatic oesophageal ulceration at the injection site was the most common 
complication and was detected at follow-up endoscopy.  Ulceration is usually of little 
consequence in the overall management of the patient, but occasionally subsequent 
sclerotherapy had to be delayed.  Our present policy is to use smaller volumes of 
sclerosant as varices decrease in size in an attempt to reduce the extent of 
ulceration.  When ulceration involves more than one quadrant of the oesophageal 
circumference, further injection should be delayed until healing has occurred to 
prevent an oesophageal stricture (Krige 2007a, Krige 2007b).  Serious complications 
were oesophageal strictures and perforation.  Oesophageal stricture was significant 
and persistent in 9 of the 25 patients with this complication and all 9 responded to 
endoscopic balloon dilatation.  Perforation of the oesophagus in this study was 
confined to emergency injection for complex recurrent bleeding (Goldberg 1995) and 






Overall survival for the entire cohort was 42% at 3 years and 26% at 5 years.  Even 
in Child-Pugh grade A patients there was an inexorable decline in the survival rate.  
Several factors including variceal size and wall tension, portal pressure gradient of 
>12 mm Hg and endoscopic variceal stigmata have been documented to predict the 
risk of bleeding and overall prognosis (Gluud 1988).  The cause of portal 
hypertension, continued consumption of alcohol and the degree of liver 
decompensation are further important predictors of rebleeding and mortality 
(Madonia 2000, Vorobioff 1996).   
 
An obvious shortcoming of this analysis is the lack of data detailing continued 
alcohol consumption, abstinence or recidivism and their relationship to rebleeding 
and survival.  However, patients’ voluntary admission or recall of continued alcohol 
use is notoriously inaccurate and may be unintentionally or intentionally misleading 
and was therefore not pursued in this study.  Others have similarly indicated that any 
study evaluating continued alcohol consumption should be viewed with caution 
because of the difficulties in confirming abstinence (Orrego 1979).  The adverse 
effects of alcohol on many tissues appear to be dose-related and abstinence at any 
stage in the disease should be encouraged.  However, the benefits to be expected in 
term of rebleeding and mortality may be modest.  Nevertheless, only abstinent 
patients are considered for liver transplantation in most major centers and this offers 
the best hope of improving long term prognosis in this patient group (Schenker 1990, 







The range of treatment options for bleeding oesophageal varices has expanded 
markedly during the past two decades.  The treatment of acute and recurrent 
variceal bleeding is best accomplished by a skilled, knowledgeable, and well 
equipped team using a multidisciplinary integrated approach (Krige 2005, Krige 
2009a).  Optimal management should provide the full spectrum of treatment options 
including pharmacological therapy, endoscopic treatment, interventional radiological 
procedures, surgical shunts and liver transplantation (Sorbi 2003).  Endoscopic 
variceal ligation has now replaced injection sclerotherapy in the elective treatment of 
esophageal varices in most centers.  Data from randomised controlled trials show 
more rapid eradication of varices with lower rates of recurrent bleeding and fewer 
complications such as strictures and perforation (Tait 1999).  However, a recent 
survey by the American College of Gastroenterology International GI Bleeding 
Registry shows that sclerotherapy is still used as frequently as banding for 
endoscopic intervention during index bleeding and more frequently than banding for 
control of variceal rebleeding (Sorbi 2003).  Likely reasons include convenience, cost 
and widespread availability.   
 
It is noteworthy that several recent randomised controlled trials comparing band 
ligation with sclerotherapy have reported a higher recurrence rate of varices in 
patients undergoing band ligation (Krige 2005).  If this observation is confirmed by 
further studies, the increased recurrence rate of varices may reduce or abolish the 
advantage of band ligation over sclerotherapy in the long term (Tait 1999).  There is 
further evidence that endoscopic sclerotherapy is the more cost effective treatment 
per life-year gained if active variceal haemorrhage is present at the index endoscopy 





treatment failure rate experienced with endoscopic ligation for active variceal 
bleeding (Gralnek 1999).  The long term data in this study has documented the 
variceal recurrence and rebleeding rate using a standard sclerotherapy technique. 
No comparable data exist for variceal ligation and ligation will require similar long 
term data to validate and vindicate its current status as the preferred endoscopic 
technique.  
 
Our current management policy is for patients to have regular endoscopic therapy in 
order to achieve early variceal eradication, appreciating that factors such as 
oesophageal ulceration and poor patient compliance may interfere with the 
endoscopic therapy programme.  After eradication of the varices, patients have 
surveillance endoscopy at six and then 12 month intervals and, if recurrent varices 
are identified, a comprehensive endoscopic treatment schedule is instituted again.  
Ultimately the use of sequential combined endoscopic techniques with variceal 
banding initially when varices are large followed by sclerotherapy when varices are 
small may enhance the endoscopic management of oesophageal varices both in 
terms of reducing complications, facilitating earlier eradication and preventing 















CHAPTER  5:  
 
AN ANALYSIS OF EARLY REBLEEDING AND DEATH WITHIN 6 
WEEKS OF INITIAL INTERVENTION IN 310 ALCOHOLIC CIRRHOTIC 
PATIENTS WITH ACUTE VARICEAL BLEEDING TREATED WITH 




Variceal bleeding is the most serious complication of portal hypertension and 
substantially alters the natural history of patients with compensated alcoholic 
cirrhosis (de Franchis 2001, del Olmo 2000). Up to 20 per cent of initial bleeding 
episodes are fatal, and as many as 70 per cent of survivors have recurrent bleeding 
after a first variceal haemorrhage (Sharara 2001). Endoscopic therapy is the 
emergency treatment of choice if actively bleeding oesophageal varices are present 
(Sharara 2001, Krige 2005, Triantos 2006). Although advances in treatment 
Baradarian 2004) have reduced overall mortality (Berry 2006, Chalasani 2003, 
Stokkeland 2006), uncontrolled or recurrent bleeding from varices and the 
consequences of ensuing liver decompensation remain the commonest causes of 
death in alcoholic cirrhotic patients (Le Moine 1992, Longacre 2006). Early 
rebleeding has been shown to be a strong predictor of mortality and recurrent 
variceal bleeding substantially increases the risk of complications which further 
contribute to mortality (Mihas 2004), emphasizing that rapid and sustained control of 







There is international consensus that the assessment of the efficacy of treatment of 
bleeding oesophageal varices should be based on specific clinical outcomes 
(Thomsen 1998, de Franchis 1992, de Franchis 2005). These include the ability to 
achieve lasting haemostasis after the first variceal bleed, the risk of further variceal 
rebleeding, and death as a consequence of progressive liver decompensation 
(Thomsen 1998). In order to provide a consistent measure of standardisation and 
accuracy in the interpretation of data from different studies, specific and uniformly 
defined end-points which incorporate rebleeding and death have been formulated.  
The Baveno consensus conferences (de Franchis 1992, de Franchis 2005) have 
recommended that rebleeding within 5 days after the initial treatment should be used 
as the first end-point to assess initial control of bleeding. As the risk of rebleeding 
and death remains high during the initial phase after the first bleed, the time frame 
recommended for the second end-point, also incorporating rebleeding and death, is 
6 weeks following the first admission to hospital (de Franchis 1992, de Franchis 
2005, Pugh 1993). 
 
Despite the widespread use of endoscopic therapy, few studies have specifically 
evaluated these endpoints in alcoholic cirrhotic patients with oesophageal varices 
(Pugh 1993, Hartigan 1997, Gluud 1988, Vorobioff 1996). Consequently, there is a 
paucity of accurate data on the efficacy of endoscopic control of bleeding, the 
frequency of early variceal rebleeding or survival in this high risk cohort. Published 
results are variable and conflicting because of small sample sizes, referral bias, 
dissimilar study end-points, differences in patient selection, methods and techniques 
of endoscopic intervention and the precise definition of rebleeding (de Franchis 





centre study was to evaluate the short-term efficacy at 6 weeks of flexible injection 
sclerotherapy in achieving control of acute variceal bleeding, and preventing 
rebleeding and death in a large cohort of consecutively treated alcoholic cirrhotic 




Consecutive adult alcoholic cirrhotic patients with endoscopically proven acute 
oesophageal variceal bleeding who were admitted to a surgical gastroenterology unit 
between January 1984 and December 2006 were assessed. All patients included in 
the study received their first emergency and all subsequent endoscopic 
sclerotherapy injections in our unit. As indicated in detail in the patients and methods 
section, all data were recorded prospectively on a standard proforma and entered on 
a computer programme maintained by a dedicated research assistant. The study 
analysis was approved by the appropriately convened Departmental and Institutional 
Ethics and Research Committees.  Data validation and quality control procedures 
followed accepted international good clinical practice guidelines for the duration of 
the study. 
 
During the 276 month study period, 632 consecutive adult patients were treated for 
oesophageal variceal bleeding in the unit. Two hundred and six patients patients had 
non-alcoholic causes of portal hypertension (53 had cryptogenic cirrhosis, 38 had 
hepatitis B–induced cirrhosis, 33 had extrahepatic portal vein thrombosis, 23 had 
cirrhosis secondary to chronic active hepatitis, and 59 patients had portal 





cholangitis, primary and secondary biliary cirrhosis, splenic vein thrombosis, Budd-
Chiari syndrome and haemochromatosis) and were excluded from further analysis. 
The remaining 426 patients had portal hypertension due to alcohol-induced cirrhosis. 
Of these, 116 patients were not included in the study group because they had 
received endoscopic variceal band ligation during the initial 6 weeks after admission 
to hospital. Twenty nine patients who had cirrhosis and an alcohol history but in 
addition had positive hepatitis B or C viral markers were also excluded from the 
study group. Data in the remaining 310 patients with alcoholic cirrhosis and proven 
oesophageal variceal bleeding who received only sclerotherapy for bleeding form the 
basis of this study. 
 
Clinical endpoints 
Control of variceal bleeding was evaluated at three time points; initial control during 
the first endoscopic intervention, variceal rebleeding within 5 days, before the start of 
long-term preventative therapy, and rebleeding within 6 weeks. The primary clinical 
endpoints of this study were (i) failure to control variceal bleeding during the first 
endoscopic intervention, (ii) early rebleeding (< 5 days) and later rebleeding (6 – 42 
days) after initial endoscopic control, and (iii) mortality at 5 days and at 6 weeks.  A 
secondary outcome of the study was assessment of the sclerotherapy-induced 
complications due to endoscopic variceal injection therapy which occurred during the 
first six weeks after the index bleed. 
 
Technique of sclerotherapy 
The injection sclerotherapy technique used has been described previously in detail 





sclerotherapy were performed using a fibreoptic endoscope (model GIF 1T20 or 
K10; Olympus Corp, Lake Success, NY) during the first decade of the study and 
video-endoscopy during the last decade. The sclerosant, 5% ethanolamine oleate, 
was injected using a combined intra- and paravariceal technique (Krige 1994, Krige 
1996, Krige 2006a, Krige 2007a). A maximum sclerosant volume of 25 ml was 
injected at any one sclerotherapy session for control of acute variceal bleeding. A 
similar volume was used when large varices (grade 4 or 5) were encountered during 
subsequent elective sclerotherapy. An intravariceal injection technique with smaller 
total volumes of sclerosant was used for elective sclerotherapy when varices were 
grade 3 or less in size (Krige 1996, Krige 2006a, Krige 2007a). The initial and the 
second sclerotherapy session, a week later, were performed during the index 
admission to hospital. Subsequent sclerotherapy was undertaken at regular intervals 
on an outpatient basis until the varices were eradicated. Repeat injection 
sclerotherapy was performed whenever residual or recurrent varices were identified 
during surveillance endoscopy. 
 
Rebleeding 
Time zero was defined as the time of admission to our hospital. Failure to control 
bleeding was defined as continued bleeding despite endoscopic injection, the 
addition of pharmacotherapy and the use of balloon tamponade. Rebleeding was 
defined as any episode of upper gastrointestinal bleeding that occurred after the 
initial bleed had been successfully controlled by sclerotherapy, or if bleeding 
occurred subsequently between scheduled treatment sessions. All such bleeding 
episodes were investigated by emergency endoscopy, performed promptly after 





Additional sclerotherapy was undertaken if bleeding was due to patent residual 
varices. Other sources of bleeding, such as gastric and duodenal ulcers, gastric 
varices, erosive gastritis or portal hypertensive gastropathy were included in the 
definition of rebleeding. For the purposes of the study, patient data were evaluated 
for 42 days from the admission date, and all bleeding events and complications 
related to the sclerotherapy and deaths during this period were recorded. 
 
Statistical Analysis 
Data were stored on a spreadsheet registry (Microsoft Excel, Redman, WA) and 
Stata software (Stata Corp 2003, Release 8, College Station, TX: StataCorp LP) was 
used for the statistical analysis. Descriptive statistical methods were used to 
determine 5 and 42 day rebleeding and mortality rates. Bivariate associations 
between categorical variables were analysed using the X2 test. The Kruskal-Wallis 
test was used to assess blood requirements in units of blood in each of the 3 Child-
Pugh grades. For all analyses, a p value less than 0.05 and a 95% confidence 





The 310 patients evaluated included 242 men and 68 women (mean age: 51.7 
years; range: 24 - 87 years). Forty four patients were Child-Pugh grade A, 122 were 
grade B and 144 were grade C when assessed on their first admission to hospital 
(Table 5.1). Two hundred and thirteen patients required a blood transfusion during 
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Minnesota tube was used in 44 patients and vasopressin or octreotide was used in 
43 patients (Table 5.1). Eighteen patients received both balloon tube and 
vasopressin.  Significantly more Child-Pugh grade C patients required a major (>6 
units) blood transfusion, the use of a balloon tube and vasopressin to control variceal 
bleeding (Table 5.1). 
 
Day 0 to 5 rebleeding 
Emergency endoscopic injection sclerotherapy, supplemented with balloon 
tamponade when necessary, controlled acute variceal bleeding in 304 of 310 (98%) 
patients (Figure 5.1). In 6 (1.9%) patients, variceal bleeding was not controlled 
despite using pharmacologic and endoscopic therapy and balloon tamponade 
(Figure 5.1). A further 32 patients had recurrent variceal bleeding within 5 days of 
initial endoscopic control and required a further 39 emergency endoscopic variceal 
injection procedures (sclerosant volume: mean 16.1 ml, median 15 ml, range: 4 to 30 
ml) to achieve definitive endoscopic variceal haemostasis. The 5 day endoscopic 
failure rate in achieving variceal haemostasis was 12.3% (38 of 310 patients). 
Day 6 to 42 rebleeding 
Rebleeding after the initial 5 day assessment and up to 6 weeks after the index 
variceal injection occurred in 44 (15.7%) of the 281 patients who survived more than 
5 days (Figure 5.1). Seven of the 44 patients had bled during the first 5 days and had 
further rebleeding episodes during this later period. These 44 patients had a total of 
48 bleeding episodes and underwent a total of 83 repeat variceal injections 
(sclerosant volume range: 2 to 30 ml, mean 13.5 ml, median 12.3 ml) in the 6 to 42 
day period. In this group 38 bleeding episodes were from varices and 10 from non-





(n=2), Mallory Weiss tear (n=1), oesophageal ulceration (n=2), and 4 sites were not 
identified with certainty during endoscopy. 
 














Number of patients with no rebleeding Number of patients alive 
Day 5 
Day 42 
Grade A = 0 
Grade B = 5 
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Of the 44 patients who rebled, 13 (29.5%) died in the 6 week period. Overall 75 
(24.2%) patients rebled during the 6 week assessment period after initial control 
during the index admission (Figure 5.1). The incidence of rebleeding increased 
according to the Child-Pugh scores. Twenty five (15%) of the 166 patients in Child-
Pugh grades A and B rebled compared to 50 (34.7%) of the 153 patients in Child-
Pugh grade C (Table 5.2). Significantly more Child-Pugh grade C patients rebled 
than Child-Pugh grade A or B patients (p<0.001) (Table 5.3). 
 






























Grade A Grade B Grade C 
Child-Pugh 
Score 
5 6 7 8 9 10 11 12 13 14 15 
n 15 29 53 36 34 39 30 37 22 9 6 
rebleeding 1 3 8 5 8 15 12 13 5 4 1 






Seventy seven patients (24.8%) died during the 6 week study period (Figure 5.1). 
Twenty-nine (9.3%) died within 5 days of admission and 48 (15.4%) between day 6 
and 42. No Child-Pugh grade A patients died, 14 Child-Pugh B patients died, and 63 
Child-Pugh grade C patients died. Liver failure was the commonest cause of death 
and occurred in 29 patients. Twelve patients died of hepatorenal failure and 11 died 
of pneumonia and respiratory failure. 
 
Table 5.3  Rebleeding according to Child-Pugh grade 
 











A 44 4 9%     
B 122 21 17.2%     




Death in 25 patients was a consequence of continued or recurrent variceal bleeding. 
Survival at 5 days and 6 weeks in Child-Pugh grade A patients was 100% and 100%, 
in Child-Pugh grade B patients 96% and 92.7%, and in Child-Pugh grade C patients 
83.4% and 73%, respectively (Table 5.4). Significantly more Child-Pugh grade C 
patients died than Child-Pugh grade A or B patients (Table 5.5). Mortality increased 
exponentially as the Child-Pugh score increased with a mortality of 78% for a Child-































5days died 6-42 days died Alive
 
Child-Pugh Grade Grade A Grade B Grade C 
Child-Pugh Score 5 6 7 8 9 10 11 12 13 14 15 
N 15 29 53 36 34 39 30 37 22 9 6 
Deaths 0 0 1 3 10 9 12 20 10 7 5 




Table 5.5 Mortality according to Child-Pugh grade 
 












A 44 0 0     
B 122 14 11.4%     









Sclerotherapy related oesophageal complications 
The 310 patients received 786 injection treatments (342 emergency, 444 elective) 
during a total of 919 endoscopy sessions in the 42 day period. A total of 338 
complications were documented in 159 patients during surveillance or unscheduled 
endoscopy after a prior variceal injection. Minor complications of sclerotherapy were 
common after acute injection for active bleeding and included dysphagia, transient 
fever and pulmonary atelectasis. Mucosal ulceration at an injection site was found at 
follow-up endoscopy on 333 occasions in 155 patients. An oesophageal stricture at 
the injection site occurred in 5 patients after sclerotherapy.  None required 
oesophageal dilatation and all 5 resolved spontaneously. No intramural oesophageal 
hematoma or oesophageal perforations occurred in any of the 310 patients. 
 
DISCUSSION 
This study used a large single centre dataset of alcoholic cirrhotic patients with portal 
hypertension and bleeding varices to assess the efficacy of endoscopic injection 
sclerotherapy in achieving primary haemostasis and preventing subsequent variceal 
rebleeding and death. The data demonstrated that endoscopic therapy was highly 
effective in controlling acute bleeding from oesophageal varices and that ultimate 
survival was influenced by both rebleeding and underlying liver reserve. Sustained 
control of acute bleeding has been shown to be a critical requirement in variceal 
management because each subsequent bleed worsens marginal liver function 
(Graffeo 1994). An analysis of data on death due to uncontrolled variceal bleeding 
which included 8 combined studies involving 1488 patients reported an 8% median 
mortality for exsanguinations which occurred within 48 hours of admission to hospital 





uncontrolled bleeding occurred in 6.2% of patients (de Franchis 2007).  However, 
despite urgent endoscopic and pharmacological therapy, variceal bleeding recurs in 
up to 20% of patients after the initial endoscopic intervention (Abraldes 2007, Garcia-
Tsao 2007).  In addition, early variceal rebleeding significantly increases the risk of 
death within 6 weeks of the initial bleed (Abraldes 2007, de Franchis 2007). Although 
initial endoscopic intervention controlled acute variceal bleeding in 98% of patients 
10.3% rebled within 5 days and 24.2% rebled during the first 6 weeks. The 6 week 
rebleeding rate in the present study was higher than the 18.6% (D’Amico 2003a) and 
19% (Graffeo 1994) reported by other authors probably because of two factors.  This 
study had a strict prospective rebleeding definition and the study population 
consisted of a high risk alcoholic cirrhotic cohort.  The incidence was similar to the 
23% reported by Hartigan (Hartigan 1997), but significantly lower than the 31% 
rebleeding reported in an earlier study by Graham and Smith (Graham 1981). 
 
It is clear from our observations and those of others (Jalan 2000, Garrett 1988, 
Thomopoulos 2006) that the efficacy of sclerotherapy in controlling acute 
oesophageal variceal bleeding and mortality from bleeding are closely related to the 
severity of the underlying liver disease. As anticipated, mortality in our study 
increased exponentially as liver reserve diminished. There were no deaths in Child-
Pugh grade A patients and in this cohort with preserved liver function, early mortality 
was not influenced by the severity of the bleeding episode. Our data demonstrated 
that Child-Pugh grade C patients, who have the least hepatic reserve, were more 
likely to have a major bleed and require pitressin or octreotide and balloon 
tamponade in addition to sclerotherapy to control acute bleeding. We have shown in 





controlled variceal bleeding, progressive liver failure resulted in high mortality rates 
in the first 6 weeks after admission, especially in patients with a Child-Pugh score 
>13 who subsequently had an 80% mortality. 
 
Recent data show that mortality from variceal bleeding has decreased substantially 
from the 42% mortality reported in the seminal study by Graham and Smith in 1981 
(Graham 1981) to current levels of around 20% (Abraldes 2007). This significant 
improvement in survival reflects improvement in both the general management of 
severely ill cirrhotic patients and the treatment of hepatic decompensation which 
strongly influence the prognosis (Wiesner 2001). While it has been suggested that 
complications of portal hypertension, including variceal bleeding, are predictors of 
mortality in patients with liver cirrhosis, survival appears to be largely dependent on 
the severity of the underlying liver disease and it is now recognised that the degree 
of hepatic dysfunction is of overriding prognostic significance for patient survival 
(Wiesner 2001). Our study evaluated mortality at two time points: at 5 days when 
mortality is considered a direct consequence of the bleeding episode and at 6 weeks 
when mortality is a function of the adequacy of liver reserve. Overall survival for the 
entire cohort was 90.6% at 5 days and 75.2% at 6 weeks. The survival rate at 6 
weeks in our cohort of decompensated alcohol-related cirrhotic patients was similar 
to the 23.6% (D’Amico 2003), 18.4% (Thomopoulos 2006), 19.0% (Graffeo 1994), 
17.5% (Chalasani 2003) reported by other authors, but higher than the 15.3% 
mortality reported by Boix et al. in 274 patients with cirrhosis of different aetiologies 






Although several prognostic models have been proposed to predict mortality in 
patients with cirrhosis, the Child-Pugh score remains the most widely used scoring 
system both in clinical practice and in clinical research (D’Amico 2006) and is equal 
to or superior than other predictive systems in determining mortality within the first 
six weeks after a major variceal bleed (D’Amico 2006, Angermayr 2003, Garcia-Tsao 
2008, Atkinson 2008, Sanders 2002). In a systematic review of 118 studies of 
cirrhotic patients, the most common independent predictor of death was the overall 
Child-Pugh score, followed by each of the five components of the Child Pugh score 
(D’Amico 2006). The advantages of the Child-Pugh score over more complex scores 
such as the Model for End-Stage Disease (MELD) score, is that the Child-Pugh 
score is simple and easy to use and can be calculated at the bed-side using mental 
arithmetic. Two significant flaws in the Child-Pugh score, however, are the 
subjectivity in the assessment of the degree of ascites and encephalopathy and the 
inability to distinguish mild from severe grade C patients with sufficient discrimination 
(Cholongitas 2005). The model for end-stage liver disease (MELD) score, which was 
originally designed for assessing the prognosis of cirrhotic patients undergoing 
transjugular intrahepatic portosystemic shunt (TIPS), is a continuous score relying on 
three objective variables.  MELD has replaced the Child-Pugh score in Europe and 
United States for prioritising liver donor allocation according to a "sickest first" policy  
(D’Amico 2006).  MELD best predicts 3 month survival of cirrhotic patients, 
irrespective of cause.  MELD is based on creatinine, bilirubin, and international 
normalised ratio (INR) and is considered more reproducible because the 
components do not include subjective variables such as ascites and 
encephalopathy.  However, both CP and MELD scores can vary substantially if 





ascitic paracentesis, or overzealous diuretic therapy which can increase serum 
creatinine.  In studies by Bambha and Chalasani, MELD was a clinically useful and 
objective predictor of short-term survival after acute variceal bleeding (Bambha 
2008, Chalasani 2003). The Child-Pugh grade and scores in our study showed 
significant discrimination between grade A, B, and C patients and the incidence of 
rebleeding and death at 6 weeks. 
 
Several important and unresolved issues relating to the specific roles of injection 
sclerotherapy compared to variceal banding in the management of patients with 
actively bleeding oesophageal varices remain. In most centres worldwide 
endoscopic variceal ligation has now replaced injection sclerotherapy in the elective 
treatment of oesophageal varices (Krige 2007a). Injection sclerotherapy is an 
invasive endoscopic procedure which requires a high degree of manual dexterity, 
skill and experience, especially during a major acute variceal bleed (Krige 2005, 
Krige 2007). Unlike endoscopic variceal band ligation, sclerotherapy is not 
standardised and there is wide variation in the injection technique, including the type 
and strength of sclerosant used, the method and frequency of injection, and the 
regularity of endoscopic surveillance (Jalan 2000, Krige 2007a). Data from 
randomised controlled trials of patients with acute variceal bleeding show 
equivalence between endoscopic variceal ligation and injection sclerotherapy in 
achieving initial haemostasis. Furthermore, randomised controlled trials indicate that 
ligation achieves more rapid eradication of varices with lower rates of recurrent 
bleeding and fewer complications such as strictures and perforation during elective 
therapy (Tait 1999). Despite these advantages, a survey by the American College of 





used as frequently as banding for endoscopic intervention during index bleeding and 
more frequently than banding for control of variceal rebleeding (Sorbi 2003). The 
practical advantages of endoscopic sclerotherapy include its ability to achieve 
definitive control of variceal bleeding under direct vision, ease of use, convenience 
and low cost. A recent meta-analysis assessing emergency sclerotherapy for acute 
variceal bleeding in randomised trials suggests that sclerotherapy at the time of the 
initial endoscopy should remain the first choice therapy (Triantos 2006). An 
additional consideration reported in several randomised controlled trials comparing 
band ligation with sclerotherapy is a higher long term variceal recurrence rate in 
patients undergoing band ligation (Tait 1999). If this observation is confirmed by 
other studies, the consequences could reduce or even abolish the long term 
advantage of band ligation over sclerotherapy (Madonia 2000).  The results of this 
study using sclerotherapy serve as the reference level for comparison by future 
endoscopic ligation studies. 
 
A major strength of this study is that it was conducted in a single centre in a defined 
and homogenous population of consecutive patients using a uniform endoscopic 
injection technique which was supervised by the same group of investigators during 
the study period.  In order to provide the highest possible level of uniformity and to 
minimise differences in the zero-time entry, only patients who presented with their 
first variceal bleed and received their initial and subsequent treatment in our unit 
were evaluated.  The data were collected prospectively in this study and follow-up 
was complete with no patients lost.  The study design minimized possible biases that 
may have resulted from patient selection, referral policies and local variations in 





provided consistent and objective end-points in the study.  The robustness of this 
study is enhanced by the prospective data collection, restriction of subjects to 
alcoholic cirrhotics and the complete follow-up of the cohort. 
 
A number of limitations of this study are relevant.  An obvious deficiency is the lack 
of data detailing continued alcohol consumption or abstinence in patients as a risk 
factor influencing survival.  Previous studies by Vorobiof et al have described 
increases in portal pressure when alcoholic cirrhotics patients consume alcohol 
(Vorobiof 1996, Lucey 2008). In addition, Luca et al have shown that variceal 
bleeding in cirrhotic subjects has been linked with alcohol use (Luca 2007).   Other 
investigators have reported that patients’ voluntary admission or recall of continued 
alcohol use are notoriously inaccurate and may be misleading and was therefore not 
used as a variable in this study (Garcia-Pagan 2008).   Another important aspect is 
that although the endoscopists and the technique of sclerotherapy remained 
constant, this study assessed patients over a 26 year period during which 
improvements in supportive care invariably would have occurred.   
 
The results of our study clearly define the course and prognosis of patients with 
decompensated alcohol-related cirrhosis and bleeding varices. Despite substantial 
improvement in overall survival in recent years (Chalasani 2003, Carbonell 2004), 
the 6 week mortality after variceal bleeding remains discouragingly high, especially 
in Child-Pugh grade C patients (Thabut 2007) who succumb either from uncontrolled 
initial variceal bleeding or early rebleeding, or subsequently from the consequences 
of infection, liver and renal failure in the first weeks after a bleeding episode. As 





detrimental systemic consequences which lead to progressive deterioration of liver 
function (Thomopoulos 2006). The presence of advanced Child-Pugh score >13 in 
this study identified those patients at higher risk of dying. Our study confirms the 
observations of others (Hartigan 1997) that in experienced centres endoscopic 
injection sclerotherapy can be performed safely and effectively in alcoholic cirrhotic 
patients with actively bleeding oesophageal varices. However, even under optimal 
conditions, currently available treatment options fail to control initial variceal bleeding 
or prevent early rebleeding in up to 20% of patients, some of whom may require 
rescue intervention. Because most patients who fail first line endoscopic and 
pharmacological therapy are high risk and have marked liver decompensation 
complicating the variceal bleeding, TIPS has become the most widely used salvage 
therapy but still has an overall mortality in excess of 30% (Vangeli 2002). The 
essential future requirements necessary to improve survival in these high risk 
patients are self evident and include effective control of acute variceal bleeding, 
prevention of further rebleeding and minimizing deterioration of liver function. The 
early recognition of endoscopic failures and implementation of newer technologies 
for local control including self-expanding oesophageal metal stents (Zehetner 2008), 
enhanced efficacy of long-acting drugs (Lo 2008) and improved quality PTFE coated 














CHAPTER  6:   
 
A MULTIVARIATE ANALYSIS OF PREDICTIVE RISK FACTORS FOR 
REBLEEDING AND DEATH IN ALCOHOLIC CIRRHOTIC PATIENTS WITH 
ACUTE VARICEAL BLEEDING TREATED WITH EMERGENCY 





Bleeding from oesophageal varices is the most serious complication of portal 
hypertension and accounts for most cirrhosis-related deaths (Krige 2005b).  One 
quarter of cirrhotic patients who present with a major first variceal bleed, die as a 
consequence of the bleed (Krige 2007a). Early mortality from uncontrolled bleeding 
ranges from 5 - 8% (Bosch 2003, D’Amico 2006). After control of the index bleed, 
there is a 70% chance of rebleeding with a similar mortality if further effective 
treatment is not given (Sharara 2001, Triantos 2006).  Mortality is related to several 
factors including failure of rapid control of initial bleeding, early rebleeding, the 
presence and severity of underlying liver disease and the functional hepatic reserve 
(Burroughs 2008).  Optimal emergency management requires an efficient and 
organised team to provide accurate initial assessment of the patient, effective 
resuscitation, rapid endoscopic diagnosis, successful intervention with control of 
bleeding, and prevention of early rebleeding as well as the anticipated complications 
of liver decompensation including spontaneous bacterial peritonitis, progressive liver 
and renal failure or hepatic encephalopathy (Kravetz 2007).  The rational modern 
treatment of oesophageal varices requires a clear understanding of the risks of 
rebleeding, the hazards of liver decompensation and the likely response and benefits 






Despite the widespread use of endoscopic therapy, few studies have provided robust 
prognostic factors which accurately predict rebleeding or death in alcoholic cirrhotic 
patients with bleeding oesophageal varices (D’Amico 2006, Garcia-Pagan 2008).  
Consequently there is no general agreement or international consensus which 
specific risk factors have the best prognostic value for early rebleeding and mortality 
after variceal bleeding.   Published results are variable and conflicting because of 
small sample sizes, referral bias, dissimilar study end-points, differences in patient 
selection, techniques of endoscopic intervention and the precise definition of 
rebleeding.   In addition, the spectrum of variables and differences among alcoholic 
cirrhotics make formulation of a prognostic model complicated.  To overcome the 
complexities of these variations, a large data base is required which includes the 
outcome variable and the intervention components and variables for each patient 
(Christensen 1997).  The objective of this study was to identify by multivariate 
analysis and internal validation the prognostic variables predicting rebleeding and 
death at 6 weeks in alcoholic cirrhotic patients admitted to hospital with a first 
variceal bleed. 
PATIENTS AND METHODS 
Patient population 
The patient information for this study was obtained from the prospectively collected 
database and included consecutive adult patients with endoscopically proven acute 
oesophageal variceal bleeding who were admitted to the surgical gastroenterology 
unit between January 1984 and December 2006 and who were enrolled in a 
longitudinal observational study.  All study data were recorded on a standard 





research assistant.  In order to assess risk factors in a defined population and to 
minimize possible confounding variables, only those patients with bleeding 
oesophageal varices due to alcohol related cirrhosis who were treated with injection 
sclerotherapy were analysed.  All patients received their first emergency and all 
subsequent endoscopic variceal sclerotherapy injections in our unit.  Patients with 
non-alcoholic cirrhosis or other causes of portal hypertension as well as those 
treated by endoscopic variceal ligation, were excluded from the analysis to maintain 
a homogenous cohort.  The diagnosis of cirrhosis was established by clinical 
evaluation, laboratory data, findings on radiological imaging including ultrasound and 
portal venous doppler assessment, and in selected patients, liver biopsy and hepatic 
vein wedge pressure measurements.  Cirrhosis was considered to be alcohol related 
if patients gave a history of sustained heavy alcohol consumption over several years 
and exclusion of other causes.   
 
Therapeutic intervention for variceal bleeding 
All patients with haematemesis underwent urgent upper gastro-intestinal endoscopy 
soon after admission and resuscitation to identify the source of bleeding and were 
treated with injection sclerotherapy if bleeding oesophageal varices were found. The 
injection sclerotherapy technique used has been described in detail previously (Krige 
1996, Krige 2007, Krige 2006).  Patients with haemodynamic instability or a 
significant drop in haemoglobin level (<8g%) were given a packed red cell 
transfusion to a haemoglobin level of 10g% and the blood volume transfused was 
recorded.  The initial and the second sclerotherapy session, a week later, were 
performed during the index admission to hospital.  Endoscopic details including the 





at each intervention were recorded.  Subsequent sclerotherapy was undertaken at 
regular intervals at an outpatient clinic until the varices were eradicated.   
 
Data Collection 
All patients had a complete medical assessment at their initial presentation to 
hospital including documentation of clinical, biochemical and endoscopic factors that 
might contribute to variceal rebleeding and mortality.  To identify potential risk factors 
related to rebleeding and death, a retrospective analysis of the prospectively 
collected data was performed. Fifteen variables related to clinical and biochemical 
data, as well as details of the endoscopic intervention including size of varices and 
sclerosant volume, were analysed.  
 
Data Synthesis and Analysis 
The primary endpoints of the study were rebleeding and death at 42 days. Time zero 
was defined as the time of admission to our hospital. Failure to control bleeding was 
defined as continued bleeding despite endoscopic injection and the addition of 
pharmacotherapy and the use of balloon tamponade.  Rebleeding was defined as 
any episode of upper gastrointestinal bleeding that occurred after the initial bleeding 
episode had been successfully controlled by sclerotherapy, or bleeding that occurred 
subsequently between scheduled treatment sessions.  Mortality was defined as 
death from any cause.  The study design and analysis was approved by the 
appropriately convened Departmental and Institutional Ethics and Research 
Committees.  Data-validation and quality-control procedures followed accepted 






Continuous variables were dichotomised on the basis of existing literature (Pugh 
1973).  Tested variables included albumin level (<25 vs >25 g/L), INR (<2.3 vs >2.3), 
total bilirubin level (<51 vs >51umol/L), ascites (nil and mild vs moderate and severe) 
and encephalopathy (nil and mild vs moderate and severe), variceal size (grade 
1,2,3 vs 4,5) and sclerosant volume given per sclerotherapy session (1-15 vs 16-30 
ml).    The categorical variables included gender, age (<60 years vs >60 years), 
pitressin, the need for balloon tube tamponade. and number of variceal 
sclerotherapy injections used to control the acute bleed (1 vs >1). 
 
Statistical Analysis 
Bivariate associations between categorical variables were analysed using the x2 test.  
The Kruskal-Wallis test was used to assess blood requirements in units of blood in 
each of the 3 Child-Pugh grades.  Logistic regression was used to estimate odds 
ratios (OR) with 95% confidence intervals (CI) for adjusted and unadjusted effects. 
Initially each risk factor was examined independently which produced the unadjusted 
OR and 95% CI.  The significant candidate variables identified by univariate analysis 
underwent multivariate logistic regression analysis to produce a prognostic model 
(“the training set”) representing rebleeding and death in the first 6 weeks after 
admission to hospital.  The performance and discriminative ability of the constructed 
models to predict rebleeding and mortality at 6 weeks was assessed using receiver 
operating characteristic (ROC) analysis.  The prediction accuracy was quantified 
using the concordance index (C-index) which is equivalent to the area under the 
ROC curve and reflects the ability of a model to discriminate participants (or patients) 
who develop the event of interest (i.e. rebleeding or death) from those who do not.  





predictive power.  For all analyses, a p value less than 0.05 and a 95% confidence 
interval that did not span unity were considered the thresholds of statistical 
significance.  Stata software (Stata Corp 2003, Release 8, College Station, TX: 
StataCorp LP) was used for statistical analysis.   
 
Validation process 
The developed models were tested for validity and concordance in a further set of 
alcoholic cirrhotic patients with bleeding varices (“the test set”). Model discrimination 
between the training (derivation) set and the test (validation) set was evaluated using 




During the 276 month study period, 632 consecutive adult patients were treated for 
bleeding oesophageal varices.  Patients with non-alcoholic causes of portal 
hypertension (n=206) or who had received endoscopic variceal band ligation (n= 
116) were not included in the study.  The remaining 339 patients had portal 
hypertension due to alcohol-induced cirrhosis.  Of these, 29 had cirrhosis and an 
alcohol history, but in addition had positive hepatitis B or C viral markers and were 
also excluded from the study group.  Data in the remaining 310 patients with 
alcoholic cirrhosis and proven oesophageal variceal bleeding who received only 
endoscopic injection sclerotherapy for bleeding form the basis of this study.   
 
The 310 patients (242 men, 68 women) had a mean age of 51.7 years (range: 24-





444 elective) during 919 endoscopy sessions in the 6 week period after the first 
variceal bleed.  Forty four (14.2%) patients were Child-Pugh grade A, 122 (39.4%) 
were grade B and 144 (46.4%) were grade C when assessed on their first admission 
to hospital.  Two hundred and eleven patients required a blood transfusion during the 
initial hospital admission.  Balloon tamponade was used in 44 patients and 
vasopressin or octreotide was used in 43 patients.  Eighteen patients required both 
balloon tube and vasopressin.   
 
Outcome 
6-week rebleeding rate 
Emergency endoscopic injection sclerotherapy, supplemented with balloon 
tamponade when necessary, controlled acute variceal bleeding in 304 of 310 (98%) 
patients.  In 6 (1.9%) patients, the initial acute variceal bleeding was not controlled 
despite using pharmacologic and endoscopic therapy and balloon tamponade. 
Overall 75 (24.2%) patients rebled during the 6 week assessment period after initial 
control during the index admission.  
 
Overall Mortality 
Seventy seven patients (24.8%) died during the 6 week study period.  Twenty-nine 
(9.3%) died within 5 days of admission and 48 (15.4%) died between day 6 and 42. 
Liver failure was the commonest cause of death and occurred in 29 patients.  Twelve 
patients died of hepatorenal failure and 10 died of pneumonia and respiratory failure.  
Death in 25 patients was a consequence of either continued or recurrent variceal 






Rebleeding and mortality analysis 
Factors related to variceal re-bleeding within 6 weeks 
Univariate analysis was used to determine the unadjusted risk factors for rebleeding 
and death.  When predictors of rebleeding during the first 6 weeks were considered, 
logistic regression analysis found that >6 units of blood transfused, the presence of 
ascites and a bilirubin level >51 mmol/L were the best set of significant predictor 
covariates (Table 6.1). However, in the final stepwise multivariate logistic regression 
analysis model, only two variables, bilirubin levels greater than 51 mmol/L and >6 
units of blood transfused during the initial hospital admission were significant 
predictors of rebleeding (Table 6.2). 
 
Factors related to 6-week mortality after variceal bleeding 
Univariate logistic regression analysis found that >6 unit blood transfusion, pitressin 
or octreotide infusion, the presence of encephalopathy and ascites, the need for a 
balloon tube to control acute bleeding, a prolonged INR >2.3, a low serum albumin 
level <2.5g/L, and increased bilirubin levels >51 mmol/L  were significant predictors 
of death at 6 weeks after the initial variceal bleed (Table 6.3).  In the final multivariate 
logistic regression analysis model, six variables, encephalopathy, ascites, bilirubin 
levels >51 mmol/L, a prolonged INR >2.3, an albumin level <25 g/L and the need for 
balloon tube tamponade were significant predictors of death within the first 6 weeks 
(Table 6.4).  
 
Validation of study data 
The validity of the models identified from the multivariate analyses for rebleeding and 





another 55 alcoholic cirrhotic patients treated subsequently in our unit (“the test set”). 
The data are shown in the receiver operating characteristic (ROC) curves in figures 
6.1 and 6.2.
Table 6.1 Univariate analysis of categorical variables predicting variceal rebleeding 
 
Variable Class Total Rebleed % Rebleed X2 P-value Odds Ratio 95% CI 
Gender Male 242 58 24%     
 Female 68 17 25% 0.03 0.860 1.05 0.56 – 1.97 
Age <=60 years 226 52 23%     
 >60 years 84 23 27.4% 0.63 0.424 1.26 0.71 – 2.23 
Blood Transfusion <=6 Units 128 44 34.4%     
 >6 Units 85 31 36.5% 9.62 0.002 2.36 1.36 – 4.09 
Bilirubin (μmol/l) <=51 186 35 18.8%     
 >51 124 40 32.3% 7.32 0.007 2.05 1.21 – 3.47 
Albumin (g/l) >=25 251 57 22.7%     
 <25 59 18 30.5% 1.58 0.208 1.49 0.79 – 2.79 
INR <=2.3 284 69 24.3%     
 >2.3 26 6 23.1% 0.01 0.890 0.93 0.36 – 2.42 
Ascites 1, 2  166 30 18.1%     
 3 143 45 31.5% 7.50 0.006 2.08 1.22 – 3.53 
Encephalopathy 1, 2 239 52 21.7%     
 3 70 23 32.8% 3.62 0.057 1.75 0.97 – 3.16 
Variceal grade 1, 2, 3 191 41 21.5%     
 4, 5 119 34 28.5% 2.01 0.155 1.46 0.86 – 2.47 
Pitressin No 267 61 22.8%     
 Yes 43 14 35.6% 1.90 0.168 1.63 0.81 – 3.27 
SBTube No 266 60 22.6%     
 Yes 44 15 34.1% 2.73 0.098 1.77 0.89 – 3.52 
 
Table 6.2 Multivariate logistic regression model for rebleeding 
 
The area under the ROC curve for each model in the test set was not significantly 
different from the corresponding area in the training set, indicating that the predictive 
sensitivity and specificity observed in the training set were accurately reproduced in 
the test set.  The concordance (c)-statistic yielded values in the model for death which 
ranged from 0.84 to 0.87 indicating a robust model with good predictive accuracy (Fig 
6.1).  The model predicting the likelihood of death at 6 weeks was expressed as a box 
plot showing the distribution of the predicted probabilities of death (Fig 6.2).  The 
calculated threshold for death in the box plot was 30% with the proposed model 
accurately predicting a high risk of dying in those patients above the 30% threshold.  
The concordance (c)-statistic in the model for rebleeding at 6 weeks was less 
predictive with values ranging from 0.56 to 0.63 indicating that the selected variables 
in the proposed model for variceal rebleeding at 6 weeks were less likely to identify 
those patients who might rebleed than those likely to die (Fig 6.3).  Similarly, the box 
plot (Fig 6.4) indicated that the proposed model for rebleeding was less accurate at 
predicting those patients who were likely to rebleed within the 6 week period, 
suggesting that the candidate variables selected by uni- and multivariate analyses, 
which mainly represented liver function, were more accurate in predicting survival 




Risk factor P-value Odds Ratio 95% CI 
Bilirubin >=52 μmol/L 0.025 1.85 1.08 – 3.16 
Blood transfusion > 6 Units 0.008 2.14 1.22 – 3.76 
Table 6.3 Univariate analysis of categorical variables predicting death 
 
Variable Class Total Died <= 42 days % Died X2 P-value Odds Ratio 95% CI 
Gender Male 242 63 26%     
 Female 68 14 20.5% 0.84 0.359 0.73 0.38 – 1.41 
Age <=60 years 226 55 24.3%     
 >60 years 84 22 26.2% 0.11 0.737 1.10 0.62 – 1.95 
Blood Transfusion <=6 Units 225 41 18.2%     
 >6 Units 85 36 42.4% 19.24 <0.001 3.29 1.90 – 5.70 
Bilirubin (μmol/l) <=51 186 25 13.4%     
 >51 124 52 41.9% 32.35 <0.001 4.65 2.67 – 8.07 
Albumin (g/l) >=25 251 48 19.1%     
 <25 59 29 49.1% 23.07 <0.001 4.08 2.24 – 7.44 
INR <=2.3 284 60 21.1%     
 >2.3 26 17 65.3% 24.99 <0.001 7.05 2.99 – 16.61 
Ascites 1, 2  166 19 11.4%     
 3 143 58 40.5% 34.80 <0.001 5.27 2.94 – 9.45 
Encephalopathy 1, 2 239 36 15%     
 3 70 41 58.5% 54.78 <0.001 7.97 4.40 – 14.42 
Variceal grade 1, 2, 3 191 41 21.5%     
 4, 5 119 36 30.3% 3.03 0.082 1.58 0.94 – 2.67 
Pitressin No 267 54 20.2%     
 Yes 43 23 53.5% 21.95 <0.001 4.53 2.32 – 8.86 
SBTube No 266 50 18.8%     
 Yes 44 27 61.4% 36.64 <0.001 6.86 3.47 – 13.54 
 
Table 6.4 Multivariate logistic regression model for death 
 
Risk factor P-value Odds Ratio 95% CI 
Encephalopathy Grade 3 <0.001 5.69 2.78 – 11.63 
Ascites Grade 3 0.011 2.52 1.23 – 5.16 
Bilirubin >=52 μmol/L 0.012 2.40 1.12 – 4.80 
INR >=2.3 0.003 4.93 1.70 – 14.24 
Albumin <=24 g/l 0.012 2.58 1.23 – 5.40 






Figure 6.1 The ROC curves of the models generated with the Training and 


















0.00 0.25 0.50 0.75 1.00
1-Specificity
ROC area (Training Data): 0.87 ROC area (Test Data): 0.84
Reference













Figure 6.3 The ROC curves of the models generated with the Training and 
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This is the first study to examine risk factors for variceal rebleeding and death in an 
exclusively alcoholic cirrhotic population with acute bleeding oesophageal varices 
treated with emergency injection sclerotherapy.  The study used data from easily 
obtainable clinical and biochemical information to identify risk factors which were 
validated in a subsequent patient sample.  The risk factors included clinical 
(encephalopathy, ascites, balloon tube tamponade, >6 unit transfusion) and 
biochemical (bilirubin >51 mmol/L, INR >2.3, albumin <2.5mg/dL) data.  As 
expected, most of the selected variables reflected the severity of the underlying liver 
disease and the magnitude of the bleeding episode (the need for a >6 unit blood 
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limited to alcoholic cirrhotic patients in order to have a clearly defined group and a 
uniform intervention in a population known to have a high rebleeding and mortality 
rate as more than 85% of the patients in this study were Child-Pugh grade B and C.    
The study demonstrated that although initial endoscopic intervention was effective in 
controlling initial acute variceal bleeding from oesophageal varices, one in four 
patients rebled during the first 6 weeks.  The 6-week mortality rate in our cohort of 
decompensated alcohol-related cirrhotic patients was 24.8% which is similar to the 
23.6% reported by D’Amico et al (D’Amico 2003) but higher than the 18.4% 
(Thomopoulos 2006), 17.5% (Chalasani 2003), 15.3% (Boix 2007) and 14.5% 
(Carbonell 2004) mortality reported by other authors, a difference which may reflect 
the alcoholic population in our study.   
 
Several previous studies have sought to identify prognostic indicators associated 
with early variceal rebleeding. In these studies multivariate analyses have 
demonstrated that active bleeding at emergency endoscopy (D’Amico 2003, Ben-Ari 
1999, Siringo 1991, Zhao 2002, Jalan 2000), variceal size (Poynard 1987), Child-
Pugh grade (D’Amico 2003, Thomopoulos 2006, Zhao 2002, Poynard 1987, Sanders 
2002), Child Pugh score (Ben-Ari 1999, Siringo 1991, Bosch 2008, Bhasin 2004), 
hematocrit levels (D’Amico 2003, Bosch 2008), bacterial infection (Zhao 2002, Bosch 
2008, Goulis 1998, Bernard 1999), encephalopathy (Ben-Ari 1999), portal vein 
thrombosis (D’Amico 2003), platelet count (Ben-Ari 1999), hepatocellular carcinoma 
(Poynard 1987, Bosch 2008), continued alcohol abuse (Ben-Ari 1999, Poynard 1987, 
Bosch 2008), hypoalbuminaemia (Zhao 2002) and a hepatic venous pressure 
gradient >20mm Hg (Bosch 2008, Avgerinos 2004, Monescillo 2004, Moitinho 1999) 





factors for early rebleeding and significant predictors of risk for 5-day failure.  The 
aggregate conclusions of these studies are however discordant and the predictive 
value of the combined results difficult to assess from the data (Krige 2009).  
Substantial differences in the studies include an absence of rigorous endoscopic 
criteria for defining variceal bleeding, a lack of standardisation of time of entry, and in 
patient sampling (percentage of alcoholics, percentage of Child-Pugh patients, active 
bleeding at endoscopy).  Using multivariate regression analysis in the present study, 
two variables, bilirubin levels greater than 51 mmol/L and >6 units of blood 
transfused were significant predictors of rebleeding which is consistent with the 
reports of others (Ben-Ari 1999, Zhao 2002) and are markers reflecting the severity 
of the underlying liver disease and the magnitude of the bleeding episode.  
 
There is a wide variation in the reported mortality rates after the first episode of 
variceal bleeding related in particular to differences in the interpretation of time ‘zero’ 
and the inclusion of patients beyond the first 48 hours of onset of initial bleeding. In 
addition some studies include patients who have had a first bleed as well as patients 
who present with subsequent variceal bleeds.  In these selected groups mortality 
rates differ markedly.  Published studies also include widely differing proportions of 
alcoholic and Child-Pugh grade C patients. (del Olmo  2000) The mortality rate in 
this study was 9.3% at 5 days and increased to 24.8% at 6 weeks. In an analysis of 
published data the most consistently reported predictive factors associated with an 
increased mortality at six weeks are active bleeding at endoscopy (de Franchis 
2005), variceal size (Bosch 2003), hypovolaemic shock (Chalasani 2003, 
Thomopoulos 2006, de Franchis 2005), units of blood transfused (Le Moine 1992), 





grade (Thomopoulos 2006, Sanders 2002, Bosch 2003, Graffeo 1994, Prindiville 
1987, Yang 2007), MELD score >15 (Amitrano 2005), HVPG >20mmHg (de Franchis 
2005), renal failure (de Franchis 2005, Cardenas 2001), blood urea or creatinine 
(Chalasani 2003, Ben-Ari 1999, Bosch 2008, Garden 1985, Lata 2006, Gatta 1994), 
total bilirubin (Lata 2006, Gatta 1994, Hori 2006), INR (Le Moine 1992, Garden 1985, 
Lata 2006), ascites (Hori 2006), hepatic encephalopathy (Ben-Ari 1999, Le Moine 
1992, Garden 1985, Srikureja 2005), albumin (Prindiville 1987, Lo 2004), bacterial 
infection (Yang 2007) and hepatocellular carcinoma (Bosch 2008, de Franchis 2005, 
Amitrano 2005, Gatta 1994, Hori 2006), continued alcohol abuse (Bosch 2008) and 
age (Carbonell 2004) has been previously reported. We used univariate and multiple 
logistic regression analyses to determine which variables were most predictive of 6 
week mortality.   The key finding in our study was the identification in the final 
multivariate regression analysis model of 6 independent prognostic factors for overall 
survival at 6 weeks.  
 
Several studies have evaluated the clinical factors associated with early mortality 
after endoscopic intervention for acute variceal bleeding. Previous investigators have 
shown that the severity of the bleeding episode (shock on admission to the hospital) 
and the Child-Pugh grade (Thomopoulos 2006) are independent predictors of short-
term mortality while others have reported that a Child-Pugh score of >9, orthostatic 
hypotension, systolic blood pressure <100mmHg, diastolic pressure of <60mmHg, 
failure to control bleeding, placement of a Minnesota tube, airway intubation, 
transfusion requirement >5 units, and aspiration pneumonia were associated with an 
increased in-hospital mortality (Chalasani 2003, Bhasin 2004).  In a retrospective 





variables studied, encephalopathy, prothrombin time and the number of blood units 
transfused within 72 hours had independent prognostic value (Le Moine 1992).  
Gatta et al found that s-creatinine, ascites on admission, diagnosis of hepatocellular 
carcinoma and prothrombin index were the best set of significant predictor co-
variates (Gatta 1994). Other investigators have shown that the severity of bleeding 
as assessed by shock on admission to the hospital and the Child-Pugh grade  
(Thomopoulos 2006) are independent predictors of short-term mortality while others 
have reported that a Child-Pugh score of >9, orthostatic hypotension, systolic blood 
pressure <100mmHg, diastolic pressure of <60mmHg, failure to control bleeding, 
placement of a Minnesota tube, airway intubation, transfusion requirement >5 units, 
and aspiration pneumonia were associated with an increased in-hospital mortality 
(Chalasani 2003, Bhasin 2004).    
 
Although several prognostic models have been proposed to predict mortality in 
patients with cirrhosis (Chalasani 2003, Thomopoulos 2006, Bhasin 2004, Le Moine 
1992, Garden 1985, Gatta 1994), the Child-Pugh score remains the most widely 
used scoring system both in clinical practice and in clinical research (D’Amico 2006) 
and is superior to any other predictive factor in determining mortality within the first 
six weeks after a major variceal bleed (Jalan 2000, Garcia-Tsao 2008, Atkinson 
2008, Sanders 2002, Angermayr 2003). In a systematic review of 118 studies of 
cirrhotic patients, the most common independent predictor of death was the overall 
Child-Pugh score, followed by each of the five components of the Child Pugh score 
(D’Amico 2006).  The advantages of the Child-Pugh (C-P) score over other more 
complex scores such as the Model for End-Stage Liver Disease (MELD) score, is 





using mental arithmetic.  Two significant flaws in the Child-Pugh score, however, are 
the subjectivity in the assessment of the degree of ascites and encephalopathy and 
the inability to distinguish mild from severe grade C patients with sufficient 
discrimination (Cholongitas 2005).  In a comparative study testing the ability of 
MELD and CTP scores in predicting mortality following acute variceal bleeding in 
239 cirrhotic patients, Chalasani et al found that MELD was not superior to the 
commonly used C-P score (Chalasani 2003).  These authors stress that calculating 
the MELD score is complex while the C-P system is well established, its components 
are easily obtained and is easy to calculate at the bedside (Chalasani 2003).  In 3 
studies by Bambha (Bambha 2008), Chalasani (Chalasani 2003), and Amitrano 
(Amitrano 2005) MELD was a clinically useful and objective predictor of short-term 
survival after AVH.  Prognostic scoring in acute variceal bleeding continues to evolve 
and updated versions of the original C-P and MELD scores are now available (Huo 
2008).  The C-P grade and scores in our study showed significant discrimination 
between grade A, B, and C patients and the incidence of rebleeding and death at 6 
weeks.  In our study, each of the individual components of the C-P classification 
correlated with survival using multivariate analysis and was validated in the test 
group, independently confirming the accuracy of the C-P grading classification.   
 
The proposed risk predictor models generated in this study were shown to be valid 
and predictive.  The concordance (c)-statistic showed that the predictive models had 
values between 0.83 and 0.87 indicating excellent predictive accuracy.  As in 
previous studies (D’Amico 2003) prognostic indicators of 6 week mortality were 
related predominantly to the degree of liver decompensation rather than the severity 





to the severity of underlying liver disease.  The multivariate analysis selected each of 
the components of the Child-Pugh grade, emphasizing the inherent value of the 
Child-Pugh system.  In addition our study showed that balloon tamponade and >6 
units of blood reflected the magnitude of the variceal bleed.  The concordance 
statistic was less good for the prediction of rebleeding, suggesting that additional 
factors, other than liver function, such as variceal size or portal pressure, may be 
responsible for variceal rebleeding.  
 
A major strength of this study is that it was conducted in a single centre in a well 
defined population of consecutive patients using a standard endoscopic injection 
technique and was supervised by the same group of investigators during the study 
period. All included patients were at a well defined stage in the course of cirrhosis 
(inception cohort) thereby homogenising the study population and avoiding the error 
of overfitting which has influenced of significant proportion of previous studies 
(D’Amico 2006). In order to provide the highest possible level of uniformity and to 
minimise differences in the zero-time entry, only patients who received their initial 
and subsequent treatment in our unit were studied.  The robustness of this study is 
enhanced by the prospective data collection, restriction of subjects to alcoholic 
cirrhotics and the complete follow-up of the cohort.  The use of rebleeding and death 
as the main outcomes provided consistent and objective end-points in the study.  
Unlike other studies which included non-consecutive patients, incomplete reporting 
of inclusion and exclusion criteria and have incomplete follow-up or inclusion of 
patients at differing disease stages without separate analyses, our study design 






This study has several important limitations. The study did not test all the previously 
reported risk factors for variceal rebleeding and death in the univariate and 
multivariate analysis as this study was a retrospective analysis of prospectively 
documented data. Future prospective studies evaluating the full spectrum of 
proposed risk factors from other centres will be necessary to provide the definitive 
risk equation. Although the technique of sclerotherapy remained constant, this study 
assessed patients over a 26 year period during which improvements in supportive 
care, vasoactive drugs and antibiotic therapy have occurred.  In this study 
prophylactic antibiotics were given initially only to patients with ascites to prevent 
spontaneous bacterial peritonitis.  In the light of compelling new data, antibiotics are 
now given to all patients with acute variceal bleeding (Thalheimer 2005).  
Endoscopic banding has now replaced injection sclerotherapy in most units, 
although a recent meta-analysis concludes that banding and sclerotherapy are 
equally effective for acute variceal bleeding (Triantos 2006). 
 
Despite the development of several scoring systems for risk stratification in patients 
with portal hypertension and bleeding oesophageal varices, only the Child-Pugh 
classification and more recently, the MELD score, have universal appeal.  This lack 
of integration into clinical practice of the new systems may be due to insufficient 
validation, complex formulae with cumbersome calculations for daily bed-side use, 
limited clinical applicability, or inability to identify patients with significant but non GI 






Despite substantial improvement over the past two decades in the overall survival 
after variceal bleeding, the 6 week mortality remains discouragingly high, especially 
in Child-Pugh grade C patients (Thabut 2007). Patients die from uncontrolled 
bleeding, early rebleeding, infection, liver and renal failure in the first weeks after a 
bleeding episode. Factors independently associated a higher mortality are poor liver 
function, severe portal hypertension with a HVPG>20mmHg and active bleeding at 
endoscopy.  The essential requirements necessary to improve survival are effective 
control of acute variceal bleeding, prevention of further rebleeding and minimising 
deterioration of liver function. 
 
Identification and knowledge of accurate prognostic data predicting early rebleeding 
can ideally provide a powerful tool to identify at an early stage those patients in 
whom conventional treatment is likely to be unsuccessful and who require urgent 
implementation of an aggressive salvage strategy or identify those with a very poor 
prognosis in whom chances of survival are slim. In this study risk factors to predict 
early rebleeding and death in alcoholic cirrhotic patients with variceal bleeding were 
calculated from easily obtained clinical, biochemical and endoscopic data and was 
validated in an independent sample.  Future prospective studies incorporating and 
evaluating the full spectrum of prognostic factors including clinical variables, renal 
function and liver biochemistry, endoscopic intervention, portal pressures and 
validation of the new scoring systems will be a valuable addition to improving the 











SUMMARY AND  CONCLUSIONS 
 
Study 1 
The first study in this thesis evaluated the incidence of variceal eradication, variceal 
recurrence and rebleeding and death in a large cohort of patients with alcohol-
induced cirrhosis and bleeding varices treated with serial endoscopic variceal 
injection sclerotherapy.  The study sought to determine accurate long term survival 
data in alcoholic patients with cirrhosis who had bled from oesophageal varices and 
tested the validity of the hypothesis that eradication of oesophageal varices by 
repeated injection sclerotherapy would reduce recurrent variceal bleeding and death 
from bleeding varices.   
 
The study evaluated 287 consecutive alcoholic cirrhotic patients who presented with 
acute oesophageal variceal bleeding and underwent a total of 2565 upper 
gastrointestinal endoscopic sessions which included 353 emergency and 1015 
elective variceal injection treatments during the study period.  Rebleeding after the 
index injection sclerotherapy procedure occurred in 104 of the 287 (36.2%) patients 
before eradication.  These 104 patients had a total of 170 bleeds during 164 
subsequent admissions before the varices were eradicated.  Ninety one patients 
bled from varices and 13 patients bled from non-variceal sources.  The 91 patients 
had 124 variceal bleeds which were successfully treated with acute emergency 
injection sclerotherapy on 113 occasions.   
 
Eradication and subsequent recurrence of oesophageal varices after sclerotherapy 





more than 3 months.  Oesophageal varices were eradicated in 147 of the 182 
patients (80.7%) after a median of 5 injections (range: 1 to 14).  Mean survival in 
these 147 patients was 47.1 months (median 36.8 months) with the mean survival in 
Child-Pugh grades A, B and C of 40.2, 37.4 and 24.0 months.  Oesophageal varices 
remained eradicated in 69 patients (mean follow-up from eradication: 34.6 months, 
median 23.6 months; range 1 to 174). Mean survival in these 69 patients in whom 
varices remained eradicated was 39.6 months (median 31.7 months).  Forty five of 
the 78 (57.7%) patients with recurrence of oesophageal varices after eradication 
presented with variceal bleeding after a mean of 16 months (range: 0.5 to 172 
months).  
 
Minor complications of sclerotherapy were common after acute injection for active 
bleeding and included dysphagia, transient fever and pulmonary atelectasis.  A total 
of 747 complication events were documented in 234 patients during surveillance or 
unscheduled follow-up endoscopy after a prior variceal injection.  Mucosal ulceration 
at the injection site was found at follow-up endoscopy on 531 occasions in 199 
patients.   An oesophageal stricture at the injection site occurred in 25 patients after 
sclerotherapy, 9 of whom required oesophageal dilatation on 29 occasions with relief 
of symptoms.  Two patients developed an intramural oesophageal haematoma after 
sclerotherapy which resolved on conservative therapy.  Perforation of the 
oesophagus occurred in 8 patients as a consequence of repeated sclerotherapy to 
control of recurrent acute variceal bleeding.  Five of these 8 patients survived, 






Cumulative survival of the 287 patients by life table analysis was 67% at 1 year, 42% 
at 3 years, 26% at 5 years and 13% at 10 years.  Survival according to Child-Pugh 
grade A was 68% at 3 years, 48% at 5 years and 37% at 10 years.  Survival of Child-
Pugh grade B patients at 3 years was 54%, 34% at 5 years and 17% at 10 years, 
and survival of Child-Pugh grade C patients was 21% at 3 years, 13% at 5 years and 
7% at 10 years. Two hundred and one (70%) of the 287 patients died during the 
course of the study.  Liver failure was the commonest cause of death and occurred 
in 113 patients. Hepatorenal failure was the cause of death in 23 patients.  Twelve 
patients died of pneumonia, 37 of multi-organ failure, often precipitated by bleeding 
varices and 3 died of bleeding from other sites.  
 
Ultimate survival and outcome of treatment in this consecutive cohort of patients was 
disappointing.  Although varices were eradicated in 82% of patients who survived 
more than 3 months, recurrent varices ultimately developed in 57% of patients, half 
of whom had further variceal bleeding.  Several important and unresolved problems 
related to the role of repeated sclerotherapy in the long-term management of 
patients with oesophageal varices remain.  There is increasing recognition that an 
important limitation of long-term sclerotherapy is the substantial incidence of 
rebleeding which is a particular feature of the early phase after endoscopic therapy 
has begun.  The most common source of recurrent bleeding before variceal 
eradication in this study was from patent residual varices which occurred in one third 
of our patients.  Urgent repeat endoscopy is essential since in most patients with 
recurrent bleeding, varices were the source and were effectively treated by 
sclerotherapy.  Serial sclerotherapy successfully eradicated oesophageal varices in 





obliteration in 53% of patients, this was associated with rebleeding in only 30% 
which would support the validity of the concept of variceal eradication as a specific 
endpoint of treatment.   
 
While the risk of rebleeding diminishes with time as the variceal channels are 
obliterated, some recurrent bleeds are major and may contribute to deaths from liver 
failure.  Any protocol for long-term endoscopic management of variceal haemorrhage 
requires a firm definition of treatment failure which allows alternative treatment 
options to be instigated.  That such a definition is difficult to formulate, is reflected in 
the major discrepancies in the proportion of treatment failures in the larger controlled 
trials.  There is consensus that patients who have life-threatening variceal bleeding 
after an adequate course of endoscopic treatment should be regarded as failures of 
long-term treatment and in this cohort a TIPS shunt gives the best results.  Other 
logistic problems related to long-term sclerotherapy include the need for lifelong 
follow-up with repeated injections because most varices ultimately recur in time.  
Surviving patients place an increasing burden on hospital resources, even when 
sclerotherapy is performed on an outpatient basis.    
 
The long term data in this study has documented the variceal recurrence and 
rebleeding rate using a standard sclerotherapy technique. No comparable data exist 
for variceal ligation and ligation will require similar long term data to validate and 
vindicate its current status as the preferred endoscopic technique. Our current 
management policy is for patients to have regular endoscopic therapy in order to 
achieve early variceal eradication, appreciating that factors such as oesophageal 





programme.  After eradication of the varices, patients have surveillance endoscopy 
at six and then 12 month intervals and, if recurrent varices are identified, a 
comprehensive endoscopic treatment schedule is instituted again.  Ultimately the 
use of sequential combined endoscopic techniques with variceal banding initially 
when varices are large followed by sclerotherapy when varices are small may 
enhance the endoscopic management of oesophageal varices both in terms of 
reducing complications, facilitating earlier eradication and preventing recurrence. 
 
Study 2 
The second study demonstrated that endoscopic therapy was highly effective in 
controlling acute bleeding from oesophageal varices and that ultimate survival was 
influenced by both rebleeding and underlying liver reserve. Sustained control of 
acute bleeding has been shown to be a critical requirement in variceal management 
because each subsequent bleed worsens marginal liver function.  Although initial 
endoscopic intervention controlled acute variceal bleeding in 304 of the 310 patients, 
one quarter of the patients rebled during the first 6 weeks.  There were no deaths in 
Child-Pugh grade A patients and in this cohort with preserved liver function, early 
mortality was not influenced by the severity of the bleeding episode. Our data 
demonstrated that Child-Pugh grade C patients, who have the least hepatic reserve, 
were more likely to have a major bleed and require pitressin or octreotide and 
balloon tamponade in addition to sclerotherapy to control acute bleeding.  The study 
showed that in this high risk group, even when sclerotherapy successfully controlled 
variceal bleeding, progressive liver failure resulted in high mortality rates in the first 6 






The results of this study clearly defined the course and prognosis of patients with 
decompensated alcohol-related cirrhosis and bleeding varices. Despite substantial 
improvement in overall survival in recent years, the 6 week mortality after variceal 
bleeding remains discouragingly high, especially in Child-Pugh grade C patients who 
succumb either from uncontrolled initial variceal bleeding or early rebleeding, or 
subsequently from the consequences of infection, liver and renal failure in the first 
weeks after a bleeding episode.  As shown in this study, most deaths were due not 
to bleeding, but to the detrimental systemic consequences which lead to progressive 
deterioration of liver function.  The presence of advanced Child-Pugh score >13 in 
this study identified those patients at higher risk of mortality. Our study confirms the 
observations of others that in experienced centres endoscopic injection 
sclerotherapy can be performed safely and effectively in alcoholic cirrhotic patients 
with actively bleeding oesophageal varices. However, even under optimal conditions, 
currently available treatment options fail to control initial variceal bleeding or prevent 
early rebleeding in up to 20% of patients some of whom may require rescue 
intervention.  Because most patients who fail first line endoscopic and 
pharmacological therapy are high risk and have marked liver decompensation 
complicating the variceal bleeding, early recognition of endoscopic failures and 




The third study is the first detailed evaluation and analysis to examine risk factors for 
rebleeding and death in an exclusively alcoholic cirrhotic population treated with 





clinical and biochemical information to identify risk factors which were validated in a 
subsequent sample. The risk factors included clinical (encephalopathy, ascites, 
balloon tube tamponade, >6 unit transfusion) and biochemical (bilirubin >51 mmol/L, 
INR >2.3, albumin <2.5mg/dL) data.  As expected, most of the selected variables 
reflected the severity of the underlying liver disease and the magnitude of the 
bleeding episode.  Inclusion was specifically limited to alcoholic cirrhotic patients in 
order to have a clearly defined group and a uniform intervention in a population 
known to have a high rebleeding and mortality rate as more than 85% of the patients 
in this study were Child-Pugh grade B and C.   Univariate analysis was used to 
determine the unadjusted risk factors for rebleeding and death.  When predictors of 
rebleeding during the first 6 weeks were considered, logistic regression analysis 
found that >6 units of blood transfused, the presence of ascites and a bilirubin level 
>51 mmol/L were the best set of significant predictor covariates. However, in the final 
stepwise multivariate logistic regression analysis model, only two variables, bilirubin 
levels greater than 51 mmol/L and >6 units of blood transfused during the initial 
hospital admission were significant predictors of rebleeding.   
 
Univariate logistic regression analysis found that >6 unit blood transfusion, pitressin 
or octreotide infusion, the presence of encephalopathy and ascites, the need for a 
balloon tube to control acute bleeding, a prolonged INR >2.3, a low serum albumin of 
level <2.5mg/dL, and increased bilirubin levels >51 mmol/L were significant 
predictors of death at 6 weeks after the initial variceal bleed.  In the final multivariate 
logistic regression analysis model, six variables, encephalopathy, ascites, bilirubin 





for balloon tube tamponade were significant predictors of death within the first 6 
weeks.  
 
The validity of the models identified in the multivariate analyses for rebleeding and 
death at 6 weeks in the 310 study patients (“the training set”) were tested against a 
subsequently treated group of alcoholic cirrhotic patients with endoscopically proven 
bleeding oesophageal varices who had endoscopic control of bleeding in the unit 
(“the test set”). The area under the receiver operating characteristic curve for each 
model in the test set was not significantly different from the corresponding area in the 
training set, indicating that the predictive sensitivity and specificity observed in the 
training set were accurately reproduced in the test set. The concordance (c)-statistic 
yielded values in the model for death ranged from 0.84 to 0.87, indicating a robust 
model with good predictive accuracy. The calculated threshold for death in the box 
plot was 30% with the proposed model accurately predicting a high risk of dying in 
those patients above the 30% threshold.  The concordance(c)-statistic in the model 
for rebleeding at 6 weeks was less predictive with values ranging from 0.56 to 0.63 
indicating that the selected variables in the proposed model for variceal rebleeding at 
6 weeks were less likely to identify those patients who might rebleed than those 
likely to die.  Similarly, the box plot indicated that the proposed model for rebleeding 
was less accurate at predicting those patients who were likely to rebleed within the 6 
week period, suggesting that the candidate variables selected by uni- and 
multivariate analyses, which mainly represented liver function, were more accurate in 
predicting survival or death which is a function of liver reserve than predicting 
rebleeding which may be related or dependent on additional unrecognised or 





on admission who may not benefit from standard treatment alone and to stratify 
patients in future controlled trials. 
 
Recommendations regarding the technical aspects of sclerotherapy 
Endoscopic therapy is an established and integral part of the management of acute 
variceal bleeding and the long-term treatment of patients after a variceal bleed. 
Although complications after endoscopic therapy for variceal bleeding are common, 
most are minor and do not interrupt the treatment programme. In a small group of 
patients however, the success of therapy is compromised by recurrent bleeding and 
serious procedure-related complications.  Most of the serious complications related 
to endoscopic therapy occur in patients with severe liver disease in whom control of 
bleeding is difficult.  Mature clinical judgment is necessary in acute problematic or 
complex cases and careful supervision of trainees or assistance by an experienced 
endoscopist becomes essential when critical decisions are required.   Early and 
close multidisciplinary consultation is often useful in demanding cases to facilitate 
appropriate therapy and optimal management. 
 
Injection sclerotherapy is an invasive endoscopic procedure which requires a high 
level of manipulative skill and mature judgement.  Complications related to injection 
occur mostly during acute major or recurrent bleeding when varices are large and 
the patient is restless or unco-operative. The incidence of complications varies 
widely in reported studies because of variations in patient population, the type and 








A number of critical generic technical and procedural precautions are important to 
avoid both local and systemic complications, regardless of the type or technique of 
endoscopic intervention used to control acute bleeding. Effective resuscitation must 
precede endoscopy in patients with evidence of recent major bleeding.  Diagnostic 
and therapeutic endoscopy should be performed in a well equiped unit with 
competent assistance and careful monitoring.  Early endotracheal intubation is 
crucial if major bleeding occurs.  Precise and accurately placed injections are 
essential.   Uncontrolled blind, large volume injections during active bleeding must be 
avoided.  The sclerotherapy needle should not exceed 5mm in length and a short 
bevel reduces the risk of deep injections and extravasation of sclerosant and injury 
to the underlying oesophagus.  Recurrent bleeding after injection sclerotherapy 
requires careful evaluation and repeat endoscopy to determine the source.  If 
variceal bleeding continues or recurs during the index admission despite 2 adequate 
injections, other definitive therapy should be instituted. 
 
Variceal eradication with band ligation requires fewer endoscopic treatment 
sessions, and causes substantially less oesophageal complications.  Although the 
incidence of early gastrointestinal rebleeding is reduced by band ligation in most 
studies, this does not result in an overall survival benefit relative to injection 
sclerotherapy.  Simultaneous combination therapy band ligation plus injection 
sclerotherapy of large varices confers no advantage over band ligation alone.  A 
staged approach with initial band ligation followed by injection sclerotherapy when 
varices are small requires further evaluation as the sequential combination may 
prove to be the optimal method of minimizing variceal recurrence.  Overall, current 





sclerotherapy.  Band ligation should therefore be regarded as the endoscopic 
technique of choice in the treatment of oesophageal varices. 
 
The range of treatment options for bleeding oesophageal varices has expanded 
markedly during the past three decades with a substantial reduction in mortality to 
current levels of around 20%. This significant overall improvement in survival reflects 
the progress in both the general management of severely ill cirrhotic patients and 
treatment of hepatic decompensation which strongly influence the prognosis.  
Optimal management should provide the full spectrum of treatment options which 
include pharmacological therapy, endoscopic treatment, interventional radiological 
procedures, surgical shunts and liver transplantation.  The treatment of acute 
bleeding and prevention of recurrent variceal bleeding is best accomplished by a 
skilled, knowledgeable, and well equipped team using a multidisciplinary integrated 
approach.   
 
Assessment and recommendations for future research 
This review has shown considerable variation in the quality of randomised trials in 
cirrhotic portal hypertension, especially with regard the generation of allocation 
sequence and allocation concealment which may raise the risk of selection, 
assessment and attrition bias.  Despite the plethora of randomised controlled trials in 
portal hypertensive bleeding, these deficiencies leave unanswered questions.  
Understanding the problems inherent in the design, execution and interpretation of 
clinical trials in portal hypertension is critical in deciding whether the results apply to 
the care of a specific patient. For example, when assessing endoscopic control of 





alcoholic patients who have advanced cirrhosis and liver decompensation are less 
likely to show a difference in bleeding control as death from recurrent bleeding is 
replaced by early death from liver failure in a high risk population.   
 
The statistical power of trials remains a major problem in portal hypertension trials, 
where modest survival advantages are unlikely to be detected unless large-scale, 
multicentre randomised trials are undertaken incorporating sufficient patient 
numbers.  Very few of the published trials have performed blinded outcome 
assessment.  Better understanding of the principles involved in the design and 
implementation of clinical trials and analysis of data will increase the number of high 
quality of randomised controlled trials which may resolve some of the issues. There 
is a need to use standardised definitions for the critical end points in portal 
hypertension and bleeding varices e.g. control of bleeding, rebleeding and treatment 
failures.  Issues of quality of life and cost effectiveness are becoming increasingly 
important concepts to include in trial design.  
 
The implications for future research into portal hypertension are that adequately 
powered, adequately conducted, properly reported multicentre trials need to continue 
to address unresolved issues. As patient recruitment becomes an increasing 
impediment, future study conduct require internationally accepted standard protocols 
to facilitate aggregate analyses and future meta-analyses.  In addition, the ever 
increasing demand for medical fiscal discipline and logistic efficiency require the 
issue of cost to be adequately addressed in prospective studies. These issues have 






Identification and knowledge of accurate prognostic predicting early rebleeding 
should ideally provide a powerful tool to identify at an early stage those patients in 
whom conventional treatment is likely to be unsuccessful and who require urgent 
implementation of an aggressive salvage strategy. Future prospective studies 
incorporating and evaluating the full spectrum of prognostic factors including clinical 
variables, liver biochemistry, endoscopy and portal pressures and comparative 
MELD and Child-Pugh assessment will be valuable advances in improving the 
effective and rational management of patients with bleeding oesophageal varices 
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